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Osteoporosis and fragility fractures are recognized complications of 
inflammatory rheumatic diseases. This is thought to result from the effects of 
chronic inflammation, relative immobility and corticosteroid use. A rare 
syndrome of osteoporosis in a patient with coeliac disease has been 
described which results from production of neutralizing antibodies to the bone 
protective protein osteoprotegerin (OPG). The aim of my thesis is to evaluate 
prevalence and clinical predictors of osteoporosis in a contemporary cohort 
of patients with rheumatoid arthritis (RA) and to investigate the role of OPG 
autoantibodies in the pathogenesis of osteoporosis in rheumatic diseases.  
 
In a retrospective cohort study, I found that the overall prevalence of 
osteoporosis in patients with RA was 29.9% which is in keeping with older 
reports that recorded a prevalence rate between 17% and 36%. In our 
contemporary cohort osteoporosis was significantly more common than in a 
gender and age matched control cohort (17.4%). Further analysis showed 
that only age and BMI were independent predictors of osteoporosis in RA. A 
predictive tool based on age and BMI was developed which had 91.4% 
sensitivity for the detection of osteoporosis in an independent RA population. 
 
I went on to screen for the presence of autoantibodies to OPG in patients 
with various rheumatic diseases. In a study of 75 patients with rheumatoid 
arthritis and 199 healthy controls OPG autoantibodies were detected in two 
controls (1%) compared with seven patients with RA (9.3%). The RA patients 
with detectable OPG antibodies had a longer disease duration, higher DAS28 
scores and higher levels of the bone resorption marker CTX than RA patients 
who did not have autoantibodies. Purified IgG from patients with high levels 




induced NFκB activation in a HEK293 cell based assay indicating that they 
were functional. 
 
 In a further study of 134 patients with ankylosing spondylitis (AS), 16 
patients (11.9%) had detectable OPG antibodies. The presence of OPG-Ab 
was independently associated with reduced hip bone mineral density and an 
increased risk of fractures in this population.  In patients with a longer 
disease duration we have also observed that there was a higher discrepancy 
between spinal and hip BMD in OPG-Ab positive patients compared with 
OPG ab negative patients (p=0.003). 
 
In order to investigate if OPG antibodies affected measurement of serum 
RANKL concentrations as detected by ELISA using OPG as the capture 
reagent, I measured OPG ab and free RANKL concentrations in 55 
rheumatic disease patients. Surprisingly there was a significant positive 
correlation between free RANKL and OPG Ab concentrations (r=0.430, 
p=0.001) which was the opposite to what I had expected. These findings 
reject the hypothesis that OPG ab block binding of synthetic OPG to RANKL 
in the ELISA. 
 
In conclusion, I have shown that osteoporosis is a common complication in 
RA and I have developed a new risk prediction tool for the use in clinical 
practice. I have also found that OPG antibodies are produced more 
commonly in patients with RA and AS than in healthy controls and that 
antibody levels correlate with bone resorption markers in RA and bone 
mineral density in AS patients. In vitro studies have shown that some OPG 
antibodies have functional effects on RANKL signalling. These findings raise 
the possibility that OPG antibodies may contribute to the pathogenesis of 
local and systemic bone loss in rheumatic diseases and signal the need to 
study the relationship between these antibodies and bone disease in large-








Rheumatic diseases, such as Rheumatoid Arthritis, Ankylosing Spondylitis 
and Systemic Lupus Erythematosus are chronic, frequently debilitating 
autoimmune diseases, which primarily affect joints, spine and skin but can 
also involve other organs. Patients with rheumatic diseases frequently suffer 
from osteoporosis (thinning of the bones) and are therefore more likely to 
sustain a fracture. The main aim of this thesis was to investigate why patients 
with rheumatic diseases are at increased risk of developing osteoporosis and 
I was particularly interested to see if the immune system, which is usually 
responsible for combating infections in the body, is partly responsible for the 
osteoporosis. 
 I have found that in a small proportion of patients the immune system has 
produced  auto-antibodies ( types of protein that attack parts of your own 
body) that block a bone protective protein called osteoprotegerin (OPG). 
Patients with Rheumatoid Arthritis who have these antibodies seem to lose 
bone more rapidly and patients with Ankylosing Spondylitis who have been 
shown to have increased levels of OPG antibodies have lower bone mineral 
density than patients without these antibodies. However, we do not know yet 
when and why these antibodies occur and what the best treatment for OPG 
antibody associated osteoporosis is. Further studies are required to answer 
these questions and to find out if testing patients for OPG antibodies routinely 
will help to predict the risk of osteoporosis in some patients or inform us 







Chapter 1: General introduction 
 
In this chapter I will outline current understanding of bone pathology and 
introduce the cells and regulatory mediators involved in bone turnover. In the 
second part of the introduction, I will summarize up-to-date knowledge and 
recent findings of the mechanism of bone loss in Rheumatic Diseases with a 
particular focus on the concepts of autoimmune mediated bone loss. This 
should give an overview of current understanding of bone homeostasis in 
rheumatic diseases, outline gaps of current knowledge and introduce the 






Bone is a specialized connective tissue which together with cartilage forms 
the skeletal system. The skeleton has a role as supporting organ to which 
muscles, tendons and ligaments are attached. Additionally bone acts as 
calcium and phosphate reservoir and it harbours bone marrow where blood 
cells form and mature before being released into the blood stream (Colledge 
NR et al. 2010;Rosen CJ 2013).  
The skeleton consists of two types of bone, cortical and trabecular bone as 
shown in Figure 1.1. 
 
Figure 1.1 Crosssection of human phalanx (adapted from Bone Research 
Society Teaching slides, provided by Prof Tim Arnett) 
 
Cortical bone is highly mineralized compact bone that constitutes 85% of the 
skeleton and undergoes little bone remodelling. Cortical bone is found in the 
diaphysis of long bones and the outer layer of flat bones. 
Osteons are the basic structural unit of both cortical and trabecular bone. 
Cortical osteons (Haversian system) are cylindrical structures which contain 
a central (Haversian) canal with blood vessels and nerve fibres (Fig.1.2). 




outer layer of cortical bone is the periosteum, which contains blood vessels 
and nerve fibres, and is connected with the Haversian system through 
perforating perpendicular canals (Volksman’s canal). 
 
 
Figure 1.2 Structure of cortical bone (Haversian system) 
See text for details. Adapted from https://embryology.med.unsw. 
edu.au/embryology /images/a/a6/Bone_structure_cartoon.jpg 
 
Trabecular bone is mainly found in flat bones, epiphysis and metaphysis of 
long bones. It fills the centre of bones and contains a network of                                                                                                                                                                                                                                                
trabeculae, which provides structural   strength and is surrounded and filled 
by bone marrow. Trabecular bone is, in contrast to compact bone, 
metabolically active and is therefore more affected by disorders of bone 
remodelling than cortical bone. Trabecular osteons also comprise bony 





Medullary cavity is filled with bone marrow where mesenchymal and 
haemapoetic blood lineage cells differentiate into skeletal tissue, blood 
vessels and mature blood cells (Lorenzo J et al. 2011). 
Bone matrix consists of organic and inorganic components. Type I collagen is 
the most abundant component of bone matrix and accounts for 
approximately 90% of total protein of bone. Type I collagen is formed by two 
α1 peptide chains and one α2 chain which are wound into a triple helix. After 
intracellular processing, Type I collagen is laid down in extracellular matrix, 
where single fibrils are ‘cross-linked’ to one another in order to increase bone 
strength. When bone resorption occurs these cross-links are released into 
bloodstream and act as marker for bone resorption, like N-telopeptide (NTX) 
and C-telopeptide (CTX). The other organic components which mediate cell 
adhesion include osteocalcin, fibronectin, vitronectin, osteopontin and 
osteonectin. 
The inorganic component of bone is mineral. Mineralized matrix consists of 
calcium and phosphate crystals which are present in between collagen fibrils 
in form of hydroxyapatite [Ca10(PO4)6(OH)2].This component is of vital 
importance for the bone’s rigidity and strength. However over-mineralisation 
as in osteogenesis imperfecta can lead to increased bone fragility (Colledge 








1.2 Bone Cells 
1.2.1 Osteoclasts 
Osteoclasts are multinucleated, highly specialized cells that are formed by 
fusion of multiple mononuclear osteoclast precursor cells. The principal 
action of a mature osteoclast is bone resorption. Macrophage colony 
stimulating factor (M-CSF) and Receptor Activator of NfκB Ligand (RANKL) 
are essential for osteoclast differentiation, maturation and survival (Boyle et 
al. 2003;Jones et al. 2002). Osteoclasts differentiate from haematopoetic 
stem cells initially to colony forming units for granulocytes (CFU-GM). M-CSF 
binds to its membrane receptor c-Fsm on precursors and mature osteoclasts. 
Binding of M-CSF induces the expression of receptor activator of nuclear 
factor κB (RANK) and on cells which are committed to become osteoclasts 
(Rosen CJ 2013;Teitelbaum 2000). Receptor activator of nuclear factor-κB 
ligand (RANKL), a cytokine expressed by osteocytes, osteoblasts, T-cells 
and synoviocytes binds to RANK. RANKL binds to the RANK receptor and 
induces the activation of various signaling pathways including NFκB and 
Activation Protein-1 (AP-1) which promotes the fusion of mononuclear cells 
into multinucleated osteoclasts (Takayanagi 2005;Teitelbaum 2000). The 
sequential stages of osteoclast differentiation are shown in Figure 1.3. 
1.2.1.1 Osteoclast signalling 
Beside the essential signals of M-CSF and RANKL for differentiation of 
osteoclasts there are a multitude of signalling pathways which allow fine 
tuning of osteoclast maturation and activity (Fig. 1.4). The central pathway is 
RANK signalling which results in strong NFκB activation and lineage 
commitment of osteoclasts. The binding of RANKL activates TNF-receptor 
associated factors (TRAF), in particular TRAF-6 which is essential for 
osteoclast differentiation and activation (Lomaga et al. 1999). Downstream of 
TRAF6, several kinases including mitogen activated protein kinases (MAPK) 
get activated which subsequently induce the transcription of osteoclast-







Figure 1.3  Diagram of Osteoclast differentiation 
Haematopoetic stem cells (HSC) differentiate initially into colony forming 
units for granulocytes (CFU-GM) then to Osteoclast (OC) precursors. M-CSF 




Activation of the RANK receptor can also lead to the formation and 
subsequent activation of the IKK α/IKKβ/IKKγ complex.  The catalytic IKK 
subunits (IKKα and IKKβ) and non-catalytic IKKγ mediate NFκB activation. 
Tumour necrosis factor-α (TNFα) boosts osteoclast differentiation through 
potent NFκB activation via IKK pathways and various Kinases including p-38 
and extracellular signal-regulated kinase (ERK) (Hayden and Ghosh 2004). 
Interleukin 1 enhances osteoclastogenesis via p38/ERK pathway. Beside 
above mentioned inflammatory cytokines Interleukin 6 (IL6) influences 
osteoclastogenesis positively via MAPK and/or Janus kinases (JAK) and 




(Redlich and Smolen 2012). On the other hand Interferon α (IFN-α), 
Interferon β (IFN-β) and  mainly Interferon γ attenuate osteoclast proliferation 
through negative crosstalk to RANK signaling and inhibition of activator 
protein 1 (AP1) (Takayanagi et al. 2000). 
Osteoclasts derive from the monocyte/macrophage lineage and therefore 
express an Fc receptor common gamma subunit (FcRγ) and DNAX- 
activating protein (DAP12) receptor. Both are immunoreceptor tyrosine based 
activation motif (ITAM) harbouring molecules, which interact with spleen 
tyrosine kinase (SYK), which allows activation of the essential osteoclast 
transcription factor NFATc1 via Phosphoinositide-specific phospholipase C 
(PLC) and Calcineurin. NFATc1 regulates multiple osteoclast specific genes 
such as Cathepsin K and tartrate resistant acid phosphatase (TRAP), 
together with other transcription factors. ITAM signals are not able to 
stimulate or enhance osteoclastogenesis without RANK stimulation and are 
therefore called co-stimulatory signals (Takayanagi 2005). However Koga et 
al (Koga et al. 2004) demonstrated that mice deficient of FcRγ and DAP 12 
develop severe osteopetrosis and mice only lacking FcRγ develop a milder 
form of osteopetrosis. FcRγ gets activated by immune complexes and 
therefore may play a particular important role in osteoclast activation in 
autoimmune diseases with known autoantibodies such as Rheumatoid Factor 
and ACPA in Rheumatoid Arthritis. The function and importance of FcRγ in 
osteoclasts has been for a long time unknown but recent findings 
demonstrate its important role in osteoclast regulation. This pathway may 
therefore become of interest as potential therapeutic target. (Harre et al. 






1.2.1.2 Osteoclast induced bone resoption 
The resorption process starts by the adhesion of osteoclasts 

















































































































































































































































































































































































































































































































































































The attached osteoclasts form a “sealing zone” which separates the 
resorption area from extracellular space. Activated osteoclasts use a 
complex folded membrane structure, “the ruffled border”, as secretory site 
and induce bone degradation by secretion of proteolytic enzymes such as 
Cathepsin K, Matrix Metaolprotease 2, chlorid ions and acid. Resorption and 
degradation of bone matrix induces differentiation of the bone forming cells, 
the osteoblasts. This cross-talk between osteoclasts and osteoblasts is called 
coupling (Rosen CJ 2013). Overstimulation of osteoclasts leads to bone 
disease such as Osteoporosis, Paget’s Disease of Bone and bone erosions 
in Rheumatoid Arthritis (Ralston 2013;Sambrook and Cooper 2006a;Schett 
and Gravallese 2012). The majority of available treatment options for 
osteoporosis are targeting osteoclast differentiation (Cummings et al. 2009), 





1.2.2 Osteoblasts  
Osteoblasts derive from mesenchymal stem cells and mature into highly 





Figure 1.5 Diagram showing differentiation from mesenchymal stem 
cells to mature osteoblasts MSC (Mesenchymal stem cells) differentiate 
under influence of RUNX2 (runt related transcription factor)into 
osteoprogenitor cells which differentiate with help of the transcription factors 
RUNX2 and Osx (Osterix) into mature osteoblasts. Osteoblasts undergo 
either apoptosis or terminal differentiation in either osteocytes or bone lining 
cells. MSC can also differentiate to Chondrocytes under influence of Sox (sex 
determining region Y (SRY)-box) 5,6 and 9 proteins. 
 
Osteoblast differentiation and activation requires multiple signaling pathways. 
Some important signaling pathways are depicted in Figure 1.5. RUNX2 (runt 
related transcription factor) is “the master regulator of osteoblastogenesis as 
its activation allows the differentiation from mesenchymal progenitor cells into 
preosteoblasts and mature bone forming cells(Redlich & Smolen 2012). 
RUNX2 can be activated by SMAD proteins, which are phosphorylated by 




transforming growth factor-β and fibroblast growth factor and the parathyroid 
hormone (PTH)(Rosen CJ 2013). Mice lacking Runx2 were found to have 
defective bone formation due to inhibited maturation of osteoblasts (Komori 
et al. 1997;Otto et al. 1997). 
The zinc finger transcription factor Osterix (Osx), acting downstream of 
Runx2 (Fig 1.5), was also found to be essential for the development of 
osteoblasts (Lecka-Czernik et al. 1999) as osterix deficient mice are unable 
to form bone (Koga et al. 2005;Nakashima et al. 2002). Another important 
signaling pathway is Wnt-Frizzeled-β catenin pathway.  WNT glycoproteins 
bind to a receptor complex which consists of the Frizzeled receptor alongside 
associated low-density lipoprotein receptor related proteins (LRP) such as 
LRP 4, LRP5 and LRP6(van Amerongen and Nusse 2009). Once activated 
the Frizzled receptor signals via β catenin. Inhibitors of the WNT pathway are 
important as they efficiently reduce osteoblast function and as they recently 
became central to drug development in the treatment of osteoporosis. 
Sclerostin, a cytokine secreted by osteocytes, binds to LRPs and inhibits  
binding of WNT to the complex(Rosen CJ 2013).  
 
Dickkopf 1 (DKK1) inhibits osteoblastogenesis in a similar way to Sclerostin 
but requires an additional co-receptor called Kremen in order to bind and 
eliminate LRP(Diarra et al. 2007).Parathyroid Hormone (PTH) also uses the 








Figure 1.6 Key signalling pathways in Osteoblast differentiation. The 
runt related transcription factor 2 (Runx2) together with Osterix (Osx) are 
essential factors for osteoblast differentiation. Pathways activating these 
factors involve: The stimulation of SMAD proteins by bone morphogenetic 
protein (BMP) and transforming growth factor β (TGF-β); activation of 
mitogen activated protein kinases (MAPK) through pathways shown above 
including fibroblast growth factor (FGF) and Parathyroid hormone (PTH); 
through WNT-Frizzled pathway which uses and associated low-density 
lipoprotein receptor related proteins (LRP) which uses β catenin signaling 
 
The main action of osteoblasts is the production of extracellular matrix. This 
includes Type 1 collagen, alkaline phosphatase and osteocalcin which, laid 
into resorption pits, is the starting point for newly formed bone (Katagiri and 
Takahashi 2002). Beside their anabolic role Osteoblasts also stimulate and 
regulate bone resorption through secretion of m-CSF, RANKL and OPG 






Osteocytes derive from the Osteoblast cell lineage and are the most 
abundant cells of bone. After a bone remodeling cycle osteoblasts transform 
either into bone-lining cells or osteocytes, encased in bone(Lorenzo et al. 
2011) (Fig. 1.5). 
For a long time osteocytes were thought to be physiologically inert. However 
more and more evidence shows the importance of osteocytes in bone 
metabolism. These cells not only monitor for mechanical stimulation, 
pressure changes and bone quality, they also orchestrate bone remodeling 
through secretion of crucial cytokines and proteins such as RANKL and 
Sclerostin. Further products are Fibroblast growth factor 23 (FGF23) and 
Dentin matrix acidic phosphoprotein 1 (DMP1), which are regulators of 
phosphate and mineralization metabolism. DMP1 also serves as marker of 
osteocyte viability and activity (Bonewald 2011;Lorenzo et al 2011).   
1.2.4 Chondrocytes 
Chondrocytes are the first skeletal cells to appear during embryogenesis. 
Chondrocytes are derived from mesenchymal stem cells and mature into 
cells able to secrete extracellular matrix.  Chondrocytes produce cartilage 
which mainly consists of type II and type X collagen and proteins such as 
elastin and aggrecan (Karsenty and Wagner 2002). The crucial transcription 
factor for chondrocyte maturation is sex determining region Y (SRY)-box 9 
(Sox9) (Bi et al. 1999). Sox9 promotes chondrocyte differentiation and 
expression of aggrecan and Type II collagen. Sox 5 and Sox6, also 
belonging to the HMG box class DNA binding proteins, bind to Sox 9 and 
enhance its function. All three Sox proteins also inhibit chondrocyte 
hypertrophy, which is the final stage of a chondrocyte life. In contrast, 
RUNX2, the crucial transcription factor for osteoblastogenesis, stimulates 
chondrocyte hypertrophy. These hypertrophied cells are able to express 




development and hence attracting haematopetic and osteoprogenitor cells for 
bone formation and development (Karsenty & Wagner 2002). 
 
1.3 Osteogenesis 
Skeletal morphogenesis consists of two types of bone development, 
endochondral ossification and intramembranous ossification. 
 
1.3.1 Endochondral ossification 
Endochondral ossification is the differentiation of osteochondral progenitor 
cells into chondrocytes, which form a cartilage template that transforms into 
bone.  A schematic illustration of endochondral ossification is shown in 
Figure 1.7. During embryonic development the initial stage for axial skeleton 
and long bones is hyaline cartilage.  Mesenchymal stem cells differentiate 
into chondrocytes and bone formation initially occurs at the primary 
ossification centre where chondrocytes become hypertrophic and secrete 
matrix molecules that help recruiting bone cell precursors and angiogenic 
factors such as VEGF (Vascular Endothelial Growth Factor). These factors 
promote the invasion of blood vessels, bone cells and the apoptosis of 
chondrocytes. Recruited osteoclasts resorb cartilage matrix and osteoblasts 
initially form osteoid and woven bone, which undergoes repeated 
remodelling. Subsequently secondary ossification centres are formed which 
are separated from primary ossification sites by growth plates (epiphyseal 
plates). Growth plates consist of longitudinal columns of chondrocytes which 
are organized in distinct zones, separated according to their different 
functional state. Chondrocytes in growth plates undergo rapid proliferation 
and drive the expansion of primary and secondary ossification centres which 
allows bone to lengthen. Once bone growth is completed epiphyseal and 
metaphyseal bone fuse and transforms into finalized adult bone. Remaining 
chondrocytes at both ends of long bones form the articular cartilage (Mackie 






Figure 1.7 Schematic illustration of different stages of endochondral 
ossification (adapted from: https://classconnection.s3.amazonaws.com/ 
274/flashcards/1202274/jpg/2807224_dyn1329428793213.jpg) 
 
1.3.2 Intramembranous ossification 
Flat bones which mainly derive from the neural crest are primarily formed by 
intramembranous ossification. Mesenchymal cells which are grouped in 
nodules differentiate in either osteoblasts or endothelial cell precursors. The 
presence of endothelial cells allows the formation of blood vessels whereas 
mature osteoblasts produce osteoid which gets mineralized into first bone. 
The bone formation occurs in a centrifugal way, which means ossification 
radiates out from a central point, leaving the proliferating and most immature 
cells at the periphery. Various bone spicules eventually fuse and form a 
disorganised mesh of bone matrix, which appears ‘woven’ under the light 
microscope. Woven bone undergoes repeated remodelling to finally 










Mineralization of the matrix strengthens the collagen composite, increases 
mechanical resistance and acts as source of calcium, phosphate and mineral 
homeostasis. In order to achieve a solid phase of hydroxyapatite, complex 
biochemical processes are involved. As the concentration of calcium and 
phosphate is too low in extracellular fluids to form apatite crystals, matrix 
vesicles are formed out of plasma membranes from chondrocytes and 
osteoblasts. Calcium ion channels and calcium binding lipids facilitate 
calcium influx into matrix vesicles, resulting in a high intra-vesicular Calcium 
concentration. Additionally various phosphatases cleave phosphoester 
substrates to increase inorganic phosphate (Pi) concentration within and 
outside matrix vesicles. The first stage of mineralization is driven by high 
concentrations of calcium and inorganic phosphate in matrix vesicles which 
are stored as hydroxyapatite. Hydroxyapatite crystals are then  secreted into 
extracellular space and to cluster around matrix vesicles which initiates the 
second stage of mineralization. Various mineralization points fill space 
between collagen fibrils and amalgamate until the bone matrix is fully 
mineralized.  The mineralization process is regulated by various factors 
including calcium and inorganic phosphate concentrations and mineralization 
inhibitors such as pyrophosphate, matrix gla protein and osteopontin. Various 
osteoblast derived matrix vesicle proteins regulate mineralization by 
influencing extracellular inorganic phosphate concentrations  including , 
tissue non-specific alkaline phosphatase (TNAP), a nucleotide 
pyrophosphatase/phosphodiesterase isozyme (NPP1) and ANK gene 
product(Houston et al. 2004;Rosen CJ 2013).  PHOSPHO-1,a  phosphatase 
which cleaves phosphoethanolamine (PEA) and phosphocholine in order to 
generate inorganic phosphate has been shown to play an important role in 
initiating matrix mineralization. PHOSPHO-1 increases inorganic phosphate 
concentrations inside matrix vesicles where the first steps of mineralization 




of calvaria in mouse models (Houston, Stewart, & Farquharson 2004;Roberts 
et al. 2007).  
 
1.4  Bone Remodeling Unit  
Bone is metabolically active and is frequently renewed through a combination 
of bone resorption and bone formation. It has been estimated that every year 
5-10% of bone in an adult skeleton is replaced by new bone. Bone 
remodeling occurs continuously in trabecular and cortical bone at 
microscopic small remodeling  foci called basic multicellular units (BMU).The 
remodeling process allows adequate response to micro damage and different 
mechanical loading (Lorenzo et al. 2011). Bone Remodeling consists of bone 
resorption, reversal and formation as shown in Figure 1.8 and discussed 
below. 
1.4.1 Bone resorption 
Bone resorption is initiated by the digestion of a thin layer of non-mineralized 
matrix by enzymes (collagenase, MMPs and gelatinase) secreted by 
osteoblasts and bone lining cells (Suda et al. 1997). By-products from 
mineralized bone matrix such as TGF-β, type-I collagen and Osteocalcin are 
thought to attract quiescent osteoclast precursors (QuOPs) or mature 
osteoclasts to the site of micro-damage or mechanical stress (Rosen CJ 
2013;Suda et al. 1997). Osteoclasts get activated in the presence of RANKL 
and M-CSF and bind to the bone surface through   
adhesion receptors, such as vitronectin, fibronectin and type I collagen which 
are found on the exposed mineralised bone (Lakkakorpi et al. 1991). The 
resorption process by osteoclasts is described previously in detail in 1.2.1.2 
subsection.  
 
1.4.2 Cessation of resorption and reversal phase 
The resorptive process has to be terminated in order to allow the formation of 




what drives them into programmed cell death. I would like to mention a few 
theories about the initiation of apoptosis in Osteoclasts. Firstly we know that 
Osteoclasts phagocytise Osteocytes which have been shown to be the main 
producer of RANKL, the essential cytokine for Osteoclast activity and survival 
(Elmardi et al. 1990;Nakashima et al. 2011). Secondly, the amount on 
circulating Transforming growth factor- beta (TGF-β) increases with 
resorption of bone matrix and the cytokine gets activated by acidic PH. TGF-
β has been shown to promote osteoclast apoptosis (Hughes and Boyce 
1997).Lastly osteoclasts seem to auto-regulate themselves. It has been 
shown that RANKL induces the Interferon β (IFN β) gene in osteoclast 
precursors which introduces a negative feedback loop. Increased levels of 
IFN β further inhibit osteoclast differentiation by blocking RANKL induced c-
Fos expression which is an essential transcription factor for 
osteoclastogenesis (Takayanagi et al. 2002).  
After osteoclast apoptosis and termination of bone resorption mononuclear 
cells, mostly macrophage like cells, populate the resorption pits and remove 
organic residues. A thin layer of non-collagenous mineralized extracellular 
matrix- the cement line forms the boundary at which bone resorption 
terminates and new bone deposition starts (Everts et al. 2002;Lorenzo et al. 
2011).  
1.4.3 Bone formation 
Normally bone resorption and bone formation are orchestrated in such way 
that there is a balance between the amount of bone removed during 
resorption and that replaced by formation. This coordinated process is called 
coupling. In order to initiate bone formation osteobalsts and their precursors 
have to be recruited to the site. Bone resorption releases chemo tactic 
factors such as Insulin like growth factor-I (IGF I) and TGF β which attract 
bone forming cells to the resorption pit. Subsequent differentiation and 
activation of Osteoblasts is again mediated by factors released through bone 
resorption such as IGF I and II, FGF, TGF β, BMP and Platelet derived 




Once Osteoblasts have arrived at the resorption lacuna and have 
differentiated into mature cells they start to build bone. Initially mature 
osteoblasts secrete type I collagen, Osteocalcin and Alkaline Phosphatase 
(ALP), which altogether forms unmineralized bone matrix or osteoid (Long 
2012). ALP promotes matrix maturation and mineralisation by breaking down 
pyrophosphate,an inhibitor of the mineralisation.  Furthermore Osteoblasts 
assist this process by secreting matrix vesicles containing Calcium, 
Phosphate and phospholipids which allows hydroxyapatite formation and 
hence mineralisation of osteoid. I’ve described the mineralization process in 
more detail in 1.3.3 subsection. The resulting end product is mineralized rigid 
bone (Katagiri & Takahashi 2002).  
Bone formation is terminated by a multitude of mechanism. The secretion of 
Sclerostin (SOST) by Osteocytes certainly plays a crucial role. SOST acts on 
two maturation points of osteoblast formation. It inhibits the transition from 
pre-osteoblast into osteoblasts and promotes the differentiation from mature 
osteoblasts into bone lining cells (Sutherland et al. 2004). Beside bone lining 
cells, at the terminal stage a subset of osteoblasts gets encased in bone 
matrix and become osteocytes and the remaining cells will undergo 
apoptosis.  
 The completion of the bone formation leads to the resting phase with bone 
covered by quiescent bone lining cells until the next bone remodelling cycle 










Figure 1.8. Bone Remodeling Unit Microdamage induces Osteoclast 
activation in order to resorb the damaged bone. Osteoclasts are driven into 
apoptosis and osteoblasts are activated to initiate new bone formation. 
Osteocytes regulate and coordinate bone remodelling through regulation of 
osteoblasts and osteoclasts. Newly formed osteoid undergoes mineralisation 
in order to form rigid bone, which then will be covered by inactivated 






1.5 OPG/RANKL/RANK system 
1.5.1 RANKL 
Observations during the early 80s noted that the presence of osteoblast or 
osteoblast-conditioned medium are essential for osteoclast differentiation.  
Fifteen years later Receptor activator of nuclear factor–κB ligand (RANKL) 
was identified as the key mediator for osteoclast proliferation and 
differentiation. It was first described as OPG ligand or osteoclast 
differentiation factor (ODF) (Lacey et al. 1998) and it was quickly established 
that this cytokine is identical to TRANCE (TNF-related activation induced 
cytokine) (Lacey et al. 2012;Wong et al. 1997) which we now know as 
RANKL. 
RANKL belongs to the TNF-alpha receptor superfamily and occurs in two 
forms: the 40-45kDa cellular membrane bound which is expressed by 
osteocytes, preosteoblasts and stromal cells and the 31kDa soluble cytokine.  
Recent studies demonstrated that RANKL is expressed to a large extent by 
osteocytes which are chief regulators of osteoclast differentiation (Nakashima 
et al. 2011). However multiple other cells like osteoblasts, endothelial cells, 
mesenchymal cells, chondrocytes (Bonewald 2011) and importantly also 
activated T lymphocytes and immature CD4/CD8 have been found to 
produce RANKL (Kong et al. 1999a;Suda et al. 1997). RANKL activates the 
signaling receptor RANK and stimulates together with M-CSF osteoclast 
precursors into differentiation of mature osteoclasts with bone resorbing 
activity (Lorenzo et al. 2011). RANKL also acts on T-cells and activates c-Jun 
(JNK kinase) on T-cells, promotes t-cell proliferation and plays a key role in 
lymphocyte development and lymph node organogenesis (Kong et al. 
1999b;Lorenzo  et al. 2011). RANKL knock out mice have severe 
osteopetrosis, retardation of T- and B cell development, impaired tooth 
eruption and lymphogenesis and underdeveloped mammary glands (Dougall 




Inflammatory mediators such as TNF α and IL1 can stimulate  
osteoclastogenesis either directly through a enhanced response of 
osteoclasts to RANKL and indirect by increased expression of RANKL on 
dendritic cells and T-cells (Lorenzo et al. 2011). More detailed explanation 
about the interaction of inflammatory cytokines and RANKL/OPG pathway is 
given in the section 1.7.  
1.5.2 RANK 
The receptor activator of nuclear factor-κB (RANK) is a 616-amino acid signal 
peptide with a N-terminal extracellular, short transmembrane and a large C-
terminal cytoplasmic domain. RANK is a signalling receptor expressed on the 
surface of osteoclast progenitors, mature osteoclasts, chondrocytes, dendritic 
cells, endothelial cells, smooth muscle cells and T and B lymphocytes and 
various malignant cells (Hsu et al. 1999;Lacey, Boyle, Simonet et al. 2012; 
Min et al. 2003). In vivo studies confirm the crucial importance of RANK in 
bone homeostasis as RANK knock out mice develop severe osteopetrosis 
due to an absence of osteoclasts (Dougall et al. 1999).  
Mutations in the signal peptide region of RANK protein can lead to increase 
of RANK translation products leading to increased RANK signaling. Clinical 
consequences of these mutations are seen in familial expansile osteolysis 
which is an autosomal dominant disorder leading to increased fracture risk 
secondary to focal areas of enhanced bone resorption and familial Paget’s 
Disease of Bone which is characterized by areas of increased bone turnover 
which cause bone pain and increased fracture risk (Hocking et al. 2000) 
(Khosla 2001).  
1.5.3 Osteoprotegerin 
Osteoprotegerin (OPG) was the first protein from the TNF receptor 
superfamily to be identified as crucial player in osteoclastogenesis. 
Interestingly OPG was discovered almost simultaneously by two research 
groups, Amgen (Simonet et al. 1997) and the investigators at the Snow 




factor) (Yasuda et al. 1998). In contrast to most members of the TNF 
receptor superfamily OPG exists only in soluble form. The protein consists of 
401 amino acids, one end of OPG contains a cysteine rich domain which is 
the ligand binding site, the other end has a carboxy terminal domain. The 
structure of OPG reminds of the “structure of decoy receptors which are 
encoded by certain virulence genes of poxviruses” (Khosla 2001;Lacey et al. 
2012). OPG is expressed by osteoblasts and acts as soluble decoy receptor 
for RANKL. The high affinity binding between RANKL and OPG prevents the 
stimulation of the RANK receptor and therefore inhibits osteoclast 
differentiation. Hence OPG is a potent inhibitor of osteoclast maturation and 
activation (Simonet et al. 1997;Yasuda et al. 1998). OPG mRNA was found 
in multiple tissues including lungs, kidney heart, thyroid and brain though its 
role in these tissues remains largely unknown (Khosla 2001). OPG knock out 
mice develop early onset osteoporosis (Bucay et al. 1998) but also marked 
vascular calcification, which demonstrated functional activity of OPG outside 
bone. Transgenic mice overexpressing OPG develop severe osteopetrosis 
(Yasuda et al. 1998) . 
In physiological conditions the ratio between RANKL and OPG is such that 
bone resorption and formation is balanced. Increased secretion or expression 
of RANKL leads to excessive bone resorption as seen in oestrogen 
deficiency (Eghbali-Fatourechi et al. 2003), through prolonged glucocorticoid 
administration (von Tirpitz et al. 2003); in malignancies such as multiple 
myeloma and bone metastases (Michigami et al. 2001); and in various 
inflammatory autoimmune diseases (Lorenzo et al. 2011). Further details 
about the role of OPG/RANKL system in rheumatic diseases are given below 
under the section “Mechanism of bone loss in rheumatic diseases”.  
 
The clinical importance of OPG/RANKL/RANK triad is demonstrated by the 
successful introduction of Denosumab a monoclonal Ab against RANKL as a 




Osteoporosis treatment in women with postmenopausal osteoporosis and in 
patients with metastatic cancer (Cummings et al. 2009;Lacey et al. 2012). 
1.5.4 Osteoprotegerin autoantibodies 
In 2009 Riches and colleagues (Riches et al. 2009) described a 40-year-old 
who presented with a low trauma fractures and severe osteoporosis (lumbar 
spine T score of -6.6). The patient was diagnosed with coeliac disease, 
hypothyroidism and severe high bone turnover osteoporosis. He was found 
to have markedly elevated bone turnover markers (Urinary deoxypyridinoline, 
Alkaline phosphatase) but serum osteoprotegerin and RANKL levels within 
normal range.  
A bone biopsy (Fig 1.9) showed an increased number of osteoclasts and 
osteoblasts indicating high bone turnover. Despite the commencement of 
gluten free diet he continued to lose bone and sustained further low fragility 
fractures. The patient was investigated further and serum was obtained for 
experimental studies. Immunoprecipitation studies with the patient’s serum 
found the precipitation of osteoprotegerin  at 55 kD indicating the existence of 
antibodies to osteoprotegerin.  
These newly identified antibodies were tested further in functional studies 
and they were shown to block the inhibiting effect of OPG on RANKL. These 
results strongly point towards the existence of functional OPG antibodies 
which allowed excessive bone resorption and caused severe Osteoporosis. 
As biochemical and histological findings indicated high resorptive state the 
patient was treated with Zoledronic acid – a potent bisphosphonate inhibiting 
osteoclasts, which successfully restored his bone mineral density.   
 Further detectable autoantibodies to OPG were shown in three out of 15 
patients with Coeliac Disease and low bone mineral density but none were 







Figure 1.9  (adapted from Riches et al Brief Report(Riches, McRorie, Fraser, 
Determann, van't Hof, & Ralston 2009a)) A photomicrograph of the bone-
biopsy specimen, hematoxylin and eosin stained,shows an increase in the 
numbers of osteoclasts (red arrows) and osteoblasts (black arrows). 
 
A subsequent pilot study using the same immunoprecipitation assay as 
mentioned above was performed in order to detect OPG antibodies in other 
patients with autoimmune disease. The test population included 12 patients 
with celiac disease; 6 patients with RA and 5 patients with SLE .The study 
detected the presence of OPG autoantibodies in 3/15 patients with coeliac 
disease (20%) in 1/6 (16%) of patients with RA and 1/5 (20%) of patients with 
SLE (data not published). An independent Italian research group tested 30 
patients with Coeliac Disease for the presence of OPG antibodies using the 
immunoprecipitation assay described by Riches et al.(Riches et al. 2009). 
None of the patients were found to have detectable antibodies and the 
authors concluded that OPG antibodies may be a rare phenomenon and not 




2012). This data, though derived from a preliminary underpowered study, 
demonstrated the clear need for further large-scale investigations.  
1.6 Osteoporosis  
1.6.1 Definition 
The word Osteoporosis (osteo=bone poros=brittle, porous) derives from 
Greek and means “porous” bone.  Osteoporosis is defined by low bone 
mass, deterioration of microarchitectural bone structure and cortical porosity 
(Fig 1.10) leading to increased risk of fragility fractures particularly at hip, 
spine and lower forearm (Peck et al. 1993).  
 
 
Figure 1.10 Image courtesy of Tim Arnett, University College London 
The figure shows microscopic view of the 3rd vertebrae. The left panel shows 
normal trabecular bone , the panel on the right shows osteoporotic bone with 
thinning of the trabecular structure and pitting of the bone surface as a result 





Patients who sustain fractures, frequently require hospital admissions, 
surgical intervention and in some cases prolonged periods of rehabilitation. 
Fractures reduce quality of life and can cause serious disability. Hip fractures 
are particularly devastating as one fifth of elderly individuals who sustain a 
hip fracture will die the following year (Center et al. 1999) and 50% will not 
regain their previous level of mobility (Osnes et al. 2004). Individuals who 
sustain a hip fracture are at higher risk to sustain another fracture, have 
decreased quality of life including physical and mental health and are twice 
more likely to need residential care than individuals without fractures 
(Brenneman et al. 2006;Osnes et al. 2004;Sambrook & Cooper 2006).  
In contrast to hip fractures, vertebral fractures remain frequently undiagnosed 
as only about a third of patients who sustain a vertebral fracture will seek 
medical attention (Cooper et al. 1991;Cooper et al. 1992). The majority of 
vertebral fractures occur by simple bending or lifting up light objects and only 
a quarter of vertebral fractures are a result from a fall. Nevertheless vertebral 
fractures can have a severe impact on quality of life due to pain, decreased 
mobility and increased thoracic kyphosis(Sambrook & Cooper 2006). 
Having sustained a vertebral fracture increases the risk of a further vertebral 
fracture by 10 times (Lindsay et al. 2001;Melton et al. 1999) and non-
vertebral fractures (Black et al. 1999;Melton et al. 1999) significantly. Most 
patients who have suffered vertebral fractures are therefore considered to 
have osteoporosis and treatment of osteoporosis, even in the absence of 
osteoporotic BMD as defined by DXA, should be considered.(Scottish 
Intercollegiate Guidelines Network (SIGN) publication no.142 2015).  
Beside mortality and morbidity osteoporosis related fractures have a huge 
economic impact with an estimated cost of £4.3 billion per year in the UK 






1.6.2 Pathogenesis of Osteoporosis 
Pathogenesis of Osteoporosis is multifactorial. Increased skeletal fragility is 
frequently caused through a combination of the following factors: a) reduced 
bone formation and growth through childhood and adolescence which results 
in a skeleton with reduced peak bone mass (Sambrook & Cooper 2006) 
b)increased bone resorption leading to accelerated bone loss and 
c)inadequate bone formation in response to bone resorption which at a 
cellularlevel means imbalance between osteoclast and osteoblast activity 
(Raisz 2005). Bone mass usually peaks at the age between 20 and 45 and is 
influenced by gender, genetic factors, exercise, Calcium and Vitamin D 
intake, and environmental factors during intrauterine life(Sambrook & Cooper 
2006). 
The most frequent form of Osteoporosis is postmenopausal Osteoporosis 
which is to a large extent is caused by oestrogen deficiency after the 
menopause. A significant drop of oestrogen levels during the menopause, 
increases the secretion of pro-inflammatory cytokines such as IL1 and TNF, 
which subsequently promote RANKL production and enhance 
osteoclastogenesis.  Oestrogen deficiency also drives osteoblast apoptosis 
and hence reduces bone formation.  (Eghbali-Fatourechi, Khosla et al. 
2003;Sambrook & Cooper 2006). Oestrogen has also been shown to be 
important in maintaining bone health in men as reduced oestrogen levels are 
associated with accelerated bone loss in men  and animal models 
demonstrate that male mice lacking oestrogen receptor alpha (ERα) loose 
cortical bone excessively (Almeida et al. 2013;Khosla et al. 2011). 
 Another important factor for development of osteoporosis is old age. Age 
related bone loss starts gradually after the bone mass has peaked at 20-30 
years of age. The rate of bone loss increases exponentially at around 65 
years as bone resorption surpasses bone formation. Besides its effect on 
bone, age is the strongest risk factor for low fragility fractures and that is 




Riggs 2011). Other factors attributable to old age contribute to fracture risk 
such as reduced muscle strength and proprioception and reduced visual 
acuity. Other important factor in the pathogenesis of osteoporosis, which 
were traditionally classified as causes for secondary osteoporosis are 
summarised in Table 1.1.  
For most of these conditions the current SIGN recommendation is a DXA 
assessment  for patients over 50 in particular for patients with additional risk 
factors (Scottish Intercollegiate Guidelines Network (SIGN) publication 






Secondary causes of osteoporosis 
Rheumatological Rheumatoic Diseases as outlined in chapter 1.7 
Gastrointestinal Chron’s Disease, Ulcerative Colitis, Celiac 
Disease, steatorrhoea, blind loop syndrome 
Drugs Glucocorticoids, Anticonvulsants, 
Antidepressants, GnRH agonists, 
Medroxyprogesteron acetate 
Endocrine Disorders Hyperthyroidism, Hyperparathyroidism, Cushing’s 
Syndrome, Type I +II Diabetes, Hypercalciuria, 
use of HRT 
Respiratory COPD, Asthma 
Collagen defects Marfan Syndrome and Ehlers Danlos, 
Osteogenesis imperfecta 
Metabolic diseases Chronic renal disease, ckronic liver disease, 
Homocystinuria, Gaucher’s Disease and 
hereditary Haemochromatosis 
Infections Chronic Osteomyelitis, HIV infection 
Other Care or nursing home resident, Alcoholism, 
Vitamin D and Calcium deficiency 
Table 1.1 Secondary causes of osteoporosis in premenopausal women 
and men (adapted from uptodate website (www.uptodate.com) and Sign 142 
guidelines: Management of Osteoporosis and prevention of fragility 






1.6.3 Diagnosis of osteoporosis and fracture assessment 
The most commonly used method to diagnose osteoporosis is the 
assessment of bone mineral density (BMD) with dual-emission Xray 
absorptiometry (DEXA).The results are interpreted according to the World 
Health Organisation (WHO) guidelines. Osteoporosis is defined as a BMD 
more than 2.5 Standard Deviation (SD)  below the  mean of a  young adult 
reference and BMD more than 1 SD below the young adult mean has been 
classified as Osteopenia(Sambrook & Cooper 2006a) (Kanis et al. 1994). 
BMD is an important information for fracture risk assessment although there 
are several BMD independent risk factors, which need to be considered 
when diagnosing osteoporosis and decisions about treatment being made. 
Age is by far the strongest risk factor for fractures. Recently a Danish 
study(Rubin et al. 2013) showed that age alone is as good as other tools 
such as OST(Richy et al. 2004), FRAX (Kanis et al. 2008), and ORAI score 
(Cadarette et al. 2000) in predicting fracture risk.  
1.6.3.1 FRAX 
The World Health Organisation developed  FRAX, a fracture prediction tool 
(Kanis et al.1994;Kanis et al. 2008) which is a freely available  web-based 
tool (www.shef.ac.uk/FRAX/index.aspx), shown in Figure 1.11. 
FRAX encompasses risk factors such as low body mass index (BMI), history 
of fracture, glucocorticoid use, family history of fracture, cigarette smoking, 
excessive alcohol intake and the presence of conditions, which predispose to 
secondary osteoporosis. FRAX calculates through multivariate analysis a 10- 
year hip and major osteoporotic fracture probability. In contrast to other tools 
FRAX gives the option to include Femoral Neck BMD into the fracture risk 
calculation which is undoubtedly valuable information to add to fracture risk 
prediction. Furthermore FRAX gives also treatment threshold 
recommendations based on the fracture probability and health economic 
calculations (Kanis et al. 2008;Sambrook & Cooper 2006). This approach 
results in relative underestimation of fractures compared to other tools such 




of dichotomous data entry for various risk factors and the secrecy around the 
algorithm used which limits external validation attempts (Scottish 
Intercollegiate Guidelines Network (SIGN) publication no.142 2015). 
,  
Figure 1.11 Screenshot of FRAX tool ( www.shef.ac.uk/FRAX ) 
 
1.6.3.2 QFracture 
Another frequently used fracture risk prediction tool in the UK is QFracture 
(http://www.qfracture.org/index.php). QFracture is a tool developed on data 
from GP databases from England and Wales. The initial online risk scoring 
tool was based on 2.2 million of patients and underwent external validation 
by the use of data from another 2.2 million individuals. Q fracture allows 
prediction of hip and other major osteoporotic fractures, which include 
fractures of spine, wrist, hip and shoulders. A comparison of the two most 




shown in Table 1.2(Scottish Intercollegiate Guidelines Network (SIGN) 
publication no.142 2015). 
The benefits of QFracture over FRAX are the fact that QFracture has been 
extensively validated in the UK, it can be applied to a wider age group (from 
30-100 years), it allows risk prediction from 1-10 years, and the algorithm 
used is freely available so that further validation studies can easily be 
done.Clearly the weakness is that it doesn’t take BMD in account which is 
one of the single strongest fracture risk predictors. Therefore QFracture 
assessment should be performed prior to DXA scan assessment and may 
help to decide if DXA assessment is necessary or not(Scottish Intercollegiate 
Guidelines Network (SIGN) publication no.142 2015).  A comparison of 
included risk factors considered by FRAX and Q-fracture is shown in 
Table1.2.  
1.6.3.3 Other fracture risk tools 
Garvan fracture risk prediction tool 
(http://www.garvan.org.au/promotions/bone-fracture-risk/calculator/) is a 
simpler tool taking only age, gender, fall and fracture history and BMD into 
account. Another tool based on age sex and femoral neck BMD is CAROC 
(Canadian Association of Radiologists and Osteoporosis Canada).  A few 
studies have outlined that simpler tools such as Garvan have similar 
discriminative ability for hip and osteoporotic fractures compared to more 
complex tools such as FRAX (Bolland et al. 2011) and QFracture (Bolland et 
al. 2013). In summary, there is no consensus as to which fracture risk 
prediction tool to use in every day practice. These tools depend on 




1.6.4 Bone turnover markers 
There are also several biochemical markers of bone turnover available, 
mostly useful for prediction and monitoring treatment response and 
investigating pathogenetic mechanisms of osteoporosis. To some extent 
these markers are also useful in fracture prediction (Sambrook & Cooper 
2006).The bone resorption markers, urinary C-telopeptide, cross-links of 
collagen type I (CTX) and free urinary deoxypyridinoline have been shown to 
predict fractures independently of BMD as has the  bone formation marker 







Risk factor FRAX QFracture 
Age √ √ 
Sex √ √ 
Weight √ √ 
Height √ √ 
Ethnicity x √ 
Previous fracture √ √ 
Parental history of hip 
fracture √ √ 
Smoking √ √ 
Alcohol √ √ 
Menopausal symptoms x √ 
Epilepsy (or use of 
anticonvulsants) x √ 
Cardiovascular disease x √ 
History of falls x √ 
Use of glucocorticoids √ √ 
Use of antidepressants x √ 
Bone mineral density 
(femoral neck T-score) √ (optional)  
Secondary 
osteoporosis 
Binary yes/no choice Divided into multiple 










   
Table 1.2 Risk factors included in FRAX and QFracture algorithms 
(adapted from 142 SIGN guidelines: Management of Osteoporosis and 
prevention of fragility fractures(Scottish Intercollegiate Guidelines Network 






1.7 Mechanism of bone loss in inflammatory arthritis 
1.7.1 Introduction 
As mentioned previously bone undergoes continuous remodeling and 
restructuring in order to maintain its strength and function. In healthy 
individuals, a precisely coordinated process of bone resorption and formation 
allows the repair of damaged bone and the rejuvenation of old bone. In 
patients with inflammatory rheumatic diseases the balance between bone 
resorption and bone formation gets disrupted. Rheumatoid Arthritis (RA), 
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) and Systemic Lupus 
Erythematosus (SLE) present clinically distinctively different. Rheumatoid 
Arthritis is characterized by chronic inflammation with a predilection for the 
small joints of hands and feet which frequently leads to localized bone loss in 
form of bone erosions and cartilage and joint destruction. Ankylosing 
Spondylitis is a Spondyloarthropathy and is characterized by chronic 
inflammation of the spine presenting in form of spinal pain and stiffness. The 
inflammatory process in AS promotes localized increased bone turnover 
resulting in extra bone formation in form of syndesmophytes, which leads to 
fusion of vertebral bodies and increased rigidity of the spine. Psoriatic 
Arthritis also belongs to the seronegative spondyloarthropathies and one of 
its manifestations (arthritis mutilans) can lead to localized osteolysis and 
severe localized bone destruction. Systemic bone loss in Psoriatic Arthritis 
however does not seem to differ greatly from the general population, 
although there is too little data available to draw definite conclusions. 
Although localized bone involvement in Systemic lupus erythematosus is not 
prominent, generalized bone loss in form of osteoporosis and increased 
fracture risk is a substantial burden of SLE. In view of the variety of clinical 
manifestations and bone involvement I would like to summarize the 




differences and common features of RA, AS, PsA, SLE and other rarer 
Rheumatic Diseases 
 
1.7.2 Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) is a common inflammatory arthritis affecting about 
1% of the population. RA is characterised by chronic synovial inflammation of 
small and midsized joints, which is associated with chronic pain, stiffness and 
functional impairment. The natural history of the disease is progressive 
articular damage and functional disability. Systemic complications such as 
extra-articular manifestations of the cardiopulmonary and nervous system 
reduce life expectancy of RA sufferers by 7 years.  
The cause of RA remains uncertain. The aetiology is thought to be an 
interplay between genetic predisposition (HLA-DR allele subtypes), 
immunological dysregulation and environmental factors (Burmester G et al. 
2012). 
1.7.2.1 Osteoporosis risk 
Amongst rheumatic diseases, the largest pool of evidence for accelerated 
systemic bone loss lies with Rheumatoid Arthritis (Roux 2011). 
Postmenopausal women with RA are at twofold risk of developing 
osteoporosis compared to healthy controls (Haugeberg et al. 2000a;Hauser 
et al. 2014) and men over 45 with RA have significantly reduced Hip BMD 
compared to healthy controls (Haugeberg et al. 2000b;Hauser et al 2014). 
Studies that analysed the data from Oslo registrar more than a decade ago 
detected that the overall prevalence of hip osteoporosis in pre- and 
postmenopausal women with RA was around 15%. Interestingly this figure 
has not changed greatly over the last 15 years despite the changes in RA 
assessment and treatment (Haugeberg et al 2000a;Hauser et al. 
2014;Smolen et al. 2010). Disease-specific characteristics which were 
identified most commonly as risk factors are immobility and high Health 




inflammation, glucocorticoid use and Rheumatoid Factor (RF) seropositivity 
(Haugeberg et al. 2000a;Roux 2011). The impact and mechanism of these 
risk factors are discussed below.  
Although generalized bone loss is a well-recognized complication of RA, 
there are currently no guidelines or recommendations as to when RA patients 
should be screened for osteoporosis. In order to better target DXA screening 
of patients with RA prediction tools have been developed (Haugeberg et al. 
2002a;LEMS and DIJKMANS 1998). These tools are using largely arbitrarily 
chosen variables including age, weight, inflammation, immobility and steroid 
use. Our group has recently developed a simple tool (Osteoporosis 
Prediction in Rheumatoid Arthritis- OPRA) based on age, gender and BMI. It 
detects most patients at risk of osteoporosis (91.4% sensitivity) but at a cost 
of relatively low specificity (38.2%).The development of this osteoporosis risk 
prediction tool is shown in chapter 3. 
1.7.2.2 Fracture risk 
Large case control studies have shown that RA patients have an increased 
fracture risk, which is exacerbated by the use of corticosteroids (van Staa et 
al. 2006). A recent study showed that particularly young women with RA 
have an elevated fracture risk (OR 4.3 (95 CI %, 2.4–7.8) when compared to 
healthy controls. This is unlikely a reflection of low BMD as for individuals 
under 45 years of age there is little difference between BMD in RA and the 
healthy population.(Hauser et al 2014). Rather, this points more towards 
other risk factors of fractures such as decreased bone strength due to 
decreased bone mineral content, altered bone geometry or mass distribution, 
sarcopenia and functional disability.  
Amongst the fracture risk assessment tools FRAX 
(http://www.shef.ac.uk/FRAX) and  Q-fracture 
(http://www.qfracture.org/index.php) have incorporated RA as general risk 
factor. FRAX has several limitations as it doesn’t take into account vertebral 




et al. 2015). Q-fracture on the other hand includes history of falls and 
vertebral fractures but does not take into account BMD, a measure that has a 
strong association with fracture risk. Although we know that the impact of 
reduced BMD changes significantly with age, ultimately the diagnosis and 
treatment of OP are largely based on BMD result (Sambrook & Cooper 
2006).  There is currently no consensus as to which fracture risk assessment 
tool is the most appropriate for patients with Rheumatoid Arthritis. Further 
external validation of different tools is required. 
1.7.2.3 Pathogenesis 
RA is characterized by joint swelling in form of synovial inflammation and 
cartilage and bone destruction leading to erosions, joint deformity and 
generalised osteopenia.  A summary of cell types and mediators involved in 
the inflammatory process and their interaction with osteoclasts is shown in 
Figure 1.12. 
Inflammation of the synovium promotes localized production of pro-
inflammatory cytokines, attracting lymphocytes and macrophages to the 
synovial lining and stimulating endothelial cells in synovial microvessels. The 
inflammatory infiltrate stimulates fibroblast activity leading to synovial 
hypertrophy and pannus formation (Braun and Sieper 2007;McGonagle et al. 
2007;McInnes and Schett 2011). The presence of myeloid cells and 
plasmacytoid dendritic cells that express HLA class II molecules, pro-
inflammatory cytokines and their interaction with T cell and B cell propagate 
chronic inflammation. It also promotes the differentiation of myeloid cells into 
macrophages and osteoclasts which have the potential to destroy tissue 
through the release of matrix degrading enzymes. 
 Amongst the T cell subsets Th1 and Th2 cells have been shown to suppress 
osteoclastogenesis through the expression of cytokines which inhibit 
osteoclastogenesis (IFN-γ and IL-4) (Takayanagi et al. 2000;Takayanagi 
2007). On the other hand  T-helper 17 (Th17) cells were found to be of 
crucial importance in the pathogenesis of inflammatory arthritis (McInnes & 




2006), which promotes osteoclast activation and differentiation.   TH17 cells 
promote osteoclastogenesis indirectly through IL17 production, which 
stimulates the secretion of pro-osteoclastogenic cytokines as described 
below (Sato et al. 2006). Experiments in murine models showed that 
blockade of IL17A results in reduced localized and systemic bone loss 
(Zwerina et al. 2012). Surprisingly clinical studies did not find an increase of 
TH17 circulating cells in RA patients compared to controls (Yamada et al. 
2008).  
Further T cell subset of interest are regulatory T cells (T reg) expressing 
cytotoxic T-lymphocyte antigen– 4 (CTLA-4). Despite their capacity to 
express RANKL the presence of T reg is associated with potent osteoclast 
suppression.  Zaiss et al. (Zaiss et al. 2007) recognized that the suppression 
is dependent on cell to cell contact and is largely a result of interaction of 
CTLA-4 with CD80/CD86 on osteoclast precursors and is independent of 
RANKL/OPG pathway. CTLA-4 was also shown to supress RANKL – and 
TNF mediated osteoclastogenesis independently of T cells (Axmann et al. 
2008).  Recent findings provided more insight into the molecular mechanism 
of   CTLA-4 influencing bone resorbing cells. The engagement of CD80 and 
86 activates the enzyme indoleamine 2,3- dioxygenase which triggers 
tryptophan degradation  promoting osteoclast precursor apoptosis(Bozec et 
al. 2014).Furthermore  Komatsu et al found that Forkhead box protein P3 
(FOXP3) is a transcription factor of T reg cells and is essential for their  
osteoclast suppressive function . In mouse models with inflammatory arthritis, 
T reg cells were found to have reduced or absent FoxP3 expression which 
allowed a transformation of T reg cells into Th17 cells, a process which 
exacerbates inflammation and boosts osteoclastogenesis (Komatsu et al. 
2014).  
Abatacept (Orencia; Bristol-Myers Squibb), a cytotoxic t-lymphocyte protein-4 
Immunoglobulin (CTLA4–Ig) is a chimeric protein that acts as T-cell co-
stimulation modulator. Abatacept is a licensed biologic therapeutic in 




Abatacept is of great interest to the bone field. Abatacept was shown to 
suppress the development of erosions and structural damage in RA potently 
(Genant et al. 2008;Westhovens et al. 2009) and to reduce bone loss in a 
murine model of hyperparathyroidism (Bedi et al. 2010). However to date 
there’s no data of the effect of Abatacept on systemic bone loss in humans 
but a study looking into Abatacept and its effect on BMD is ongoing (Coy et 
al. 2014). 
 
The clinical success of B-cell depletion in RA in preventing erosions and joint 
destruction provides strong evidence for the important role of B-cells in RA 
pathophysiology (Tak et al. 2011). In the field of osteoimmunology it is 
occasionally difficult to distinguish the immunosuppressive effects from bone 
protective properties of a drug. However B lymphocytes express RANKL and 
it has been shown that ovariectomy in mice induces the proliferation of 
RANKL expressing B cells (Kanematsu et al. 2000).  Onal et al. (Onal et al. 
2012) showed that ovariectomized mice lacking B cell mediated RANKL 
expression had reduced bone loss in comparison to T-cell dependent RANKL 
knock out mice with unchanged bone loss. Another mechanism why anti-
CD20 therapy successfully inhibits bone damage might be the reduction of 
Immunoglobulin producing plasma cells. Immunoglobulins have recently 
been shown to directly interact with bone cells in specific with osteoclasts 
(Harre et al. 2012;Hauser et al. 2015) and I will elaborate on autoantibody –
mediated bone loss in following section. Interestingly activated B cells have 
also been shown to produce Osteoprotegerin and μMT heavy chain-deficient 
mice which lack mature B-cells have been found to be osteoporotic (cortical 
bone) and deficient in OPG. These findings could be reversed by B –cell 






1.7.2.4 Mediators of bone loss in RA 
1.7.2.4.1  RANKL  
RANKL is together with M-CSF an essential cytokine for osteoclastogenesis 
and has been found in abundance in the hypertrophied synovium. The ability 
of synovial fibroblasts to produce RANKL is thought to be one of the crucial 
factors in the localized increase of osteoclastogenesis (Lorenzo et al.2011). 
Although Osteocytes were recently identified as the prime source of RANKL 
in the bone microenvironment (Nakashima et al. 2011) many other cell types 
have the ability to produce RANKL. In rheumatic diseases inflammatory cells 
(Kong et al. 1999a) in particular TH 17 cells (Sato et al.2006) are further 
sources for RANKL production. Inflammatory cytokines such as IL1, TNF-
alpha and PGE2 upregulate RANKL production in osteoblasts and synovial 
fibroblasts and promote differentiation of OC precursor cells (Lorenzo et al. 
2011). The crucial role of RANKL or OPGL for the development of 
osteopenia and bone destruction was demonstrated by Kong et al. (Kong et 
al. 1999a) who showed that RANKL knock out in a T cell dependent arthritis 
model in rats prevents bone erosions and systemic bone loss but does not 
impact on inflammation. The same group also showed that the destructive 
effect of T-cell mediated osteoclastogenesis can be attenuated by RANKL 
blockade through OPG.   Further murine models with T cell independent 
arthritis and RANKL knock out demonstrated that animals lacking RANKL do 
not form osteoclasts and have a severe osteopetrotic phenotype. Similar 
findings were made in humans who lack RANKL due to a mutation at 
TNFSF11, the gene encoding RANKL. These individuals develop severe 
osteoporosis due to lack of osteoclasts (Sobacchi et al. 2007) (Pettit et al. 
2001). Cohen et al showed that blockade of RANKL with Denosumab not 
only reduces systemic bone loss but also attenuates the formation of peri-
articular erosions, which is in line with previous findings of RANKL blockade 




1.7.2.4.2 Pro-inflammatory cytokines  
The inverse relationship between inflammatory markers and bone mineral 
density (Gough et al. 1994b) and bone resorption markers (Gough et al. 
1994b) in patients with RA shows that inflammation is a crucial driver of 
accelerated bone loss and even in a general population a small increase in 
CRP is associated with significantly increased fracture risk (Schett et al. 
2006).  
Early aggressive control of inflammation and immunosuppression in patients 
with RA does not only prevent bone erosions but is also thought to improve 
general bone health as demonstrated by reduced bone resorption markers 
and stable hip and spine bone density measures in RA patients who were 
tightly controlled and treated with anti-TNF early on in the disease(Guler-
Yuksel et al. 2009).  
IL1 
The IL1 superfamily includes IL1α, IL1β, IL18 and IL33. In RA IL1α and  IL1β 
are expressed in abundance in the synovial membrane by synoviocytes, 
monocytes and macrophages, B cells and chondrocytes (McInnes and Schett 
2007). IL1 promotes osteoclastogenesis as it induces RANKL and RANK 
expression in mesenchymal cells and promotes the differentiation of pre-
osteoclasts into mature osteoclasts. Although IL1 has been shown to be a 
crucial cytokine for arthritis related bone loss in animal models IL1 receptor 
blockade in humans with Rheumatoid Arthritis has been disappointing and is 
currently not used as RA treatment (Schett & Gravallese 2012).  
 
IL6 
In contrast to IL1, IL6 blockade has been shown to be an effective strategy to 
counteract inflammation and the development of bone erosions in patients 
with RA (Smolen et al. 2008). IL6 is over-expressed in the inflamed synovium 




synovial fluid of these patients. Many inflammatory cells including 
macrophages, osteoblasts and T-cells have the ability to express IL6 (Holt et 
al. 1996;Schett & Gravallese 2012). There is also data demonstrating that 
osteoclast like cell cultures which derive from pagetic bone  produce 
substantial quantities of IL6, attributing an autocrine function to IL6 (Hoyland 
et al. 1994) . However we don’t know about the role of osteoclasts in IL6 
production in rheumatic diseases. Interestingly the addition of IL6 to murine 
and human osteoclast cell cultures inhibits osteoclastogenesis (Duplomb et 
al. 2008) however in the setting of inflammatory arthritis IL6 is thought to 
have a pro-osteoclastogenic effect mediated by increased RANKL production 
by osteoblasts and by direct stimulation of osteoclast precursors through 
gp130 signalling (Schett & Gravallese 2012).  The use of Tocilizumab over a 
1 year period in a RA cohort was also associated with a mild increase of 
BMD in patients with underlying osteopenia (Kume et al. 2014). 
TNF 
TNF is expressed by a variety of cells involved in the inflammatory cascade 
in RA including monocytes, macrophages and mast cells, T and B cells, 
synovial fibroblasts and osteoblasts (McInnes & Schett 2007). 
TNF also enhances osteoclastogenesis by promoting RANKL expression and 
by inducing expression of receptors on the surface of monocytes and 
osteoclast precursors that are important co-stimulatory signals. Herman et al 
found on peripheral blood monocytes of RA patients increased expression of 
OSCAR, which is a member of the leucocyte receptor complex and is 
associated to ITAM harbouring molecules FcyR and DAP12. Stimulation of 
OSCAR is an important co-stimulatory signal cytokine independent of OC 
differentiation.  TNF-alpha was found to increase the expression of OSCAR 
in CD14 + RA monocytes markedly. (Herman et al. 2008). TNF also 
suppresses bone formation by increasing Dickkopf-1 and Sclerostin 
expression, which are potent inhibitors of the Wnt signalling pathways and 




The introduction of biological treatment which targets TNF has revolutionized 
the field of Rheumatology not only because of its rapid and potent 
suppression of inflammation but also its ability to suppress localized and 
systemic bone loss efficiently. Biologically engineered antibodies blocking 
TNF-α (Haugeberg et al. 2009;Lipsky et al. 2000;Vis et al. 2006)  were 
shown to reduce accelerated bone loss and the formation of  bone erosions, 
bringing joint damage to almost complete halt which boosts optimism to be 
able  “to cure  RA” in future. 
IL17 
 An example for indirect stimulation of osteoclastogenesis is the lymphokine 
IL17, a product of mast cells and Th17 cells, which are found in abundance in 
the inflamed synovium. IL17 potently induces RANKL expression in synovial 
fibroblasts and osteoblasts and stimulates innate immune cells to express IL1 
and TNF, as described above (Takayanagi 2009). Anti IL17 blockade not 
only suppress inflammation and the expression of pro-inflammatory cytokines 
but also shift the T- cell balance towards Th1 and Th2 cells which express 
anti-osteoclastogenic factors, such as IL4 and IFN-γ (Schett & Gravallese 
2012). Despite IL17 being a good theoretical target in RA a randomized 
placebo controlled phase II trial showed that IL17 receptor blockade in RA 
patients does not improve disease activity significantly compared to placebo 
(Pavelka et al. 2015). Similarly Secukinumab, a fully human monoclonal anti 
IL17A antibody (Secukinumab) failed to reach the primary endpoint of ACR20 
disease activity reduction (Genovese et al. 2013). Because of the 
disappointing results in reducing disease activity in RA long term effects of 
IL17 inhibition on bone in RA may not become available.  
Dkk-1 
Dickkopf related protein-1 (Dkk-1) is expressed in the synovium in patients 
with RA and its expression is enhanced by TNF. Dkk-1 is a potent 
suppressor of Wnt pathway and inhibits bone formation and therefore maybe 




repair is very interesting and important to date it is unclear whether 
antagonizing wnt path inhibitors would assist the repair of bone erosions 











































































































































































About two thirds of patients with Rheumatoid Arthritis have antibodies against 
Immunoglobulins (these are termed Rheumatoid factors (RF)) or against 
citrullinated proteins (ACPA).The presence of these antibodies is strongly 
linked to severity of disease and accumulative joint and bone damage 
(Miriovsky et al. 2010a;van Gaalen et al. 2004a). Although RF are non-
specific, ACPA have been found to be highly specific for RA and are 
detectable in some individuals 10 years prior to disease onset (van der 
Woude et al. 2010). Several recent studies have shown functional roles of 
ACPA antibodies, which correlate with increased bone loss and erosive 
disease. The impact of immunoglobulins on bone can be divided into direct 
effects on bone cells through interaction between Immunoglobulins on 
osteoclasts or osteoclast regulating cytokines, and indirect impacts through 
interaction with immune cells and subsequent alteration of the 
osteoclastogenic milieu.  
Indirect effects 
Circulating antibodies have the ability to bind with low affinity with their Fc 
portion to Fc receptors on the surface of immune cells as shown in Figure 
1.13 (Nimmerjahn and Ravetch 2008). Monocytes and macrophages express 
various types of FcyR on their surfaces. Clavel et al (Clavel et al. 2008) 
showed that ACPA containing immune complexes induced TNF-alpha 
secretion in macrophages via engagement FcyRII. Further experiments 
demonstrated that both monocytes and macrophages were responsive to 
ACPA containing immune-complexes but antibody stimulated macrophages 
produced 9 times more TNF-alpha than stimulated monocytes. The TNF-
alpha boosting effect of ACPA containing immune-complexes was observed 
in macrophages derived from both blood and synovial fluid (Laurent et al. 
2011).  
Interestingly established therapeutics for RA such as MTX and 




monocytes which might help to explain the effectiveness of these drugs in 
suppressing inflammation and preventing structural damage (Torsteinsdottir 
et al. 1999;Wijngaarden et al. 2005).  
Direct effect 
Seeling et al. have shown that FcγRIV expressed on OC precursors play a 
crucial role in bone destruction in inflammatory arthritis in mice. FcγRIV 
knock out mice were found to have a reduced number of osteoclasts and less 
bone erosions at the site of inflammation compared to litter mates with K/BxN 
serum transfer arthritis (Seeling et al. 2013). Further remarkable studies 
investigating Immunoglobulin mediated osteoclastogenesis were published 
earlier this year. A research group led by Takayanagi have demonstrated that 
under physiological conditions activation of some Fcγ receptors expressed on 
osteoclast precursors, such as FcγRIIB and FcγRIII inhibit 
osteoclastogenesis, whereas stimulation of FcγRI and IV stimulates 
maturation and differentiation of osteoclasts. In the presence of 
hypergammaglobulinaemia, FcγRIIB is downregulated and the osteoclast 
activating effect of IgG immune complexes (IC) is prevailing (Negishi-Koga et 
al. 2015). Another group led by Georg Schett identified that the level of IgG 
glycosylation impacts on the binding affinity of IgG to FcγR. Desialylated IC 
were shown in in-vitro and in-vivo experiments to potently enhance 
osteoclastogenesis. Mice treated with sialyic acid precursor, N-
actylmannosamine (ManNac), which sialytes IC, are protected from 
inflammation induced local and systemic bone loss (Harre et al. 2015).  
Anticitrullinated peptide antibodies (ACPA)  
Harre et al. have shown that citrullinated vimentin can be found on the 
surface of osteoclast precursors. Isolated antibodies against mutated 
citrullinated vimentin (MCV) were shown to bind to the surface of osteoclast 
precursor and to stimulate osteoclastogenesis through TNF-alpha increase. 
The transfer of anti citrullinated peptide antibodies (ACPA) into mice caused 
increased osteoclastogenesis and resulted in accelerated bone loss (Harre et 




 In clinical practice Kleyer and colleagues have found that ACPA positive 
healthy individuals without symptoms or signs of inflammatory arthritis have  
reduced BMD and reduced cortical thickness in comparison to ACPA 
negative individuals (Kleyer et al. 2014). 
Osteoprotegerin autoantibodies 
 We previously reported a case which illustrated a new mechanism of 
antibody mediated osteoporosis. A patient with autoimmune thyroid disease 
and coeliac disease was found to have severe osteoporosis in association 
with neutralizing autoantibodies to osteoprotegerin (OPG). The binding of 
OPG which is  a decoy receptor to RANKL results in to enhanced RANKL 
mediated osteoclastogenesis and accelerated bone resorption(Riches et al. 
2009). A subsequent study, described in this thesis (Chapter 4) 
demonstrated the presence of detectable OPG antibodies in patients with RA 
and an association between autoantibody levels and the bone resorption 
marker CTX.  Functional studies showed that purified IgG from patients who 
were tested positive for OPG antibodies inhibited the ability of OPG to block 
RANKL induced NFκB activation in vitro. This suggests that in some RA 
patients functional autoantibodies to OPG are present with the potential to 
enhance osteoclastic bone resorption. A simplified diagram about the 
mechanism of autoantibody induced osteoclast activation is shown in Figure 
1.13 
 Above findings, suggest inflammation independent mechanisms of bone loss 
in Rheumatoid Arthritis. The emerging importance of immune complexes in 








Figure 1.13 Auto-antibody mediated Osteoclastogenesis. Indirect 
stimulation of osteoclastogenesis via stimulation of FcγR on macrophages 
and monocytes by IC including ACPA leads to enhancement of inflammatory 
cascade. Direct stimulation of FcγRI,III, IV on OC by IgG including ACPA 
promotes osteoclastogenesis. OPG ab block OPG, a decoy receptor to 









1.7.2.4.4 Relative immobilisation  
 Patients with RA are less active than their healthy peers due to pain, 
weakness, fatigue and disability (Mancuso et al. 2011;Pollard et al. 
2006;Sokka et al. 2008). A prolonged period of decreased physical activity 
and chronic inflammation leads to bone loss in addition to an accumulation of 
visceral fat and sarcopenia (Lilleby et al. 2007;Santos et al. 2011;Zerwekh et 
al. 1998). Ekdahl et al have shown that longstanding active Rheumatoid 
Arthritis leads to reduced isokinetic and isometric muscle strength and 
reduced aerobic capacity (Ekdahl and Broman 1992). Change of body 
composition in form of muscle loss and addition of visceral fat associated 
with glucocorticoid use not only increase the risk of osteoporosis but also 
increases the risk of sustaining low fragility fractures (Sayer et al. 
2006;Wickham et al. 1989). These changes in body habitus also promote the 
development of other comorbidities such as atherosclerosis and insulin 
resistance and  might lead to a vicious cycle as it has been postulated that 
central obesity and inactivity may exacerbate chronic inflammation and 
worsen inflammatory symptoms (Benatti and Pedersen 2015).  
At a cellular level, unloading of the human skeleton stimulates a quick and 
sustained increase of bone resorption and to a lesser extent a decrease of 
bone formation (Zerwekh et al 1998). The underlying mechanisms include 
the upregulation of Sclerostin (SOST), a cytokine secreted by osteocytes, 
which suppresses Wnt/beta catenin signalling and leads to reduced 
osteoblast differentiation and function. Lin et al (Lin et al. 2009) showed that 
SOST(-/-) mice, when mechanically unloaded, preserve their bone mass in 
contrast to their wild type littermates implying that SOST is responsible at 
least in part for bone loss due to skeletal unloading. Skeletal unloading also 
increases bone resorption through upregulation of PDK4 (Pyruvate 
dehydrogenase kinase 4) which promotes osteoclastogenesis (Wang et al.). 
A longitudinal study including 70 RA patients allocated to either strength and 




that strength and endurance training not only improved maximum strength of 
all muscle groups (grip strength, knee and trunk extensors) and maximal 
walking speed but also maintained normal femoral neck BMD in patients with 
recent –onset RA (Hakkinen et al. 2001). A further randomized controlled trial 
showed that a 2 year high intensity weight-bearing exercise program slows 
down hip BMD decrease compared to usual care (de Jong et al. 2004).  
Additionally the beneficial effects of exercise on endothelial function were 
shown by a recently published study which found that RA patients in the 
exercise group had improved micro- and macrovascular endothelial function 
compared to patients who received usual care (Metsios et al. 2014). Contrary 
to previous beliefs when patients with RA frequently were treated with bed 
rest and immobilisation (Alexander et al. 1983), the above findings 
emphasize the importance of exercise and maintenance of normal body 
weight in the prevention and treatment of systemic bone loss in rheumatic 
diseases.  
1.7.2.4.5 Glucocorticoids 
Patients with Rheumatoid Arthritis who are treated with glucocorticoids have 
double the risk of hip fractures compared with sex matched community 
controls (Cooper et al. 1995). Even low dose Glucocorticoid use in 
Rheumatoid Arthritis has been associated with increased risk of fractures 
besides other side effects such as GI complications and serious infections 
(Saag et al. 1994). The pathophysiology of corticosteroid induced bone loss 
is complex. Glucocorticoids (GC) have a direct impact on bone remodelling 
by reduction of bone formation and bone turnover. Weinstein et al (Weinstein 
et al. 1998) have shown that chronic glucocorticoid treatment in mice 
decreases proliferation of osteoblast precursors and stimulates osteoblast 
and osteocyte apoptosis, which together leads to a reduction of bone 
formation.. These findings were confirmed on biopsies of patients with 
glucocorticoid induced osteoporosis (Hofbauer and Rauner 2009).  Long-
term glucocorticoid exposure increases the expression of the transcription 




differentiation of mesenchymal cells to adipocytes as opposed to osteoblasts. 
At the same time Runx2, a pivotal transcription factor for osteoblastogenesis 
is repressed by GC. Therefore long-term corticosteroid use leads to bone 
loss and fatty transformation of bone marrow (Hofbauer & Rauner 
2009;Vande Berg et al. 1999).  
Glucocorticoid treatment has also a significant impact on bone resorption. 
Corticosteroids suppress Osteoprotegerin (OPG) production by decreasing 
levels of the phospho-c-Jun protein and by interfering with the canonical Wnt 
–pathway by decreasing β-catenin protein expression (Kondo et al. 2008). 
This leads to an increase in RANKL/OPG ratio and subsequent stimulation of 
osteoclast proliferation (Hofbauer & Rauner 2009;Kondo et al. 2008). That 
RANKL plays an important role in the development of corticosteroid induced 
osteoporosis demonstrates the effect of administration of fully human 
monoclonal antibodies against RANKL (Denosumab) to hRANKL knock-in 
mice. Hofbauer and colleagues (Hofbauer et al. 2009) showed that a short 
course of corticosteroid treatment in hRANKL knock in mice induces 
vertebral and femoral bone loss. Concomitant administration of Denosumab 
to these mice prevented the glucocorticoid induced bone loss largely by its 
antiresorptive effect There are no definitive studies of Denosumab’s 
effectiveness in glucocorticoid induced osteoporosis in man but it has been 
shown that it is an effective treatment in preventing osteoporosis in patients 
with Rheumatoid Arthritis of whom , a third were treated with glucocorticoids 
at the time (Cohen et al 2008). Additionally to reduced OPG production 
glucocorticoids prolong the lifespan of osteoclasts which further contributes 
to the imbalance of bone formation and resorption in favour of bone 
resorption and hence to net bone loss (Jia et al. 2006;Weinstein, Jilka, Parfitt, 
& Manolagas 1998).  
Furthermore, extra skeletal actions of glucocorticoids on organs such as 
muscles, kidney and endocrine system contribute to accelerated bone loss 
and increased fracture risk in rheumatic diseases. A summary of these 




in the gastrointestinal tract (Huybers et al. 2007)  and possibly reduce tubular 
calcium reabsorption in  the kidneys (Reid and Ibbertson 1987), which leads 
to secondary hyperparathyroidism which is a strong driver of 
osteoclastogenesis and hence increased bone resorption. Glucocorticoids 
also decrease the production of sex steroids such as LH, FSH or 
Testosterone and growth hormone that puts a halt on bone turnover (Canalis 
et al. 2007).  Steroid associated muscle loss not only leads to reduced 
skeletal loading and hence increased bone loss, sarcopenia also leads to 
postural instability, which is an important risk factors for falls (de Rekeneire et 
al. 2003).  
It is important to note that glucocorticoids used as treatment in inflammatory 
arthritis are not always thought to have a negative impact on bone 
homeostasis. The strong anti-inflammatory effect of glucocorticoids reduces 
the amount of circulating pro- inflammatory cytokines such as IL1, IL6, TNF 
which in turn may reduce osteoclast differentiation and activity. For example 
patients with early Rheumatoid Arthritis treated with the COBRA regime, 
which includes the simultaneous introduction of Prednisolone, Methotrexate 
and Sulfasalazine had similar changes in bone turnover markers and in BMD 
of hip as the control group, which was treated with Sulfasalazine 
monotherapy only (Verhoeven et al. 2001). Furthermore, van Everdingen 
showed that low dose glucocorticoid therapy (10mg Prednisolone/day) in RA 
prevented bone erosions and joint space narrowing when compared to early 
RA patients who were untreated (van Everdingen et al. 2002). These findings 
might be explained through the anti-inflammatory effects of glucocorticoids, 
which at the initial stage of Rheumatoid Arthritis counteract the negative 























































































































































































1.7.3 Ankylosing Spondylitis 
Ankylosing Spondylitis (AS) is a chronic inflammatory disease that is 
characterized by inflammation, predominantly targeting the axial skeleton 
resulting into back pain and stiffness. The inflammation mostly affects 
entheses (tendon insertion sites) at spine and other sites. Frequently 
peripheral large joints such as hips, knees and ankles may be affected. The 
natural course of the disease leads to increased bone formation and 
sclerosis, which promotes the fusion of SI joints, and the production of 
bonyspurs called syndesmophytes (67). Ankylosing Spondylitis belongs to 
the family of seronegative Spondyloarthropathies, which are genetically 
linked and associated with carriage of the MHC class I variant HLA-B27. The 
prevalence ranges from 0.1-1.4% and occurs more frequently in regions and 
tribes with higher HLA-B27 prevalence such as in Scandinavian countries 
and Inuit populations. In contrast to other rheumatic diseases the age of 
onset is predominantly under the age of 30 years and it affects men more 
commonly than women with a ratio of 2:1 (Braun & Sieper 2007).  
1.7.3.1 Osteoporosis risk 
Despite localized increases in bone formation, it is well established that 
patients with AS are at increased risk of generalized bone loss (Karberg et al. 
2005;Lee et al. 1997) and vertebral fractures (Ralston et al. 1990). A recent 
Swedish study that assessed BMD at spine, hip and forearm and bone 
michroarchitecture of the limbs with HRpQCT in 69 AS patients showed that 
lumbar osteoporosis and vertebral fractures were associated to lower 
volumetric BMD and decreased microarchitecture in peripheral bone 
(Klingberg et al. 2012) suggesting that bone loss in AS is generalized. This 
study also showed that increased syndesmophyte presence was associated 
with lower lumbar spine BMD. Interestingly this correlation was found in 
several studies that pre-dated this one (Karberg et al. 2005;Lange et al. 
2005;van der Weijden et al. 2011).  In contrast to other rheumatic diseases 




(Sambrook & Cooper 2006;van der Weijden et al. 2011). Amongst men with 
AS above 50 years of age around 20% have Osteoporosis at either spine or 
hip. Amongst younger men with recent onset of AS with a mean age of 38 
years 38% were found to have osteopenia of hip or spine (van der Weijden et 
al. 2011). Accelerated bone loss occurs frequently early on in the disease 
when patients are  commonly treated conservatively with NSAID treatment 
only (van der Weijden et al.2011) . It is worth noting that the interpretation of 
spinal BMD in AS is difficult as the presence of syndesmophytes and 
calcified ligaments can  lead to overestimation of spinal BMD (Braun & 
Sieper 2007). 
1.7.3.2  Fracture risk 
Patients with axial spondyloarthropathy are at increased risk of fractures at a 
relatively young age, frequently under 40 years of age, which limits the value 
of conventional fracture risk assessment tools such as FRAX (Ralston et al. 
1990;van der Weijden et al. 2012;Vosse et al. 2006;Vosse et al. 2009).  
In established disease vertebral fractures occur 3 times more commonly in 
patients with AS than healthy controls which is likely due to reduced BMD 
and secondly due to biomechanical properties of an encased spine with 
decreased elasticity and reduced spinal mobility (Vosse et al. 2009). We 
currently don’t know if AS patients are at increased risk of hip or wrist 
fractures as to date there is no data available to show an increased non-
vertebral fracture risk in AS (Bultink et al. 2012) except in cases with co-
existing inflammatory bowel disease (Vosse et al. 2009). To reduce fracture 
risk in AS not only low BMD should be targeted but also localized bone 
formation, which encases the spine and increases its rigidity. To date it is 
unclear if bone formation is closely linked to inflammation and if fracture risk 
can be altered by anti-TNF treatment (Maksymowych et al. 2009;Schett et al. 





1.7.3.3 Pathologenesis of bone involvement in AS 
The pathology of AS and the underlying mechanism of systemic or localized 
bone loss and formation are not as well understood as in RA. The 
inflammatory process in AS presents itself predominantly as enthesitis at the 
zygopophyseal joints, hip, sacroiliac (SI) joints and peripheral tendon 
insertion sites. Clinically the most common site of inflammation in AS are the 
vertebrae. The schematic picture (Fig 1.15) below shows the sequelae of 
pathological changes. Histological samples from zygapophyseal and SI joints 
from AS patients have shown inflammatory cell infiltrates with predominantly 
T-cells, macrophages and osteoclasts.  
Bone erosions and destruction is followed by excessive bone formation which 
is similar to the endochondral bone forming process seen in embryonic 
development. Chondrocytes and osteoblasts are the cells responsible for 
extra bone formation.  
 All three stages (inflammation, bone destruction and formation) do not 
necessarily occur in sequential order and localized increased bone turnover 








Figure 1.15. Pathological changes of enthesial site of vertebra in 
Ankylosing Spondylitis (adapted from Tam et al. Nat Rev Rheumatol. 6, 
399-405 (2010).Pro-inflammatory cytokines (TNF, IL17) promote 
inflammation at the entheses of vertebrae. RANKL promotes proliferation and 
activation of osteoclasts which degrade organic matrix through expression of 
Cathepsin K. Matrix Metalloproteinase 1 is a collagen degrading enzyme and 
mostly expressed by chondrocytes. Bone destruction is followed by 
excessive bone formation which is initially driven by bone morphogenis 
proteins (BMPs) and at later stage by Wnt pathway antagonists (DKK-1, 







TNF is expressed by a variety of cells of the innate and adaptive immune 
system as previously discussed. Cells in the SI joints of AS patients have 
been shown to express high levels of TNF (Braun et al. 1995). TNF 
stimulates osteoclastogenesis directly via increased OSCAR expression and 
inhibits bone formation through increased expression of Dkk-1 and 
Sclerostin. Clinically the introduction of TNF blocker for the treatment of AS 
has been a great success. Anti- TNF treatment suppresses pain and 
stiffness, reduces peripheral synovitis, acute phase reactants and the degree 
of bone marrow oedema on MRI (Tam, Gu, & Yu 2010). It may inhibit 
generalized bone resorption since after 6 months of regular Infliximab 
administration a marginal increase of BMD spine and hip was noted in AS 
patients (Allali et al. 2003). However the role of TNF in the development of 
bone erosions and syndesmophytes is less clear as there is no convincing 
evidence that TNF blockade has an impact on syndesmophyte formation. 
This indicates that there are potentially different pathways of localized bone 
destruction with associated bone formation and systemic bone loss in AS 
(Baraliakos et al. 2005;Schett et al. 2009).  
 
IL17-IL23 
IL23R has been identified and validated by a genome wide association study 
to be one of the significant loci associated with AS (Reveille et al. 2010). 
IL23R is expressed on Th17 cells which are responsible for IL17 production. 
In contrast to RA patients, seronegative Spondyloarthropathy patients were 
found to have increased IL17 levels and increased numbers of TH17 cells 
(Jandus et al. 2008;Wendling et al. 2007). New therapeutic agents have been 
designed to target TH17 cells and its cytokines in the IL17-23 axis. 
Secukinumab is a monoclonal antibody targeting IL17A which has been 
tested in various autoimmune diseases such as RA, PsA, Psoriasis, AS, 




Secukinumab has only been approved by the FDA for the treatment of 
Psoriasis but the drug is currently undergoing further phase II and III trials in 
PsA and AS (Baeten et al. 2013;Genovese et al. 2013;McInnes et al. 2014). 
The study programme for the seronegative arthritides are promising but long-
term data and data about the impact on localized and systemic bone loss are 
outstanding (Sanford & McKeage 2015).  
 
Cathepsin K 
Cathepsin K is highly expressed by osteoclasts and acts as cysteine 
protease that degrades organic matrix such as type1 collagen (Costa et al. 
2011).  Immunohistochemistry analysis of bone tissue from AS patients and 
patients with degenerative disc disease showed a marked increase of mono- 
and multinuclear cells which are most likely osteoclasts or osteoclast 
progenitors expressing Cathepsin K (Neidhart et al. 2009).Cathepsin K 
inhibitors (Odanacatib) have been developed as medication for generalized 
osteoporosis and once on the market, it maybe of future interest to examine 
the impact of Odanacatib on bone disease in AS (Costa et al. 2011).   
 
RANKL/OPG 
RANKL levels were found to be significantly increased in serum of AS 
patients compared to healthy controls (Kim et al. 2006). This can be easily 
explained by the activation of the inflammatory cascade and the increase of 
pro-inflammatory cytokines, which boost RANKL production as explained 
above. Less plausible is the finding by Franck et al who showed that bone 
loss in AS is, amongst other factors, associated with low OPG serum levels 
(Franck et al. 2004).  Our group has recently found that autoantibodies to 
OPG are strongly associated with low hip BMD in patients with AS (Chapter 
5) and hypothesize that these antibodies may play a role in the accelerated 
bone loss in AS. 
 These findings involving the RANKL/OPG pathway may help to explain the 






It is unknown what exactly triggers excessive bone formation in AS.   
Dickkopf-related protein (DKK-1), a glycoprotein belonging to the Wnt family, 
which inhibits bone formation by interfering with Wnt/beta-catenin signaling in 
osteoblasts. Decreased levels of DKK-1 are usually associated with 
increased bone formation and in animal models DKK-1 blockade induces 
fusion of sacroiliac joints (Tam, Gu, & Yu 2010;Uderhardt et al. 2010).  
Interestingly two studies have found higher serum DKK-1 levels in AS 
patients than in healthy controls (Daoussis et al. 2010;Nocturne et al. 2015). 
One study went on to assess Dkk-1 function in vitro and demonstrated that 
DKK-1 in AS is dysfunctional as it doesn’t inhibit bone formation in the same 
way as it does in RA. Daoussis et al also showed that TNF blockade in 
patients with AS increases DKK-1 concentrations substantially which may 
suggest that anti-TNF treatment could inhibit the syndesmophyte formation 
and bone fusion although this has not been verified in clinical practice yet 
(Baraliakos et al. 2005;Schett et al. 2009;Daoussis et al. 2010).    
 
Sclerostin 
Sclerostin is expressed by osteocytes and is another endogenous inhibitor of 
Wnt signaling. A study looking into Sclerostin concentration in osteocytes in 
AS patients found decreased skeletal expression and lower circulating levels 
of Sclerostin in AS patients compared to healthy controls (Appel et al. 2009). 
Recent analysis of an early AS cohort also showed that Sclerostin serum 
concentration were significantly lower in AS patients than in healthy controls 
(Nocturne et al. 2015). As Sclerostin inhibitors may soon become available 
as monoclonal antibodies for the treatment of osteoporosis, its use in 
Spondyloarthropathies may need to be evaluated as there’s a theoretical risk 







1.7.4 Systemic Lupus Erythematosus 
 
Systemic lupus erythematosus is a multisystem autoimmune disease, which 
affects most commonly women of childbearing age. The prevalence ranges 
from 20- 150 cases per 100000 population and it is more common in 
individuals of African, Asian or Hispanic ancestry. In order to make a 
diagnosis of SLE 4 out of 11 criteria need to be fulfilled. The diagnostic 
criteria include mucocutaneous manifestations such as malar rash, discoid 
rash, photosensitivity and oral ulcers, systemic involvement in form of 
arthritis, serositis, renal involvement, neurological disorder, blood disorder 
such as anaemia, leucopenia or thrombocytopenia and autoantibody 
positivity (anti-nuclear antibody, anti-ds-DNA, anti-Smith antibody, anti-
phospholipid Ab). Treatment of SLE frequently includes corticosteroids and in 
severe cases Cyclophosphamide, both of which can have detrimental impact 
on bone (Tsokos 2011). 
1.7.4.1 Osteoporosis in SLE 
There is huge variability in the epidemiological data of SLE associated bone 
loss and the osteoporosis prevalence rate ranges from 1.6 to 60% (Bultink, 
Vis, Horst-Bruinsma, & LEMS 2012). The wide variations in prevalence are 
likely a result of different study designs and criteria but may also reflect a true 
difference in incidence according to latitude or ethnicity. A UK study (Yee et 
al. 2005) which included 242 SLE patients with a median age of 40 years 
showed that about 10% of patients had osteoporosis and 9% had a history of 
fragility fractures. The study also showed that the non-Afro-Caribbean race is 
at higher risk of reduced BMD than Afro-Caribbeans which is in keeping with 
findings in the general population (Melton et al. 2002).  In contrast, a study, 
which included 298 women with SLE from Chicago and Pittsburgh, showed 
that Afro American women had a lower BMD of lumbar spine than white 




more severe disease as shown by the increased SDI index (Systemic Lupus 
International Collaborating Clinics/American College of Rheumatology 
Damage Index) and get treated with an average higher corticosteroid dose 
(Lee et al. 2007).  
Beside race as a possible risk factor for osteoporosis the usual traditional risk 
factors, such as age, postmenopausal status and low body mass index have 
been found to be independent predictors of reduced BMD in SLE. 
Additionally disease specific risk factors such as Vitamin D deficiency (Bultink 
et al. 2005), glucocorticoid intake (Jardinet et al. 2000) and renal failure 
(Almehed et al. 2007) were also shown to be associated with low BMD. 
Clearly above markers are also indicating severe disease, which might be a 
risk factor of osteoporosis in SLE per se.  
1.7.4.2 Fracture risk 
SLE patients are at increased risk of fractures.  A large population based 
cohort study in the US found that SLE patients are at fivefold risk of fractures 
compared to healthy controls. The risk factors identified from this study were 
age and length of corticosteroid use (Ramsey-Goldman et al. 1999). A 
Swedish study showed in SLE patients an increased risk of combined 
vertebral and hip fractures with an odds ratio of 2.9 compared to age and 
sex-matched healthy controls (Weiss et al. 2010) . A more recent study also 
showed ongoing high prevalence (20%) of asymptomatic vertebral fractures 
in a Chinese SLE cohort (Li et al. 2009).  
1.7.4.3 Pathologenesis of bone involvement in SLE 
Chronic systemic inflammation can affect most organs and accelerate 
disease related bone loss. SLE is characterized by an increase of Th1 and 
Th2 T-cells, hyperactivity of T- and B-cells and an increase of circulating 
plasma cells with amplified production of autoantibodies .The stimulation of 
the innate immune system leads to increased TNF and IL17 concentration 
and subsequent increase in osteoclastogenesis and decrease of IL2 which 






SLE patients with active disease have increased levels of TNF, IL17 and 
IFNα. As mentioned above TNF and IL17 are potent osteoclast stimulating 
factors. However in contrast to the rheumatic diseases discussed previously 
TNF inhibition has not demonstrated significant benefit in the treatment of 
SLE. IL-17 remains an interesting target as TH17 cells are found in 
abundance in peripheral blood and in affected kidneys in SLE patients 
(Tsokos 2011).  Type I interferons, particularly Interferon α (IFNα) is usually 
involved in viral defence and is secreted mostly by dendritic cells through 
activation of Toll Like Receptor (TLR) signalling (TLR 7 and TLR 9). IFNα is 
an important cytokine in the pathogenesis of SLE as it has the ability to break 
self-tolerance by activating antigen presenting cells after uptake of 
autoantigens (Tsokos 2011).Interferon signalling has also been shown to be 
an important mechanism in the interplay between immune system and bone 
metabolism. Interferon γ is a potent osteoclast inhibitor (Takayanagi) and 
RANKL induced IFN β (type I interferon) expression has a negative auto-
regulatory effect on osteoclasts by interfering with c-Fos expression 
(Takayanagi Nature 2002). However, the effect of increased IFNα on bone 
metabolism in SLE is unknown (Coelho et al. 2005). Similarly no study to 
date has found an association between disease activity and low BMD 
however, several studies have shown that accumulative organ damage, 
which is a result of chronic inflammation, is associated with low BMD(Bultink 
et al. 2012).  
Vitamin D 
Vitamin D is vitally important for maintenance of normal bone homeostasis 
and muscle strength. Vitamin D regulates intestinal Calcium and Phosphate 
absorption and acts on osteoclasts, osteoblast and osteocytes directly via 
Vitamin D receptor. Vitamin D deficiency causes secondary 




bone resorption (Bikle 2012;Holick 2007). Low 1,25- Hydroxyvitamin D (1,25 
[OH]D) can be caused by a variety of mechanism in SLE. Firstly sun 
avoidance due to photosensitivity reduces 25 [OH]D production in the skin . 
Secondly renal impairment will impact on the ability to hydroxylate 25 [OH]D 
into 1,25 [OH]D. Thirdly the most commonly used DMARD in SLE, 
hydroxychloroquine, supposedly inhibits 1α hydroxylase, which allows the 
enzymatic conversion into the active Vitamin D form (Bultink et al. 2012). 
Cyclophosphamide 
Intravenous pulses of Cyclophosphamide are frequently used in lupus 
nephritis.  The use of Cyclophosphamide is associated with a number of 
potential serious side effects such as bone marrow suppression, infections  
and premature ovarian failure causing early menopause (McDermott and 
Powell 1996). Since SLE most commonly occurs in women of childbearing 
age the use of Cyclophosphamide has serious impact on fertility and bone 
health. Gonadal failure is characterized by a sharp drop of oestrogens, which 
play an important role in the maintenance of normal bone homeostasis. 
Oestrogens suppress osteoclast function by reducing RANK expression, 
increasing OPG production and decreasing lysosomal enzyme secretion 
(Kremer et al. 1995). Oestrogen also drives osteoblast differentiation and 
activation by stimulation of wnt signalling (Manolagas et al. 2013).Hence 
oestrogen deficiency induced by premature menopause increases bone 
resorption and decreases bone formation, resulting in bone loss. 
 
Glucocorticoids 
 Glucocorticoids are frequently used in patients with active SLE. The 
mechanism of glucocorticoids on bone cells has been described before. The 
use of glucocorticoids in SLE is in the majority of studies associated with 
increased bone loss. Jardinet et al showed in a longitudinal study including 
35 premenopausal women that daily use of at least 7.5mg Prednisolone is 




(Jardinet et al. 2000). Similar to RA, the use of glucocorticoids increases the 
risk of fractures significantly and in the Hopkins cohort study the cumulative 
glucocorticoid dose has been identified as independent predictor of fractures 




1.7.5 Psoriatic Arthritis 
Psoriatic Arthritis is an autoimmune inflammatory arthritis that is usually 
associated with Psoriasis. The prevalence of Psoriatic Arthritis ranges from 
0.3- 1% in the general population. About 10-30% of patients with Psoriasis 
will develop inflammatory arthritis. Psoriatic Arthritis can present in various 
forms but the most common presentation is an oligoarticular arthritis affecting 
predominantly distal joints. In contrast to RA, joint involvement occurs more 
commonly in asymmetrical distribution and frequently affects more joints of 
one digit, including distal interphalangeal joints. Additionally inflammation can 
occur around tendons or tendon insertion sites and cause dactylitis, 
enthesitis and inflammatory back pain (Gladman et al. 2005).  
1.7.5.1 Pathology 
About 20% of all Psoriatic Arthritis patients will develop severe polyarticular 
disease with joint space loss, eccentric bone erosions and ultimately joint 
destruction and deformation. Arthritis mutilans (Fig 1.15) is characterized by 
bone lysis which can result in severe destruction of the joint with telescoping 
of digits and pencil in cup appearance on x-rays. In addition, patients with 
Psoriatic Arthritis frequently developed excessive bone formation in form of 
bone spurs at sites of enthesitis or in form of ankyloses at the spine. These 
bone changes suggest a disorganised pattern of bone remodelling (Mease 




Arthritis patients with erosive disease revealed large numbers of osteoclasts 




Figure 1.15 X-ray of left hand taken from a patient with Psoriatic 
Arthritis with arthritis mutilans ( solid arrow points  towards large erosion, 





1.7.5.2 Mediators  
Psoriatic Arthritis belongs to the group of seronegative 
Spondyloarthropathies. Hence the genetics, pathophysiology and 
osteoimmunolgy aspects are in many ways similar to the one presented in 
AS. 
RANKL 
Ritchlin et al demonstrated that PBMCs isolated from Psoriatic Arthritis 
patients contain an increased number of osteoclast precursors compared to 
PBMC form healthy controls and immunohistochemistry and RT-PCR of 
synovial membranes showed increased RANK and RANKL expression in 
samples from Psoriatic Arthritis patients (Ritchlin et al. 2003). The same 
research group also showed that the addition of OPG in vitro inhibits 
osteoclastogenesis in the setting of Psoriatic Arthritis. 
TNF 
Similar to AS, anti-TNF has been shown to substantially reduce inflammation. 
The use of Golimumab and Adalimumab have shown significant reduction in 
PSarc score, significant inhibition of structural damage and generally positive 
effects on skin. On a molecular level Ritchlin et al (2003) has demonstrated 
that the addition of anti-TNF to in vitro cultured PBMCs from Psoriatic 
Arthritis patients significantly reduce the production of osteoclast precursors. 
A comparison with healthy control PBMCs suggests that PBMCs from 
Psoriatic Arthritis patients secrete significantly greater quantities of TNF α 
than PBMCs from healthy controls. Again all the favourable effects of anti-
TNF seem to involve bone resorption. Although anti TNF significantly 
reduces the extent of enthesitis (Sterry et al. 2010)  and the development of 
erosions (Kavanaugh et al. 2010;Mease et al. 2009)in Psoriatic Arthritis , no 
therapeutic agents have been shown to alter bone formation at enthesial 







Levels of circulating TH17 cells are higher in PsA than in RA (Jandus et al. 
2008). Moreover, IL17RA and IL17 producing CD4+ T cells are increased in 
synovial fluid and psoriatic plaques (Raychaudhuri et al. 2012). 
Polymorphisms in IL23R are associated with Spondyloathropathies including 
Psoriatic Arthritis (Rahman et al. 2009). Scherlock et al (Sherlock et al. 2012) 
published interesting results highlighting the importance of IL23 and its 
receptor in the development of enthesitis. The research group identified new 
IL23 receptors on CD3+ CD4-CD8- T cells. This cell population has been 
found to reside at entheseal interface between tendon and bone. These 
resident T cells have the ability to produce IL22 which increases STAT3 
signalling and hence osteoblast driven new bone formation. Animal models 
confirm above findings as increasing expression of IL23 in transgenic mice 
promotes the development of enthesitis and enthesial new bone formation 
(Sherlock et al. 2012) . Ustekinumab, a monoclonal antibody against 
IL12/23p40 initially licenced for Psoriasis is now also licensed for the use of 
Psoriatic Arthritis. The PSUMMIT trials have shown that Ustekinumab 
significantly reduces radiographic progression after 24 and 52 weeks 
compared to placebo (Kavanaugh et al. 2014). To date there is no data on 
the impact of Ustekinumab on bone mineral density or bone formation in 
Psoriatic Arthritis or Ankylosing Spondylitis. 
BMP  
Inhibition of bone morphogenic protein in spondyloarthritis animal models has 
shown changes in ankylosing enthesitis and peripheral arthritis. Noggin is an 
extracellular BMP antagonist and Lories et al have shown that mice with 
induced spondyloarthritis and a noggin gene transfer are less likely to 
develop ankylosing enthesitis than their litter mates (Lories et al. 2005). On 
the quest for therapeutics which inhibit bone formation and structural damage 
in Spondyloarthropathies BMP signalling appears to be an attractive target 





Osteoporosis risk  
The degree of systemic bone loss in PsA is controversial. Frediani et al 
(Frediani et al. 2001) found that 2/3 of patients with PsA had reduced bone 
mineral density compared to healthy controls. Interestingly this study showed 
also a high prevalence of osteopenia (56%) and osteoporosis (11%) in 
premenopausal women. Relatively high prevalence rates of OP in men (29%) 
and postmenopausal women (47%). However subsequent studies looking 
into systemic bone loss of PsA did not find a significant difference between 
bone mineral density of Psoriatic Arthritis patients when compared to a 
reference range (Busquets et al. 2014) or to age and sex-matched healthy 
controls (Pedreira et al. 2011). The latter study hypothesised that BMD in 
PsA might be preserved secondly to increased BMI and due to an element of 
excess bone formation. 
Fracture risk 
Pedreira et al (Pedreira, Pinheiro, & Szejnfeld 2011)found that PsA patients 
had an increased risk of fractures compared to healthy controls despite there 
being no difference in BMD between these groups. The increased facture risk 
was found to be associated to disease duration and a history of falls. This 
study has also demonstrated that PsA patients are more likely to become 






1.7.6 Other rheumatic diseases 
1.7.6.1 Scleroderma 
Scleroderma is an autoimmune disease characterized by microvascular 
damage, dysregulation of the innate and adaptive immunity with production 
of autoantibodies against various intracellular antigens and generalized 
fibrosis of skin and internal organs. There are two subtypes categorized 
according to skin involvement. Limited cutaneous Scleroderma usually 
affects the skin of hands, forearms and face and is associated with preceding 
Raynaud syndrome, Pulmonary Hypertension and the presence of anti-
centromere antibodies. Diffuse cutaneous scleroderma is characterized by 
extensive progressive skin involvement and by inner organ, in particular 
renal, lung and cardiac involvement. Autoantibodies associated to the diffuse 
cutaneous form are anti-topoisomerase I, anti-RNA polymerase and anti-
Fibrillarin (U3RNP). Scleroderma occurs relatively infrequently with a 
prevalence rate of <150 per million, affecting more commonly women with 
peak onset around 50 years of age. Several studies have demonstrated that 
patients with SS are at increased risk of OP and osteoporotic fractures 
(Avouac et al. 2012) (Lai et al. 2015). A comparative study with RA revealed 
that prevalence rates of OP and OP fractures in SS, (30% and 35% 
respectively) are similar to the high prevalence rates in RA (32% and 33%) 
and significantly higher compared to healthy controls (Avouac et al. 2012). A 
systematic review (Omair et al. 2013) summarized multiple risk factors for the 
development of OP, including family history of OP, age, postmenopausal 
state, low vitamin D levels, diffuse scleroderma subtype, presence of internal 
organ involvement and calcinosis. However the authors emphasize that the 
evidence of these risk factors is conflicting and further definitive studies are 
necessary. The largest study investigating osteoporotic fractures in Systemic 
Sclerosis was a Taiwanese cohort study. Lai et al analyzed the National 
Health Insurance database and identified 1712 SS patients who were 
followed up over a median period of 5.2 years. When compared to controls 




and hip fractures with a incident rate ratio of 1.78 and 1.89 respectively. The 
identified risk factors for fractures were age, being female, daily Prednisolone 
dose above 7.5 mg and bowel dysmotility treated with intravenous 
Metoclopramide administration.  
 
1.7.6.2 Primary Sjoegren Syndrome 
Sjoegren syndrome is an autoimmune disease characterized by impairment 
of exocrine gland function resulting in oral and ocular dryness. Systemic 
manifestations of Sjoegrens include non erosive polyarthralgia, renal disease 
in form of distal renal tubular acidosis and glomerulonephritis, lung 
involvement in form of interstitial lung disease, peripheral polyneuropathy and 
autoimmune thyroiditis. There is very little published data about the impact of 
Sjoegren Syndrome on bone. Several case reports have noted the 
occurrence of osteomalacia as a result of distal renal tubular acidosis (Fulop 
and Mackay 2004;Saoud et al. 2005). Distal renal tubular acidosis (dRTA) is 
frequently caused by a defect of the collecting tubule anion exchanger, or of 
hydrogen ATP pump. Bone biopsies of patients with distal renal tubular 
acidosis have revealed reduced bone formation with impaired bone 
mineralization. These findings were confirmed by in vitro studies, which 
demonstrated that acidosis impairs osteoblast differentiation and reduces 
ALP mRNA and its enzyme activity (Disthabanchong et al. 2007). A recent 
study by Garvani et al (Gravani et al. 2015) found no difference in BMD 
between pSS patients and controls however pSS patients with high urine pH 
had a significantly lower BMD than controls proposing a possible impact of 
dRTA in Primary Sjoegren’s on bone turnover.  
 
1.7.6.3 Dermatomyositis 
Dermatomyositis is an autoimmune inflammatory myopathy causing proximal 
muscle weakness. Typical skin involvement in the form of heliotrope rash and 




and over the knuckles which is accompanied by a raised, violaceous scaly 
eruption (Gottron's papules) (Robinson and Reed 2011). Active disease 
requires usually prolonged courses of high dose glucocorticoids. Single 
studies have shown that both juvenile (Stewart et al. 2003) and adult onset of 
Dermatomyositis (de Andrade et al. 2012) have been associated with 
increased risk of Osteopenia and Osteoporosis. De Andrade et al have also 
demonstrated that around a quarter of patients with Dermato-or Polymyositis 
had a history of low fragility fractures which was significantly higher 
compared to age-sex and BMI matched controls. The risk factors for 
Osteoporosis identified in this study were similar to those found in general 
population such as age, weight and menopausal state (de Andrade et al. 
2012). Treatment or prevention of Osteoporosis in juvenile DM is a 
challenging therapeutic area as the individuals affected are frequently in pre-
pubertal and early pubertal stages when they often haven’t reached peak 
bone mass yet. Furthermore the use of anti-resorptives in young women of 
childbearing age is tricky as the longterm effects of previous use of 





In summary  
Patients with Rheumatic Diseases are at high risk of OP and osteoporotic 
fractures. Many therapeutics target mediators of bone loss but long-term data 
on the use of biologic drugs and their impact on bone is largely outstanding. 
Recent insights into osteoimmunological mechanism and new discoveries of 
autoimmune mediated bone loss will help to shape future research with the 
aim of early detection, efficient treatment and ultimately prevention of 





Chapter 2: Material and Methods 
 
2.1 Laboratory Methods  
 
2.1.1 Osteoprotegerin autoantibody ELISA 
(used for the analysis of osteoprotegerin autoantibodies in RA, 
chapter 4) 
Levels of OPG antibodies were measured by a direct enzyme-linked 
immunosorbent assay (ELISA) which was developed in-house. The principles 
of the OPG ab ELISA are shown in Figure 2.1.  
Recombinant OPG (R&D Systems) was reconstituted in order to prepare an 
OPG stock solution of 100μg/ml by adding 250μl of 0.2um filtered PBS to 
25ug lyophilised powder. The reconstituted OPG was stored at 4oC.  
The OPG stock (100 ng/μl) was diluted to 0.3ng/μl using 16μl stock + 5319μl 
of coating buffer per plate. A coating buffer (Sigma) was prepared by 
dissolving 1 capsule in 100ml distilled water. Microtiter plates were coated 
(50μl/well) with 0.3 μg/ml recombinant OPG (R&D Systems, 185-OS-025,100 
μg/ml) in the coating buffer (Sigma, 0.05M carbonate- bicarbonate buffer, pH 
9.6). The 96 well plate was sealed and incubated at 4oC for 24 ± 2 hours and 
then washed 7 times with 300 μl TBST (0.05 % Tween 20, 1 x TBS, pH 7.4) 
per well. Subsequently a 1% BSA blocking buffer (1 g BSA in 100 ml TBST) 
was added and the plate was incubated at 23oC for 2 hours followed by 7 
washes again with TBST. To create a standard curve, a polyclonal non-
biotinylated anti-OPG antibody (Abcam, ab9986) was diluted in a 1% BSA 
blocking buffer in serial dilutions (from 5 to 500 μg/ml) and added to the 
appropriate wells (50μl/well). At this stage serum samples were diluted 
1:2000 in a blocking buffer (1% BSA) and added (50μl/well) in duplicates to 
the wells. Serum from the previously described index patient (Riches et al 




Negative control serum, obtained from a healthy individual with normal bone 
mineral density which tested negative in the previously described 
immunoprecipitation assay for OPG antibodies (Riches et al.2009) , was 
diluted 1:2000 in blocking buffer and added to the wells. The well contents 
were mixed by gently tapping the plate for approx. 1 min and then the plate 
was re-covered and incubated at 37oC for 1 hour. After incubation, the plate 
was washed 8 times with TBST and dried thoroughly. At this stage the 
secondary peroxidase conjugated, goat anti-human detection antibody 
detecting heavy and light chains of IgG and IgM (Jackson Immuno Research 
Labs. Inc., 109-035-127) was diluted 1: 40.000 and added to each test well. 
This step was followed by another incubation at 23oC for 1½ hours. Following 
this incubation, the plate was washed 8 times as done previously and dried. 
For visualisation, 100μl of 3,3′, 5,5′-Tetramethylbenzidine (TMB) substrate 
solution (Sigma T0440) was added to each test well. The plates were 
incubated in the dark at 23oC for approximately 5 min followed by the 
addition of 50 μl of sulphuric acid stop solution (0.16 M) to each well. Within 
30 min of adding the stop solution absorbance was measured at 450 nm with 
the microplate reader (BioTek, Synergy HT). Measurement of the optical 
density and a comparison to the standard curve allowed the computerised 
calculation (Gen5 Software) of the resulting antibody concentration in each 






Figure 2.1 Schematic depiction of principles of OPG ab ELISA. A 96 well 
plate is coated with human recombinant OPG, used as a capture antigen. 
The OPGab present in the serum will bind to the OPG in proportion to their 
concentration in the serum. HRP conjugated secondary antibodies attach to 
the bound OPG ab and can be visualized by the addition of TMB substrate. 






Figure 2.2 Typical standard curve of ELISA measuring circulating 
antibodies against OPG. The antibody concentration is calculated against a 
4 parameter logistic equation, r2=0.9996. 
 
2.1.2 OPG ab ELISA – updated  
(used for the analysis of OPG autoantibodies in Ankylosing Spondylitis, 
chapter 5) 
This second version of the original ELISA was developed in order to avoid 
the usage of a murine polyclonal antibody (produced in a rabbit) for the 
creation of the standard curve. We recognized that secondary anti-human 
IgG antibodies may bind with different affinity to the antibodies from a human 
serum and to the primary antibody used for the standard curve, which is 
produced in a rabbit. The difference in affinity may introduce an error into the 
antibody quantification through ELISA.   The protocol of the updated ELISA 
looks similar to the original one with the exception of the standard curve and 
the omission of a drying step after coating the plates with OPG. Human 
recombinant OPG (R&D Systems) was reconstituted as before to an OPG 
stock solution of 100μg/ml and stored at 4oC for later use.  































The OPG stock (100ng/μl) was diluted to 1ng/μl using 99μl stock + 9801μl of 
coating buffer per plate. The coating buffer (Sigma) was prepared by 
dissolving 1 capsule in 100ml distilled water.  
A Costar high-binding micro-titre plate (Corning) is used for the ELISA. 100μl 
of diluted OPG is added to all wells resulting in a total of 100ng OPG per well. 
After the plate was sealed with a plate sealer it was incubated at 4oC for 
approximately 24 hours (±2 hour). After the incubation process, the wells are 
washed twice with 200μl/well of phosphate-buffered saline (PBS) containing 
0.05% Tween-20 (washing buffer) wash buffer and blocked with a blocking 
solution (PBS with 3% non-fat dry milk) for 1 hour at room temperature. 
The standard curve was now prepared using serum from the index patient.  
The serum is initially diluted to 1 in 100 in binding buffer (PBS-3% bovine 
serum albumin (BSA) and is then further diluted to 1/2500, 1/5000, 1/10000, 
1/20000, 1/25000 and 1/50000. Neat positive was given an arbitrary value of 
100 units, so that the standard curve ranges from 0.002 to 0.04 units. All 
samples that measured below the lower limit of the standard curve were 
assigned 0. All serum samples from patients that needed to be analyzed 
were diluted to 1/1000 (typically 2μl of the sample was added to 198μl of the 
binding buffer, with a second dilution step of 30μl added to 270μl of the 
binding buffer) and added to the wells. After 1 h of incubation at room 
temperature, the plates were washed five times with wash buffer. Now the 
secondary antibody that was a peroxidase conjugated goat anti-human 
detection antibody (Jackson ImmunoResearch) was diluted to 1:20,000 and 
added at a volume of 100ul per well. The plate was incubated again at room 
temperature for 1 hour and subsequently washed five times. For the final 
step of colour development 100μl of TMB substrate solution (Sigma) was 
added to each well and the plate was incubated at 24oC for 30 minutes to 
permit for colour development. In order to avoid interference from UV light 
the plate was covered with foil during this incubation step. Finally 100μl of 
TMB stop solution (KPL) was added to each well of the plate and the optical 




of 640nm. Sample concentrations were calculated by an automated four-





2.1.3 RANKL and OPG measurements 
2.1.3.1 Free serum RANKL measurements  
Free soluble RANKL levels were measured using an Enzyme-Linked 
Immunosorbent Assay (ELISA) (BI-20452, Biomedica Gruppe Vienna, 
Austria) that detects soluble, uncomplexed human RANKL by using 
recombinant OPG as the capture antigen. All samples were defrosted from 
minus 70°C and brought to room temperature prior to assay. Wash buffer, 
standards and controls were reconstituted according to the manufacturer’s 
protocol and added to the respective wells. 100 µl of undiluted serum sample 
was added to the respective wells. The duplicate samples were diluted to 
1:10 by adding 10ul of the corresponding serum sample to 90 µl of the Wash 
buffer which had already been added to the wells. The assay was performed 
according to the manufacturer’s protocol. To each well 100 µl of biotinylated 
anti sRANKL antibody was added and the plates were incubated overnight 
(20 hours) at room temperature while being vigorously shaken by a plate 
shaker. After incubation, the wells were aspirated and washed 5 times with 
300 µl wash buffer. Into each well 200 µl conjugate was added and the plates 
were incubated at room temperature for 1 hour. After incubation the plates 
were washed again 5 times. First 100 µl of Amplifier A and subsequently 100 
µl of Amplifier B were added, followed by incubation at room temperature. 
After 20 min the absorbance was read with a micro plate reader periodically 
at 490nm every 5 minutes in order to establish the correct time point for the 
addition of the stop solution.  After 30 minutes the highest standard reading 
had an optical density (OD) value of 2.0, the blank a value of less than 0.2 
and the reaction was stopped by the addition of 50 µl STOP solution to each 
well. The absorbance at 490nm with a reference at 630nm was measured 
with a micro plate reader. The manufacturer indicates that the intra- and 
interassay coefficients of variation (CV) for free sRANKL are 3–5% and 6–




to the protocol) and the same sample 1:10 diluted as duplicate the intraassay 
CV rose to 78.92% which made the second diluted sample reading invalid. 
 
2.1.3.2 Total serum RANKL measurements 
Total RANKL levels (free RANKL and RANKL complexed to OPG) were 
measured using a commercially available ELISA (Cat.No.: RD193004200R, 
BioVendor, R&D) which uses polyclonal RANKL antibodies as capture 
antigens. The assay was performed according to the manufacturer’s protocol. 
Serum samples were brought from minus 70°C to room temperature and 
diluted to 1:100 by adding 2.5 µl of serum to 247.5 µl of dilution buffer 
(provided by a commercial kit). The standards, controls and wash solutions 
were reconstituted with dilution buffer using the volumes stated in the 
Certificate of Analysis just prior to the assay. 100 µl of standards, controls, 
and samples were pipetted (in duplicate) into the appropriate wells. The plate 
was incubated at 2-8oC overnight with shaking at ~300 rpm. After incubation 
the plates were washed 5 times and dried, 100 µl of biotin labelled antibody 
was added followed by 1 hour incubation at room temperature. All the wells 
were washed again 5 times and 100 µl of Streptavidin-HRP Conjugate was 
added to each well. The plates were incubated at room temperature for 1 
hour whilst being shaken vigorously. After another wash cycle (5 times) 100 
µl of substrate solution was added to each well. The plate was covered with 
foil to protect it from light and incubated for 25 min at room temperature. The 
colour development was stopped by the addition of 100 µl of stop solution 
and the absorbance was determined by a microplate reader at 450nm with a 
reference of 630nm. The intraassay CV according to the manufacturer is 7% 
and inter-assay CV 11-13% for this method. We obtained an intraassay CV 





2.1.3.3 Serum Osteoprotegerin measurements 
The Osteoprotegerin (OPG) concentrations in the serum samples were 
measured with a commercially available ELISA kit (Human Osteoprotegerin 
ELISA, Cat.No.: RD194003200, BioVendor, R&D). The assay was performed 
according to the manufacturer’s protocol. Serum samples were brought from 
minus 70°C to room temperature. Standards, controls were reconstituted with 
the dilution buffer using the volume stated on the Certificate of Analysis. The 
prepared standards and the reconstituted controls were further diluted 3 
times with the dilution buffer (100 µl standard + 200 µl of dilution buffer). 100 
µl of the diluted standards, controls, dilution buffer (Blank) and samples were 
pipetted in duplicates into the appropriate wells. The plate was incubated at 
room temperature for 1 hour with shaking at ~300 rpm. Subsequently, the 
wells were washed 3 times with 350 µl of the prepared wash solution and 
dried by inverting the plate onto paper towels. 100 μl of the biotin labelled 
antibody was added to each well and the plates were incubated at room 
temperature for 1 hour with shaking (300rpm). The wells were washed again 
3 times followed by the addition of 100 µl of Streptavidin-HRP conjugate with 
30 minutes incubation at room temperature with shaking. After the wells had 
been washed again 3 times 100 µl substrate solution was added to each 
well. The plates were covered with foil to protect from light and incubated for 
10 min at room temperature. Colour development was then stopped by the 
addition of 100 µl of stop solution and the absorbance at 450nm (with a 
reference of 630 nm) was determined.  The intra and inter-assay CV are, 
according manufacturer, 3-5% and 2-9% respectively. We obtained an 
intraassay CV of 4.1% when analyzing 39 samples.  
 
2.1.4 Serum CTX measurements 
We measured C-terminal telopeptides of Type I collagen (CTX) 
concentrations in serum  according to the manufacturer's instructions using 
an automated chemiluminescence assay (CTX-1 IDS-iSYS, CLIA, 




reported inter-assay coefficient of variation was 5.2 and 2.5%. The limit  of 
quantification (LoQ) was 0.033 ng/ml and the reported range of the CTX-I 
assay was  0.05 to 6.0 ng/ml(Seres et al., 2010).  
 
2.2 Immunoglobulin purification  
Immunoglobulins (IgGs) were purified from serum in order to investigate the 
effect of IgGs on free RANKL measurements. Furthermore purified IgGs 
were used in the functional assay and in order to investigate if purified IgGs 
containing high concentrations of OPG ab have the ability to neutralize OPG. 
2.2.1 Melon Gel Immunoglobulin G (IgG) purification 
 
 This type of IgG purification enables the purification of antibodies from 
serum. The method is based on direct filtration of IgGs as the Melon Gel 
Resin contains a proprietary ligand which binds most proteins but is unable to 
bind IgGs. 
 
2.2.1.1 Buffer Exchange Procedure  
To avoid the need of diluting the serum sample when performing the Melon 
Gel Igg Spin purification we performed a buffer exchange of the serum 
sample using a Zeba™ Desalt Spin Column (Thermo Scientific Pierce, 
89882). This allowed the preparation of the serum sample with the 
purification buffer which was immediately used for IgG purification. The buffer 
exchange was performed according manufacturer’s protocol. 
 The spin columns were placed in 2.0 ml collection tubes. The tubes were 
centrifuged at 1,500 × g for 1 minute to remove storage solution. 300 μl of 
Purification buffer was added on top of the resin bed and the tubes were 
centrifuged at 1,500 × g for 1 minute to remove the buffer. The previous step 
was repeated three additional times and the buffer was discarded from the 
collection tube. Now the column was placed in a new collection tube, the cap 




resin bed. The collection tube containing the serum sample was centrifuged 
at 1,500 × g for 2 minutes and the buffer exchanged sample was collected. 
For each serum sample this procedure was performed twice with two 
separate columns in order to obtain 260 μl of buffer exchanged serum.  
 
2.2.1.2 Spin-column Procedure for IgG Antibody Purification  
Melon™ Gel IgG Spin Purification Kit (Thermo Scientific 45206) was used for 
purification of IgG from serum. The purification was performed according to 
the manufacturer’s protocol. Melon Gel IgG Purification Support was brought 
to room temperature. 500 µl of gel slurry was dispensed into a spin column 
which had been placed in a micro-centrifuge tube. The uncapped 
column/tube assembly was centrifuged for 1 min at 5,000 × g, then the spin 
column was removed and the flow-through discarded. At this point 300 µl of 
purification buffer was added to the column, briefly centrifuged (10 s) and the 
flow-through was discarded. After two washes the bottom cap was placed 
onto the column. The undiluted serum samples (260 µl of buffer exchanged 
serum) were added to the column.  The columns were capped and incubated 
for 5 min at room temperature with end-over-end mixing. Subsequently the 
bottom cap was removed from the columns and top cap loosened. The spin 
columns were re-inserted in the collection tube and centrifuged for 1min at 
5,000 × g in order to obtain purified antibodies.  
2.2.2 IgG purification with Protein G Spin columns  
 
2.2.2.1 Procedure for Antibody Purification  
In order to purify Immunoglobulin (IgG) from 200 μL of serum we have used 
IgG purification with NAb™ Protein G Spin columns, 0.2mL for Antibody 
Purification (Thermo Scientific). To start columns, buffers and patient sera 
were equilibrated to room temperature. The storage solution in the spin 
columns were centrifuged for 1 minute (5000 g) and the flow through (storage 
solution) discarded. The column was prepared by adding 400μL of Binding 




in 500mL of ultrapure water) which was mixed briefly and discarded through 
centrifugation (5000 g). This step was repeated once. The spin column was 
then capped and 250 μL of antibody-containing serum sample was added. 
Column and serum were mixed at room temperature (24°C)  by end-over-end 
mixing for 10 minutes. The spin column was placed in a collection tube and 
centrifuged for 1 minute. The resulting flow through contained the nonbound 
sample components whereas the IgG were captured by Protein G coated 
spin column. Now the columns were washed three times by adding 400μL of 
Binding Buffer, brief mixing of buffer and resin and centrifugation of buffer. 
Before collecting the purified immunoglobulins, 40μL of Neutralization Buffer 
(1M Tris•HCl, pH 8.5 ) was put into the collection tubes.  The spin column 
were put into one of the collection  tubes and 400μL of IgG Elution Buffer (pH 
2.8) was added to the spin column, mixed gently and centrifuged for 1 
minute. The same step was repeated twice but the spin column was placed 
each time into different prepared collection tubes resulting in three different 
elution fractions.  In order to determine which fraction(s) contain the purified 
antibody the protein content was quantified using Nanodrop technology with 
the Spectrophotometer Nanodrop reader 1000 3.7.0 (Thermo Scientific) by 
measuring the relative absorbance of each fraction at 280nm. The elution 
fractions were either used immediately for the functional assay or stored at -
20°C.   
 
In order to re-use the columns, the columns were washed three times with 
400μL of Elution Buffer and then three times with 400 μL of Storage Solution 
(0.02% sodium azide in phosphate-buffered saline (PBS)). The regenerated 








2.2.3 HEK-293 NF-KB reporter assay  
We studied the functional effects of OPG antibodies on RANKL induced 
nuclear factor kappa B (NFκB) activation in the human-Embryonic-Kidney cell 
line, HEK-293 (Promega, E8520). The HEK-293 cells were cultivated in 75T 
flasks in growth medium (90% DMEM, 10% FCS, 1% Penicillin/Streptomycin 
(Pen/Strep, 50ug/ml Hygromycin B) and  were maintained between 10% and 
90% confluence in a 37°C, 5% CO2 tissue culture incubator. Growth medium 
was changed every 2 to 3 days and the cells required passaging every 4 
days. 2 days before the assay the medium was changed to Hygromycin free 
growth media (90% DMEM, 10% FCS, 1% Penicillin/Streptomycin). One day 
before the assay 200 µl cell suspension was aliquoted into a 96 well plate at 
a density of 5.5x 105 cells/ml. The cells were incubated overnight and 2 hours 
prior to the assay the medium was changed to a serum free medium (97% 
DMEM, 2% TCH, 1% Pen/Strep) in order to serum-starve the cells. The cells 
were stimulated with 20 µl of 50 and 100 µg/ml RANKL , 100 µg/ml OPG ,in 
the presence or absence of  purified IgG from the index patient known to 
have functional OPG antibodies as a positive control (Riches et al., 2009)or  
purified IgG from RA patients that tested positive or negative for OPG 
antibodies in this study. The IgG samples were diluted at 1:20 and 1:40. 
Following addition of these reagents, the cells were incubated for 3 hours. 
Subsequently, 150µl of the cell suspension was removed and discarded and 
the final analysis was performed on the remaining 50 µl of cell suspension. 
Then, 50 µl of Alamar Blue was added to each well in order to assess cell 
viability. Alamar Blue was measured with an excitation wavelength of 560 nm 
and an emission wavelength of 590 nm. Finally 50µl of one-Glo reagent 
(Promega E6120) were added to all 96 wells and the resulting luminescence 
was read after 3 minutes, 4 hours and 6 hours with the microplate reader 
(BioTek,Synergy HT). The Glo-response luminescence results were divided 






Chapter 3: Prevalence and predictors of 
Osteoporosis in Rheumatoid Arthritis  
 
3.1 Abstract 
Osteoporosis has previously been reported to be twice as common in 
patients with rheumatoid arthritis (RA) as compared with controls but these 
studies predate the introduction of aggressive management of RA. The aim 
was to evaluate prevalence and clinical predictors of osteoporosis in RA in a 
contemporary cohort and to develop a clinical tool for the identification of 
patients at risk. The prevalence of osteoporosis was related to clinical and 
demographic variables in 304 consecutive RA patients undergoing DEXA at 
a single centre between 2009 and 2010 and compared to the frequency of 
osteoporosis in a population based cohort of 903 subjects. The results of this 
study showed that the RA cohort were predominantly female (81.9%), with an 
average (±SD) age of 63.5±11.8 years and a disease duration of 9.6±10.2 
years. Osteoporosis was present in 91(29.9%) patients at either the spine or 
total hip compared with 157/903(17.4%) of age and gender matched controls. 
In RA patients, osteoporosis was associated with female gender (p=0.002), 
age (p<0.001), time since menopause (p<0.001), BMI (p<0.001), ESR 
(p=0.006), Larsen score (p=0.011) and co-morbidities (p=0.020), but logistic 
regression analysis showed that only age and BMI were independent 
predictors. A predictive tool based on age and BMI was developed which had 
91.4% sensitivity for detection of osteoporosis in an independent RA 
population. In conclusion the prevalence of osteoporosis in RA remains high 
in the modern era despite aggressive management and the use of biologic 
therapy. Most RA patients with osteoporosis can be identified by a simple 








Rheumatoid arthritis (RA) is associated with reduced bone density 
(Haugeberg et al., 2000a, Sinigaglia et al., 2000, Haugeberg et al., 2000b) 
and an increased risk of fragility fractures (van Staa et al., 2006).  The 
pathophysiology of osteoporosis is complex with contributions from general 
risk factors such as age, low body weight and postmenopausal status, along 
with disease-specific risk factors such as decreased mobility, corticosteroid 
use and production of pro-inflammatory cytokines (Gough et al. 
1994b;Haugeberg et al. 2000a;Laan et al. 1992;Sinigaglia et al. 2000). The 
importance of inflammatory disease as a pathogenic factor is emphasised by 
the fact that there is a positive correlation between disease activity and 
biochemical markers of bone resorption in RA (Gough et al. 1994b). Analysis 
of data from the Oslo registrar over a decade ago indicated that about 15% of 
RA patients had osteoporosis at the femoral neck as defined by dual energy 
x-ray absorptiometry (DEXA) (Haugeberg et al., 2000a). By comparing BMD 
values in the RA population with those from the manufacturer’s reference 
range it was estimated that the risk of osteoporosis was increased by two-
fold as compared with the general population (Haugeberg et al., 2000a).  
Since this time there have been major changes in the management of RA 
with earlier and more aggressive use of synthetic disease modifying 
antirheumatic drugs (DMARD) and deployment of biologic agents for patients 
who do not respond adequately (Smolen et al 2010). Since there is evidence 
that control of inflammation with TNF alpha inhibitors in RA may protect 
against systemic osteoporosis as well as preventing local bone erosions (Vis 
et al., 2006)  we have evaluated the prevalence and risk factors for the 
development of osteoporosis in a contemporary population of patients with 
RA presenting to a UK referral centre. We also developed an algorithm for 




factors for the disease within this population with the aim of better targeting 
DEXA to patients at highest risk of having osteoporosis.  
 
3.3 Patients and Methods 
 
3.3.1 Rheumatoid Arthritis cohort  
All patients attending a DEXA scan at the Western General Hospital are 
audited with the acquisition of basic demographic data, detailed information 
on osteoporosis and fracture risk factors, lifestyle factors and calcium intake. 
Patients with Rheumatoid Arthritis were identified by the selection of referring 
physician and review of case notes. Additional clinical data was collected 
through review of digital and paper case notes.  
The study cohort comprised all patients with rheumatoid arthritis who had 
been consecutively referred for DEXA examination over a 24-month period 
between January 2009 and December 2010. In the resulting group of 304 
patients, information was collected on gender, age, weight, height, alcohol 
intake, smoking, age at menopause, self-reported non-vertebral fractures and 
dietary calcium intake (assessed by food frequency questionnaire) at the time 
of the DEXA scan according to routine practice. Details of disease duration, 
presence of rheumatoid factor and anti-CCP antibodies, erosions, 
inflammatory markers, and anti-rheumatic and anti -osteoporosis drug 
treatment were obtained through case note review.  Inflammatory activity 
around the time of DEXA examination was assessed by taking the average of 
3 measurements of ESR and/or CRP performed within a 1 year window 
before the time of DEXA. For statistical analysis we classified anti-rheumatic 
and anti-osteoporosis treatments into categories of current use, past use 
(more than 6 month before the DEXA assessment) and ever use.  We also 
collected information on the following co-morbidities: cardiovascular disease, 




renal and liver impairment, gastrointestinal disease, diabetes, thyroid disease 
and cancer. The frequency of osteoporosis in the RA population was 
compared with that in a population based cohort of 903 subjects (709 women 
and 194 men) of average (±SD) age of 62.7±10.3 years who underwent 
DEXA scanning as part of the ORCADES study. Details of this study have 
previously been described (Estrada et al. 2012). Relevant clinical and 
demographic information was collected in the controls as described for the 
cases and patients with RA excluded. The prediction tool for osteoporosis 
described in this paper was evaluated in an independent cohort of 171 RA 
patients (130 women and 41 men) with average age of 60.8±12.3 years and 
average BMI of 28.0±5.8 kg/m2 who underwent DEXA scanning at our centre 
between 2010 and 2013. Information about the RA population was obtained 
through an audit of data that had been collected during routine clinical 
practice hence ethical approval was not required. 
 
3.3.2 ORCADES cohort 
The Orkney Complex Disease (ORCADES) study is a population-based 
study for health research, designed to identify genetic risk factors for complex 
diseases (Orkney Research Ethics Committee approval - 27/02/2004). Out of 
a total population of 12000 Orcadians 2000 healthy volunteers have been 
recruited into this cross-sectional study. Most of the patients (1578) had a 
bone mineral density assessment by DEXA and beside basic demographic 
measures, data on fracture risk factors, family history and medical and 
surgical history had been collected. Dr James Wilson has kindly allowed 
access to plasma and serum of 200 healthy controls for the measurement of 
OPG ab and subsequent calculation of a normal range for OPG ab. 
Furthermore I’ve been given access to the BMD data of 2000 healthy 
controls for the use as a control cohort which was used to compare BMD and 
osteoporosis prevalence between Rheumatoid Arthritis patients and healthy 




samples from the Orcades to the Edinburgh Clinical Trials Unit. Recruitment 
and characteristics of this cohort was described before (Estrada et al. 2012). 
 
3.3.3 Joint erosions  
Hand radiographs were reviewed and scored for the presence of erosions 
and joint damage using the modified Larsen score as previously described 
(Larsen, 1995). In total 140 sets of radiographs were available for analysis in 
the study cohort.  
 
3.3.4 Measurements of BMD measurements and fracture risk 
assessment 
Measurements of BMD in all study populations were made by dual-energy X-
ray absorptiometry (DEXA) at the lumbar spine (L1-L4) and femoral neck 
using a Hologic QDR 4500 osteodensitometer. Vertebral fractures were 
initially ascertained on lateral spine images from T4 to L4 using vertebral 
fracture assessment (VFA) software of the DEXA device. All vertebral 
fractures were subsequently confirmed on review of lateral x-rays of the 
thoracolumbar spine by radiologists according to normal clinical practice. 
Vertebral morphometry was not performed. Data on non-vertebral fractures 
was obtained by questionnaire and validated by analysis of case records 
and/or radiology reports.  
 
3.3.5 Statistical analysis 
Statistical analyses were performed using SPSS version 16.0 (SPSS, 
Chicago, IL, USA). Two tailed independent student t-test was used for 
between-group comparisons of continuous data. If the variables were not 
normally distributed,  Mann Whitney U test was applied. The chi-square test 
was used to evaluate for differences between categorical variables. Binary 
stepwise logistic regression was used to identify independent predictors of 
osteoporosis and fractures with inclusion of variables that were significantly 




analysis.   The 95% confidence intervals (CI) were calculated for differences 
between means and odds ratios (OR) for paired data.   
Sensitivity and specificity were calculated according to standard methods and 
receiver operating characteristics (ROC) curves were constructed to identify 








3.4.1 Patient Characteristics  
Relevant clinical and demographic characteristics of the RA cohort are 
shown in Table 1 broken down by gender. The mean age of the study 
population was 64 years and 81.9% were female. There was no significant 
difference between genders for age, BMI, current smoking status, 
seropositivity, disease duration, Larsen scores or fractures. As expected, 
men were taller and heavier than women, had significantly higher BMD 
values (p=<0.001), higher alcohol consumption (p=0.016), had previously 
smoked more often (p=0.034) and had higher CRP levels (p=0.005). Nearly 
all of the patients (96.8%) had been treated with a disease modifying drug 
(DMARD), 53.6% had received glucocorticoids in the past and 33% were on 
either oral glucocorticoids or received regular intramuscular glucocorticoid 
injections at the time of the DEXA scan. For patients on glucocorticoids, the 
average dose was 7.4±10 mg prednisolone daily with men receiving a 
significantly higher dose than women (p=0.009) (Table 3.1). About one 
quarter of patients (22.7%) had previously received anti-TNF treatment and 
17.1% were receiving anti-TNF treatment at the time of the DXA scan. About 
one fifth of patients (20.7%) were receiving a bisphosphonate and 26.6% 





Table 3.1 Patient demographics and disease characteristics of RA 
cohort 




Demographics     
Age, yrs,  63.8  ± 11.8 62.3 ± 11.5 0.398 
BMI (kg/m2) 27.5 ± 6.1 26.9 ± 4.4 0.527 
Post-menopausal  210 (84.3) -  
Age at menopause (yr)  46.9 ± 6.5 -  
Current Smoker  64 (25.7) 19 (34.6) 0.183 
Cigarettes per day  15.3 ± 7.3 15.8 ± 5.1 0.808 
Drinks alcohol  70 (28.5) 23(41.8) 0.053 
Alcohol units/week   6.41 ± 5.0 14.1 ± 20.7 0.016 
Calcium intake, (mg/day)  818.0 ± 388 833 ± 38 0.643 
Disease characteristics     
Disease duration (months) (n=279) 129.1 ± 129.1 152 ± 139 0.280 
Time from diagnosis to DEXA (n=220) 109.1 ± 117.8 140.4 ± 141.6 0.135 
RF or CCP positive   143 (70.5) 41 (80.4) 0.200 
CRP mg/l (n=199)  27.4 ± 38.3 39.2 ± 43.0 0.005 
ESR mm/h (n=252) 32.8 ± 23.5 33.3 ± 22.5 0.814 
Erosions (n=221)  83 (47.2) 19 (45.2) 0.823 
Larsen score (n=140)  50.52 ± 25.49  46.48 ± 26.39  0.454 
Number of co-morbidities 0.92 ± 0.92 0.91 ± 0.87 0.945 
Current DMARD therapy (Y/N) 202 (81.1) 46 (83.6) 0.664 
Current Biologic  therapy (Y/N) 56 (22.5) 9 (16.4) 0.316 
Current steroid therapy (Y/N) 76 (30.8) 23 (41.8) 0.114 
Current Prednisolone dose mg (n=89) 6.0 ± 6.5 12.4 ± 17.3 0.009 
Spine BMD (g/cm2) 0.89 ± 0.15 0.99 ± 0.13 <0.001 
Total hip BMD (g/cm2) 0.78 ± 0.16 0.88 ± 0.14 <0.001 
Osteoporosis of Spine or Hip 84 (33.7) 7 (12.7) 0.002 
Vertebral fracture  25 (10.0) 7 (12.7) 0.557 
Non-vertebral fractures 83 (33.3) 9 (16.4) 0.013 
Hip fracture 13 (5.2) 1 (1.8) 0.276 
Values are number (%) or mean (standard deviation). The number of observations available 
is shown in brackets for variables with >1% of missing data. BMI=Body Mass Index, 
RF=Rheumatoid Factor, ACCP = Anti-cyclic Citrullinated Peptide, CRP = C reactive protein 
ESR= Erythrocyte Sedimentation Rate, Rad.= Radiographic erosions on hand or feet x-rays, 






3.4.2 Risk factors for osteoporosis  
Relevant clinical and demographic variables in patients with and without 
osteoporosis as defined by a BMD T-score of -2.5 or less on DEXA at the 
spine or femoral neck are summarised in Table 3.2. Osteoporosis was 
associated with female gender, age, BMI, years since menopause, number of 
co-morbidities, Larsen Score, CRP and ESR. There was no association 
between seropositivity for rheumatoid factor or CCP, previous or current 
glucocorticoid intake, anti-TNF treatment or DMARD therapy.  As expected 
vertebral and non-vertebral fractures were more common in patients with 





Table 3.2 Clinical and demographic characteristics of patients from the 
study cohort with and without osteoporosis 
 
Normal 
BMD Osteoporosis p-value 
Number  213 (70.1) 91 (29.9)  
Female gender 165 (77.5) 84 (92.3) 0.002 
Age (yrs) 60.5±11.2 70.6±9.8 < 0.001 
BMI  (kg/m2)  28.8±5.7 24.1±4.6 < 0.001 
Age at Menopause (n=196) 47.2±6.2 46.5±7.1 0.901 
Years since Menopause 16.4±10.1 24.6±10.9 <0.001 
Calcium intake (mg) (n=304) 834±430 790±430 0.949 
Ex-Smoker 89 (41.8) 38 (41.8) 0.997 
Current Smoker 59 (27.7) 24 (26.4) 0.812 
Alcohol drinker (n)(n=305) 69 (32.9) 24 (26.4) 0.264 
Alcohol units/week 8.18±12.86 7.88±5.48 0.912 
Duration of RA (months) (n=283) 133±127 134±141 0.938 
Seropositive  (n=255) 133 (73.9) 51 (71.8) 0.740 
Erosions (n=221) 76 (47.8) 26 (44.1) 0.624 
Larsen score (n=140) 47.07± 26.38 56.59± 22.42 0.011 
ESR (mm/hr) (n=252) 30±22 40±26 0.006 
CRP  mg/l (n=199) 26±37 38±44 0.023 
Ever received glucocorticoids  119 (56.4) 43 (47.3) 0.144 
Current glucocorticoid  73 (34.6) 26 (28.6) 0.306 
Current Prednisolone dose (mg) (n=89) 8.3±11.4 4.8±3.8 0.162 
Ever received anti-TNF therapy  53 (24.9) 16 (17.6) 0.164 
Number of co-morbidities 0.85±0.9 1.1±0.9 0.020 
Vertebral fracture 15 (7.1) 17 (18.7) 0.002 
Hip fracture 2 (0.9) 12 (13.2) 0.001 
Non-vertebral fractures 48 (22.5) 44 (48.4) 0.001 
 
Values are numbers (%) or mean ± SD. P-values refer to the difference 
between the groups assessed by t-test for continuous variables and chi-
square test for categorical variables. Numbers in parenthesis show the 
number of patients in which data was available for variables where data was 
missing in more than 1% of subjects; BMI=Body Mass Index,RF=Rheumatoid 







 Multivariable logistic regression was used to identify the independent 
predictors of osteoporosis. For this analysis factors that were associated with 
osteoporosis in the case control study at a p-value of 0.05 or less were 
entered into the model, except CRP which was excluded due to a large 
number of missing values. This revealed that the only independent predictors 
of osteoporosis were age (OR=1.08, 95% CI 1.03, 1.14) and BMI (OR=0.82, 
95% CI 0.74, 0.91).  The variables ESR (OR=1.01 CI 0.99, 1.03), number of 
co-morbidities (OR=1.05 CI 0.57, 1.96), gender (OR=0.44 CI 0.14, 1.42), 
Larsen score (OR =1.01 CI 0.99, 1.03) and years since menopause 
(OR=1.00 CI 0.91,1.10) failed to reach statistical significance. Overall the 
regression model explained 44 % of variance (Nagelkerke R2=0.44). Further 
logistic regression analysis of the RA study group in which patients receiving 
bisphosphonates were excluded revealed very similar results to those 




3.4.3 Prevalence of osteoporosis in RA population versus 
controls 
Levels of BMD at the lumbar spine and total hip in RA cases and controls are 
illustrated in Figure 3.1, broken down by gender. Levels of BMD were 
significantly lower in female RA cases as compared with female controls from 
the age of 45 years onwards (Panels A and B). In males, total hip BMD was 
also significantly lower from the age of 45 onward. There was also a trend for 
lower spine BMD in men but this was not significant at any individual time 
point (Panels C and D). However overall spine BMD in men was significantly 
lower in the RA population than in healthy controls (-0.7±1.6 vs. -1.3±1.3, 
p<0.001). The overall prevalence of osteoporosis at spine and total hip (as 
defined by a T-score less than -2.5) in the cases and controls is summarised 





Figure 3.1 Spine and Hip BMD of RA patients and healthy controls (HC) 
BMD= Bone Mineral Density *p< 0.05 **p<0.01 ***p<0.001 
 
3.4.4 Development of a diagnostic algorithm  
Based on the logistic regression analysis we developed an algorithm with 
which to predict the presence of osteoporosis in RA considering men and 
women separately. A receiver-operator curve (ROC) analyses showed that 
age and BMI alone were significant predictors of osteoporosis with an area 
under the curve (AUC) of 0.848 (CI 0.798-0.891). Addition of other variables 
such as ESR, sex and number of co-morbidities into the model did not 
improve the ROC (AUC = 0.861 [95% CI 0.812-0.910]) curve significantly ( 
p=0.74) . Based upon this, we divided subjects into four BMI categories (<20, 
20-24.9, 25-29.9 and >30) and four gender specific age categories (<44.9, 
45-54.9, 55-59.9 and > 60 for women and <49.9, 50-59.9, 60-69.9,>70 for 




score based on age and BMI alone with which to identify patients at low, 
medium or high risk of having osteoporosis. The prevalence of osteoporosis 
(at either spine or femoral neck) in RA patients according to these age and 
BMI strata are shown in Figure 3.2. Using these stratification variables we 
developed an algorithm which we named the osteoporosis prediction in RA 
(OPRA) tool. The OPRA risk assessment tool is freely accessible under 
http://www.opradxa.org.uk/opratool.htm .  
 
Table 3.3  Prevalence of osteoporosis in RA patients (study cohort) and 
controls  
 Spine OP  Total Hip OP  
Age 
groups  
Cases Controls p-value Cases Controls p-value 
<45 0 (0%) 1 (2.4%) 1.000 0 (0%) 0 (0%) 1.000 
45-54 4 (7.8%) 4 (2.5%) 0.103 2 (4.3%) 1 (0.6%) 0.133 
55-64 16 (18.0%) 41 (14.1%) 0.397 8 (9.5%) 6 (2.1%) 0.002 
65-74 20 (25.3%) 51 (17.5%) 0.146 10 (13.7%) 17 (6.0%) 0.028 
75+ 17 (28.8%) 31 (25.2%) 0.596 24 (41.4%) 16 (13.4%) <0.001 
All 57 (19.3%) 128 
(14.2%) 
0.036 44 (15.8%) 40 (4.5%) <0.001 








Figure 3.2 The prevalence of osteoporosis in the study cohort, divided 
in different subgroups of individuals according to age category and 
body mass index, is shown.  The BMI categories were 0 (>30 kg/m2 ); 1 (25-
29.9 kg/m2 ); 2 (20-24.9 kg/m2) and 3 (<20 kg/m2). The age categories were 
0 (<44.9 women, <49.9 men); 1 (45-54.9 women; 50-59.9 men); 2 (55-59.9 
women, 60-69.9 men) and 3 (>60 women and >70 men). OPRA= 
Osteoporosis prediction in rheumatoid arthritis is based on point allocation 

















































































The performance of OPRA was evaluated in an independent cohort of 171 
RA patients (41 men and 130 women) who underwent DEXA scanning at our 
unit between 2010 and 2013.  The tool had a sensitivity of 93.5% in women 
and 75% in men for the prediction of osteoporosis with a specificity of 34.3% 
and 48.6% respectively. The positive predictive value was 30.9% in women 
and 13.6% in men and negative predictive value 94.4% and 94.7% 
respectively. We compared the performance of OPRA with other tools that 
have been used for the prediction of osteoporosis including OST (Richy et 
al., 2004), ORAI (Cadarette et al., 2000), and OSIRIS (Sedrine et al., 2002). 
The results are shown in Table 3.4. The OPRA tool was more sensitive than 
the other tools in predicting osteoporosis in both men and women but had 
lower specificity when compared with the other risk assessment tools. The 
only other prediction tool which has been tested in men (OST) was a poor 






Table 3.4 Performance of the osteoporosis risk assessment tool 
developed in this study (OPRA) with other risk assessment tools in the 
replication cohort.   
  OPRA OST ORAI OSIRIS 
Sensitivity (%)      
All  91.4 73.5   
Women  93.5 80.00 83.87 80.00 
Men  75 25.00 - - 
Specificity (%)      
All  38.2 61.90   
Women  34.3 58.16 46.46 59.77 
Men  48.6 72.22 - - 
PPV (%)      
All  27.6 32.90   
Women  30.9 36.92 32.91 36.36 
Men  13.6 89.66 - - 
NPV (%)      
All  94.5 90.20   
Women  94.4 90.48 90.20 91.23 
Men  94.7 9.09 - - 
For OPRA, the values shown are for subjects with a score of three or more. 
The values shown refer to prediction of osteoporosis at either the spine or 
femoral neck. OST= Osteoporosis Self-Assessment Tool (Richy et al., 2004), 
ORAI= Osteoporosis Risk Assessment Instrument (Cadarette et al., 2000), 
OSIRIS=Osteoporosis Index of Risk (Sedrine et al., 2002), PPV= Positive 






3.4.5 Risk factors for fractures 
Age, years since menopause, spine BMD and total hip BMD were 
significantly associated with the presence of vertebral fractures in a case-
control analysis (Table 3.4). When we performed logistic regression analysis 
entering these factors into the model we found that only age (OR 1.06 CI 
[1.01- 1.12]) and total hip BMD (OR 0.04 CI [ 0.01- 0.89) were independent 
predictors. Non-vertebral fractures were significantly associated with female 
gender, Larsen score, spine BMD and total hip BMD in a case control 
analysis (Table 3.4 ). Subsequent logistic regression analysis identified only 
spine (OR 0.07 CI [0.01-0.89]) and hip BMD (OR 0.03 CI[0.01-0.05]) as 



















(89.5) 32 (10.5) 
 
212 (69.7) 92 (30.3) 
Female gender 
224 
(82.4) 25 (78.1) 
 








)  27.4±5.7 27.1±6.9 
 
27.7±5.5 26.6±6.5 
Age at Menopause (n=196) 47.0±6.4 46.0±7.6 
 
47.1±6.3 46.4±6.9 










(40.1) 18 (56.3) 
 
90 (42.5) 37 (40.2) 
Current Smoker 72 (26.5) 11 (34.4) 
 
60 (28.3) 23 (25.0) 
Alcohol drinker (n)(n=305) 87 (32.3) 6 (18.8) 
 
66 (31.6) 27 (29.3) 
Alcohol units/week 8.3±11.8 7.6±5.0 
 
8.5±13.0 7.8±6.6 
Duration of RA (months) 
(n=283) 131±127 157±165 
 
125±127 152±140 
Seropositive  (n=255) 
166 
(73.5) 18 (72.0) 
 
135 (75.0) 49 (69.0) 
Erosions (n=221) 93 (47.9) 9 (37.5) 
 
72 (45.9) 30 (49.2) 





ESR (mm/hr) (n=252) 32±23 41±24 
 
34.4±24.2 29.4±20.6 
CRP  mg/l (n=199) 29±36 36±31 
 
31.9±43.6 24.4±26.6 
Ever received glucocorticoids  
145 
(53.7) 17 (53.1) 
 
113 (53.8) 49 (53.3) 
Current glucocorticoid  91 (33.7) 8 (25.0) 
 
91 (33.7) 8 (25.0) 
Prednisolone dose (mg) 
(n=89) 7.2±10.3 6.6±5.6 
 
7.8±11.4 5.6±3.4 
Ever received anti-TNF  65 (23.9) 4 (12.5) 
 
46 (21.7) 23 (25.0) 

















Table 3.4 Comparison of demographic and clinical characteristics of RA study group 
with and without vertebral or non-vertebral fractures. Values are numbers (%) or mean ± 
SD. * p<0.05; ** p<0.01 and *** p<0.001, Numbers in parenthesis show the number of 
patients in which data was available for variables where data was missing in more than 1% 






3.4.6 Fracture prediction with OPRA  
We evaluated the ability of the OPRA tool predicting fractures in the study 
cohort. This showed that 97% of patients with vertebral fractures and 85% of 
patients with non-vertebral fractures would have been correctly identified by 
OPRA . The specificity when using our model for fracture prediction was 
27.4% and 26.1% respectively. Further details are listed in Table 3.5.  
 
Table 3.5 Sensitivity and Specificity of OPRA model in fracture 







Sensitivity    
All  84.8 96.9 
Women  88 100 
Men  55.6 85.7 
Specificity 
   
All  27.4 26.1 
Women  24.7 22.8 
Men  37.0 41.7 
    
PPV    
All  33.6 13.4 
Women  36.9 12.6 
Men 
 
 14.7 17.6 
NPV    
All  80.6 98.6 
Women  80.4 100 
Men  81.0 95.2 
Sensitivity, specificity and predictive values of proposed model for fracture 
prediction. The inclusion criteria are patients with 3 points or more according 
to the OPRA scale, based on BMI and age (see Figure 3). OP= Osteoporosis 
of Hip or Spine PPV= Positive Predictive Value, NPV= Negative Predictive 








This study of patients with RA has shown that the overall prevalence of 
osteoporosis was 26.5% which is significantly higher than the prevalence of 
osteoporosis in a gender and age matched control cohort. These 
observations are in keeping with previous reports which recorded a 
prevalence of osteoporosis ranging between 17% and 32% at the spine and 
15 to 36% at the hip (Haugeberg et al. 2000a;Sinigaglia et al.2000). As in 
previous studies (Gough et al. 1994a;Lodder et al. 2004;Orstavik et al. 
2004;Sambrook et al. 1987) the presence of osteoporosis in our cohort was 
associated with female gender, increasing age, years since menopause, and 
low body mass index.  Disease activity has been identified previously as a 
risk factor for bone loss in RA (Gough et al. 1994a;Laan et al. 1993;Lodder et 
al. 2004;Roldan et al. 2006) and in keeping with this we observed a 
significant association between the levels of inflammatory markers and 
osteoporosis. Neither of these variables emerged as independent predictors 
of bone density in the logistic regression analysis however. Unfortunately 
DAS28 measurements were not recorded systematically in the study cohort 
and in view of this we were unable to evaluate possible associations between 
this measure of disease activity and osteoporosis. Although Larsen scores 
were associated with osteoporosis in the case control study they did not 
emerge as an independent predictor of osteoporosis in the logistic regression 
analysis. The relatively high prevalence of osteoporosis observed in this 
study, which is comparable with that observed in studies performed almost 
15 years ago (Haugeberg et al. 2000a;Sinigaglia et al. 2000) indicates that 
the more aggressive approach to management of RA that has been widely 
adopted over recent years has not been accompanied by a major reduction 
in the proportion of RA patients who develop osteoporosis. This is in keeping 
with the fact that Haugeberg did not identify DMARD use as a determinant of 




(Haugeberg et al. 2002b).  I would like to acknowledge that the patients for 
this study had an average disease duration of 10 years which means many 
patients of this cohort were diagnosed and treated before the change of 
treatment paradigm advocating early aggressive treatment. Furthermore this 
study was unable to check whether early aggressive treatment and treat to 
target approach have been adopted correctly by all clinicians and health care 
professionals treating early RA patients.  
Although there is evidence that anti-TNF therapy can arrest systemic bone 
loss in RA over a 12 month treatment period (Vis et al. 2006) only one 
quarter of our patients had received anti TNF therapy.  The observations 
here therefore suggest that in routine clinical practice, classical risk factors 
such as age, low BMI and gender play a predominant role in the 
pathogenesis of systemic osteoporosis in patients with RA (Haugeberg et al 
2000a;Sambrook & Cooper 2006). Although we did not observe an 
association between corticosteroid use and osteoporosis, this may be 
explained by the fact that the average dose of prednisolone was less than 
10mg daily and that about half (48.4%) of the patients on steroid therapy 
were also on bone protective treatments (data not shown).  
We found a positive association between the number of other co morbidities 
and osteoporosis in the RA cohort. The likely explanation for this is that these 
co morbidities are strongly related to age (Michaud et al. 2011) which could 
account for the fact that co-morbidity did not emerge as independent 
predictor of osteoporosis in the logistic regression.  
An interesting finding to emerge from this study was that there was a 10 year 
delay between the diagnosis of RA being made and the first request for 
DEXA scanning.  This indicates that, in routine clinical practice, DEXA is not 
a priority investigation in patients with RA, especially in the first few years 




In an attempt to better target DEXA screening of patients with RA previous 
efforts have been made to develop prediction tools based on clinical risk 
factor analysis (Haugeberg et al. 2002a;Lems and Dijkmans 1998). In these 
studies, the risk criteria and cut off values were chosen arbitrarily which 
differs from the approach used here where the OPRA risk assessment tool 
was based on the outcome of logistic regression analysis. The negative 
predictive value and positive predictive value of the OPRA tool in our 
population (94.4% and 30.4% respectively) did not differ significantly from 
existing tools that have been used for the prediction of osteoporosis in 
women, including the osteoporosis self-assessment tool (OST) (Richy et al. 
2004) the osteoporosis risk assessment instrument (ORAI) (Cadarette et al. 
2000)  and the osteoporosis index of risk (OSIRIS) (Sedrine et al. 2002). 
However  OPRA was clearly superior to the only other available tool (OST) in 
the prediction of osteoporosis in men (Table 4). Further studies would be of 
interest to establish the performance of OPRA in comparison with existing 
tools in other cohorts. We were unable to evaluate the Lems-Dijkman (Lems 
& Dijkmans 1998) and Haugeberg models (Haugeberg et al. 2002a) in our 
population since HAQ data were not collected in our study but a previous 
analysis by Nolla reported a sensitivity of  86% for the Lems-Dijkman tool and 











Osteoporosis and fragility fractures are recognized complications of  
rheumatoid arthritis which are thought to result from the effects of chronic 
inflammation, relative immobility and corticosteroid use. A rare syndrome of 
osteoporosis has previously been described in a patient with autoimmune 
disease caused by production of neutralizing antibodies to the bone 
protective protein osteoprotegerin (OPG). Here we screened for the presence 
of OPG autoantibodies in patients with rheumatoid arthritis and evaluated 
their clinical significance. 
In order to measure OPG antibodies we developed an ELISA to detect OPG 
autoantibodies in serum and measured antibody levels in 75 patients with RA 
and 199 healthy controls. The functional effects of the antibodies were 
investigated by their ability to block the inhibitory effects of OPG in a RANKL 
induced NFκB reporter assay. Autoantibodies to OPG were detected in 2 
controls (1%) compared with 7 patients with RA (9.3%; χ2= 19.2, p=0.001). 
The RA patients with detectable OPG antibodies had a longer disease 
duration (p=0.01), higher DAS28 scores (p=0.02) and higher levels of the 
bone resorption marker CTX (p=0.01) than RA patients who did not have 
autoantibodies. Purified IgG from patients with high levels of OPG antibodies 
blocked the ability of recombinant OPG to inhibit RANKL induced NFκB 
activation in a HEK293 cell based assay (p<0.01). 
In conclusion, autoantibodies to OPG were present in about 10% of this 
series of patients with RA and were associated with disease activity, disease 








Rheumatoid Arthritis (RA) is a chronic inflammatory disease principally 
targeting the synovium which is characterized by periarticular bone erosions 
and cartilage destruction which if untreated can lead to progressive joint 
damage and deformity. Patients with RA also have an increased risk of 
generalized osteoporosis (Haugeberg et al. 2000b). This is thought to be 
multifactorial in origin and caused by decreased mobility, corticosteroid use, 
vitamin D deficiency and the production of proinflammatory cytokines such as 
IL1, IL6, TNF (Redlich et al. 2002) which stimulate bone resorption through 
activation of the receptor activator of NFκB Ligand (RANK) signaling pathway 
(Kong et al. 1999a;Romas et al. 2002). It has more recently been 
demonstrated that bone loss can occur very early during the course of RA 
(Kleyer et al. 2014) (Guler-Yuksel et al. 2009;Machold et al. 2007) due to the 
osteoclast-activating effects of antibodies directed against citrullinated 
proteins (ACPA) (Harre et al. 2012). We previously reported the occurrence 
of severe osteoporosis in a patient with autoimmune thyroid disease and 
coeliac disease in association with neutralizing autoantibodies to 
osteoprotegerin (OPG), an inhibitor of RANK signaling (Riches et al. 2009).  
The aim of the present study was to determine if autoantibodies to OPG also 
occur in RA and to relate the presence of these antibodies to clinical 






4.3 Patients and Methods: 
 
4.3.1 Patients Rheumatoid Arthritis cohort for OPG ab study 
Patient recruitment took place at the outpatient department of the Western 
General Hospital in Edinburgh between January 2011 and December 2012. 
We included 75 consecutive patients with a clinical diagnosis of Rheumatoid 
Arthritis who attended the outpatient clinic for a routine review. We collected 
information on patient’s demographics, disease characteristics, co-
morbidities, medication history and risk factors of osteoporosis through a one 
to one interview and undertook a retrospective case note analysis for disease 
duration, medication history and ACPA or Rheumatoid Factor status. Clinical 
examination and disease activity assessment (DAS 28) were performed on 
the day of recruitment. Each patient donated a sample of serum and plasma 
for the study when undergoing routine blood test for clinical purposes. The 
samples were stored frozen at -80oc until analysis.  
Measurements of BMD were made by dual-energy X-ray absorptiometry 
(DEXA) using a Hologic QDR 4500 osteodensitometer at the lumbar spine 
(L1-L4) and the femoral neck. Patients with rheumatic diseases had a DXA 
scan performed in a time frame of 5 ± 15 months from the time of recruitment 
into the study. 
 
4.3.2 Healthy control cohort 
For the healthy control data serum and plasma were obtained from a 
population based cohort with normal bone mineral density. Recruitment and 
characteristics of this cohort was described before (Estrada et al. 2012).  
 
4.3.3 DXA measurement 
Measurements of BMD were made by dual-energy X-ray absorptiometry 
(DEXA) using a Hologic QDR 4500 osteodensitometer at the lumbar spine 
(L1-L4) and the femoral neck. For healthy controls the DXA scan was done at 




scan performed in a time frame of 5 ± 15 months from the time of recruitment 
into the study. 
 
4.3.4 Serum measurements 
Serum and plasma samples were stored frozen at -80oc until analysis. 
OPG ab serum concentrations were analyzed as described in Chapter 2.1.1.  
CTX measurements are described in Chapter 2.1.4. Details of 
immunoglobulin purification are outlined in Chapter 2.2.2 and the functional 
assay in Chapter 2.2.3. 
 
4.3.5 Statistical methods 
Analyses were performed using SPSS version 16.0 (SPSS, Chicago, IL, 
USA). Two tailed independent student t-test was used for between-group 
comparisons of continuous data. If the variables were not normally distributed 
Mann Whitney U test was applied. The results are shown as the mean ± SD. 
Chi-square tests were used to test for differences between categorical 
variables and the results are shown as total numbers and percentages.  
Correlations between OPG antibodies levels, serum CTX and DAS28 were 
performed using Spearman’s rank correlation test.  
 
4.3.6 Ethics 
Approval for the study was sought from NHS Lothian Tissue Governance 
Committee. All subjects provided informed consent prior to participation of 
the study. The R&D ID number is 2011/BRP/05, RTB: South East of Scotland 






4.4.1 Clinical characteristics of the RA cohort and controls 
Clinical characteristics of the Rheumatoid Arthritis patients and 200 healthy 
controls are shown in Table 4.1 and Table 4.2. RA patients were slightly 
older than the controls (p=0.01) but there was no significant difference in 
gender distribution. The average spine and hip BMD t-score was higher in 
the healthy control group than in the RA cohort (p=0.01 and p=0.01). Women 
with RA were significantly younger than healthy controls when going through 
the menopause. Most of the RA patients (80%) were Cyclic citrullinated 
peptide (CCP) antibody or rheumatoid factor (RF) positive, but 13 (17%) 
were CCP or RF negative and in 2 (3%) patients the serological status was 
unknown. The RA patients had on average high disease activity with a mean 
DAS28ESR score of 5.43± 1.31. Amongst the RA cohort 13 patients were 
treatment naïve and had symptoms for less than one year which was defined 







Table 4.1: Demographics and clinical characteristics of study population 
 RA (75) Controls (199) p value 
Demographics    
Age (years) 61.52± 13.10 55.74 ±13.89 0.002 
Women, n(%) 54 (72%) 126 (70%) 0.177 
Height (cm) 162.69 ± 9.45 166.44 ± 8.78 0.004 
Weight (kg) 70.15 ± 14.54 79.04 ±16.31 0.001 
BMI (kg/ m2) 26.45 ± 4.68 28.44 ±  4.85 0.005 
Age at menopause 44.86 ± 6.42 50.16 ± 3.96  0.001 
Bone mineral density  
Spine BMD (g/cm2) 0.91 ± 0.17 1.08 ± 0.09 0.001 
Spine BMD T-score -1.37 ± 1.51 0.15 ± 0.79 0.001 
Spine Osteoporosis, 17 (28.3%)  0 (0%) 0.001 
Hip BMD (g/cm2) 0.84 ± 0.17 1.00 ± 0.07 0.001 
Hip BMD T-score -0.95 ± 1.28 0.21 ± 0.34 0.001 
Hip Osteoporosis 9 (14.8%)  0 (0%) 0.001 
 
Values are mean ± standard deviation or number (%).  
BMI=Body Mass Index, BMD=Bone Mineral Density. Spine BMD 






Table 4.2 Clinical characteristics of RA cohort 
 
Disease Duration (Years)* 7.18 ± 8.56  
Early disease1 13 (17.3%) 
ESR (mm/hr) 30.74 ± 19.96  
DAS 28  5.43 ± 1.32 
Medications  
Ever DMARD  57 (76%) 
Synthetic DMARD 35 (46.7%) 
Current anti-TNF 8 (10.7%) 
Ever anti TNF 23 (30.7%) 
Current  Glucocorticoid 23 (30.7%) 
Current Glucocorticoid dose* 5.05 ± 4.94 
Osteoporosis treatment 16 (21.3%) 
Values are mean ± and number (%). 1Early RA was defined as a disease 
duration <1 year and not currently on DMARD treatment. *Disease duration 
and current glucocorticoid dose were not recorded in 2 patients and DAS28 







4.4.2 Antibodies to OPG in cases and controls 
Circulating levels of OPG antibodies in cases and controls are shown in 
Figure 4.1. Subjects were considered to have tested positive for OPG 
antibodies if the levels were higher than 3 standard deviations above the 
mean in the healthy controls. According to this definition 2 (1%) out of 199 
healthy controls were positive for OPG antibodies compared with 7 out of 75 
patients (9.3%) of the RA cohort (p=0.01). The mean levels of OPG 






Figure 4.1 Osteoprotegerin antibody concentrations in healthy controls 
(n= 199) and patients with Rheumatoid Arthritis (n=75) . The 
demarcated area (blue line) depicts the normal range (mean ± 3SD of 
healthy controls). *** = p=0.001 (difference between number of cases with 


































4.4.3 Association between OPG ab and clinical 
characteristics in RA  
Associations between OPG antibody positivity and the clinical characteristics 
of RA are shown in Table 4.3. Patients with RA who tested positive for OPG 
antibodies were associated with duration of the disease, high disease activity 
(DAS28 ESR) and increased levels of the bone resorption marker CTX. 
Despite this there was no association with bone mineral density at either the 
spine or hip. Of interest was the fact that all patients who tested positive for 
OPG antibodies were female and were seropositive for anti CCP antibodies 
or Rheumatoid factor, although this was not statistically significant.  
 
Table 4.3: Relation between OPG autoantibodies and selected clinical 
variables  





Age  63.3 ± 11.8 61.5±13.2 p=0.64 
Female Gender 7/7 (100%)  47/68 (70%) p=0.18 
Disease Duration (years) 16.0±12.3 6.4±7.8 p=0.01 
ACPA or RF positive* 7/7 (100%) 53/66 (80%) p=0.34 
DAS 28 6.1±0.6 5.4±1.4 p=0.02 
Serum CTX (ng/ml) 0.30±0.08 0.16±0.10 p=0.01 
Hip BMD (g/cm2) 0.86±0.26 0.84±0.16 p=0.82 
Spine BMD (g/cm2) 0.94±0.23 0.91±0.16 p=0.67 
Data are shown as mean ± SD or numbers (%). *Data on CCP and RF status 
was unavailable for 2 patients. The comparison of CTX levels was performed 







There was a positive correlation between OPG antibodies and disease 
activity as assessed by the DAS28 score (Fig 4.2A). Further analysis of each 
DAS 28 component shows that there was a positive association between 
OPG antibody levels and the number of swollen (r= .341 p=0.006) and tender 
joints (r= .343, p=0.006) but not with global disease activity (VAS) (r= .039 
p=0.761) or ESR  (r=.157 p=0.182). There was a positive association 
between OPG antibody levels and levels of the bone resorption marker CTX 






Figure 4.2. Correlation of OPG ab concentrations and DAS 28 ESR 
(disease activity score). B: Correlation between OPG ab concentrations 
and bone resorption markers CTX (patients who received antiresoptive 
treatment at time of sample collection were excluded). rs=correlation 




4.4.4 Functional analysis of OPG antibodies  
In order to determine if the OPG antibodies we detected in patients with RA 
had functional effects on RANKL induced NFκB signaling we investigated 
IgG samples from patients who tested positive or negative for OPG 
autoantibodies in cell based NFκB reporter assay. Isolated Immunoglobulin 
concentrations from OPG ab positive patients (2.76± 0.93 μg/μl) did not differ 
significantly from IgG concentrations from patients tested negative for OPG ab 
(3.20± 1.70 μg/μl, p= 0.57). The cell assay showed that the addition of 
Immunoglobulin from four of six OPG antibody-positive patients partially 
(n=1) or significantly (n=3) reversed the inhibitory effect of OPG on RANKL-
induced NFκB activation compared with zero of seven negative patients 
(p=0.02, Fisher’s exact test). A representative experiment is shown in Figure 
4.3. Amongst the OPG antibody negative samples there was no difference 







Figure 4.3 shows the level of NfκB activation of human embryonic-kidney 
(HEK-293) cells, stably transfected with NF-kB luciferase reporter vector in 
the presence of various combinations of treatments. The column  without 
stimulation depicts the negative control. Stimulation of cells with RANKL 
(50ug/ml) increase NF-kB response significantly (++, p<0.001). Addition of 
OPG (100 µg/ml) attenuates stimulation significantly (**, p<0.001). The 
addition of 20µl of purified IgG from OPG ab positive patients neutralize OPG 
action and increase NfkB activity significantly (##,p<0.001 and ^^, p=0.004 
respectively).The addition of IgG from patients tested negative for OPG ab (2 
white columns) did not abrogate the inhibitory OPG effect on RANKL( p= 






This study showed that autoantibodies to OPG can be detected in a 
proportion of patients with RA and are more commonly present than in 
healthy controls. We also found an association between levels of 
autoantibodies to OPG and the bone resorption marker CTX and found that 
purified IgG from patients who tested positive for OPG antibodies inhibited 
the ability of OPG to block RANKL induced NFκB activation in vitro. This 
suggests that in some RA patients functional autoantibodies to OPG are 
produced which have the potential to enhance osteoclastic bone resorption.  
Previous studies have shown that autoantibodies to citrullinated peptides 
contribute to bone loss in RA by interacting with the Fc receptor on 
osteoclasts (Harre et al. 2012). Although we cannot exclude the possibility 
that the autoantibodies to OPG detected here might also affect 
osteoclastogenesis by binding Fc receptors, the observation that samples 
from patients who tested positive were able to block the inhibitory effect of 
OPG on RANKL induced NFκB activation suggests that they exert  a specific 
effect on the RANK pathway.  
The correlation between high disease activity and OPG antibody levels may 
be an epiphenomenon as we know that patients with autoantibodies against 
citrullinated proteins develop more aggressive disease than seronegative 
patients (Miriovsky et al. 2010;van Gaalen et al. 2004). It is therefore possible 
that patients with a propensity to develop ACPA may also be more likely to 
develop antibodies against OPG. At the present time we have no information 
with regard to the time course of OPG antibody development in RA. Although 
patients with OPG antibodies tended to have a longer disease duration than 
those that tested negative and it would be of interest to test for the presence 
of OPG antibodies in population based cohorts and cohorts of patients with 
early arthritis. 
Whilst we found a positive association between OPG antibodies and the 
bone resorption marker CTX, there was no association with BMD. We think 
that this may be explained by the fact that this was a relatively small study 




variables influence BMD including  age, gender, BMI and other genetic and 
environmental factors (Sambrook and Cooper 2006).  Future studies of larger 
cohorts would be needed to adequately address this issue. Similarly, our 
study was too small to detect possible associations between OPG antibody 
levels and bone erosions. This however would be of interest given the crucial 
role that OPG/RANKL system plays in the pathogenesis of localized bone 
loss and the development of bone erosions (Kong et al. 1999;Romas et al. 
2002).   
While further work will need to be done to fully explore the clinical 
significance of the findings reported here, the present study shows that OPG 
antibodies are produced more commonly in RA patients as compared with 
controls and that some have functional effects on RANKL signaling. This 
raises the possibility that OPG antibodies may contribute to the pathogenesis 
of local and systemic bone loss in RA and signal the need to study the 
relationship between these antibodies and bone disease in large-scale 







Chapter 5: Osteoprotegerin autoantibodies and 
Ankylosing Spondylitis 
5.1 Abstract  
Osteoporosis and vertebral fractures are recognised complications of axial 
spondyloarthritis (axSpA) but the underlying causes are incompletely 
understood. Osteoprotegerin (OPG) is a bone protective protein that acts as 
a decoy receptor for RANK-L and inhibits osteoclastogenesis. Previous 
studies have demonstrated that antibodies to OPG (OPG-Ab) may develop in 
patients with autoimmune diseases and be associated with osteoporosis and 
increased bone turnover. The aim of this study was to determine whether 
OPG-Abs were detectable in axSpA patients and whether they were 
associated with bone health. 
 Patients with a clinical diagnosis of axSpA were recruited from routine 
outpatient clinics at two centres in the United Kingdom between 2011-2015. 
Patient demographics and disease characteristics as well as history of 
fractures were recorded. All had BMD assessment using antero-posterior 
dual-energy X-ray absorptiometry (AP-DXA). Serum levels of OPG-Ab were 
measured for each patient using an in-house ELISA. Patients were 
considered to be positive for OPG-Ab if values were ≥13units (3 standard 
deviations above mean in healthy controls). Associations between OPG-Ab 
and BMD and fractures were assessed using logistic regression, adjusted for 
age, gender, duration since diagnosis, BMI and study centre. 
We studied 134 patients, of whom 75% were male. The mean age was 47 
(SD±15) years and median disease duration from diagnosis was 6.5 years. 
16 patients were tested positive for OPG-Ab (11.9%). The presence of OPG-
Ab was associated with lower hip BMD, and an increased number of 
fractures. There was no association between OPG-Ab and patient 
demographics, disease characteristics or activity. In patients with a longer 




and hip BMD in OPG-Ab positive patients compared with OPG ab negative 
patients (p=0.003). Logistic regression revealed an association between 
OPG-Ab and disease duration (OR 1.04; 95%CI 1.00, 1.07; P=0.045). Strong 
independent association were seen with hip T-score (ORadj 0.43; 95%CI 
0.22, 0.85; P=0.015) and history of fractures (ORadj 4.78; 95%CI 1.37, 16.7; 
P=0.014).  
In conclusion this cross-sectional study demonstrates that OPG-Ab were 
present in 11.9% of axSpA patients. OPG-Ab was strongly and independently 
associated with hip BMD and history of fractures. This raises the possibility 
that OPG-Ab may play an important role in accelerated bone loss and 






Ankylosing spondylitis (AS) is an autoinflammatory condition which is 
predominantly characterized by localized inflammation at entheses which 
causes back pain and stiffness and localized new bone formation in form of 
syndesmophytes. Despite osteoproliferation being a cardinal problem in axial 
SpA, AS patients are at increased risk of systemic bone loss and of 
developing generalized Osteoporosis (Braun & Sieper 2007;Donnelly et al. 
1994;Karberg et al 2005). Accelerated bone loss and the presence of 
osteoporosis is particularly problematic in a fused and rigid spine, thus 
vertebral fractures is not an uncommon complication in AS (Ralston et al. 
1990;Vosse et al. 2009), even in early disease(van der Weijden et al. 2012).  
The main driver for systemic bone loss in AS are thought to be immobility 
due to functional incapacity (van der Weijden et al.2011)  and systemic 
inflammation characterized by  increased inflammatory cytokines (anti-TNF, 
IL6 and IL17) which promote osteoclast proliferation and  bone resorption 
(Franck, Meurer, & Hofbauer 2004;Gratacos et al. 1999;Wendling et al. 
2007).  However there are many unanswered questions regarding the 
pathogenesis, prevention and treatment of OP in Spondyloarthropathies.  In 
contrast to general population men are at higher risk of developing OP 
(Sambrook & Cooper 2006;van der Weijden et al. 2011) and fractures (Vosse 
et al. 2006;Vosse et al.2009)  at a younger age which limits the value of 
conventional fracture risk assessment tools such as FRAX. We know that 
treatment with anti-TNF reduces BMD loss (Allali et al. 2003) but it is unclear 
if bone formation is closely linked to inflammation and if fracture risk can be 
altered by  anti-TNF treatment (Maksymowych,et al. 2009;Schett et al. 2009).  
 These uncertainties highlight the need to investigate other mechanism which 
may impact on AS related bone loss. 
 Autoantibodies have recently come into spotlight in the pathogenesis of 
localized and systemic bone loss in RA (Harre et al. 2012;Hauser et al. 
2013;Hauser et al. 2015;Kleyer et al. 2014). In specific OPG ab, which 
neutralize the bone protective effect of OPG were found to correlate with 




arthritidis, autoantibodies are not thought to have a significant role in axSpA. 
However a few SpA patients were found to be positive for OPG-Ab in an 
early pilot study (Hauser et al. 2013).  
The aim of this study was to determine whether OPG-Ab were detectable in 





The Ankylosing Spondylitis cohort consists of patients recruited from routine 
outpatient clinics at the Western General Hospital in Edinburgh and Aintree 
University Hospital in Liverpool. The cohort included patients recruited from 
January 2011 to February 2015. I’ve recruited all AS patients belonging to 
the Edinburgh cohort. Inclusion was by clinical diagnosis based on the 
modified New York criteria for AS and/or the ASAS criteria for axSpA. 
Patients attending a general Rheumatology clinic were invited to give serum 
and plasma samples. BMD measurements were performed as necessary for 
routine clinical care. At the time of the clinical assessment I’ve collected data 
on demographics, disease characteristics, medication history, risk factors of 
osteoporosis and fracture history. Disease activity and functional status were 
assessed using BASDAI, spinal pain VAS and BASFI, along with ESR and 
CRP at the time of obtaining samples for this study.During DEXA scanning 
additional detailed information on risk factors for osteoporosis was recorded 
including patient demographics, BMI and calcium intake. Duration of disease 
since diagnosis was divided by the median into long (≥6.5years) and short 
(<6.5years). The difference in BMD (g/cm2) between spine and hip was 
calculated and compared between OPG-Ab status and disease duration. 





5.3.2 BMD assessment 
BMD was assessed by dual-energy X-ray absorptiometry (DEXA) of the 
lumbar spine (L1-L4) and the femoral neck using Hologic QDR4500 at 
Edinburgh and Lunar iDXA (GE Healthcare) at Liverpool. DXA scans were 
performed within a median of 11 months from study recruitment.  
 
5.3.3 Osteoprotegerin autoantibody measurement  
This was performed as described in Chapter 2.1.2. Each sample was run in 
triplicates and the assay repeated at least once on a different day.  
Coefficient of variation for the ELISA was 10.4%.An arbitrary unit for OPG-Ab 
titre was generated from standard curve created using serum from the index 
patient previously described (Riches et al. 2009). Previous studies of healthy 
controls with normal BMD was used to define the limits for positivity as three 
standard deviations above the mean. Positivity was defined as greater or 
equal to 13 units. 
 
5.3.4 Statistics 
Statistical analysis was performed using SPSS 19. Variables were assessed 
for normality of distribution using skewness-kurtosis test. Mann-Whitney U 
test was used to compare non-parametric, Student’s t-test for parametric and 
Chi-squared or Fisher’s exact tests for categorical variables. Non-parametric 
data was transformed prior to linear regression. Association between OPG-
Ab and disease characteristics assessed with univariate logistic regression. 
Association with BMD and fractures were assessed by linear and logistic 
regression, respectively (adjusted for age, gender, duration since diagnosis, 






This study received ethical approval from both the Edinburgh (Lothian 
Research Ethics Committee, RTB REC No: 10/S1402/33. and Liverpool sites 







5.4.1 Demographics and clinical characteristics 
The axSpA cohort consisted of 134 patients with complete DXA data; 53 from 
Edinburgh and 81 from Liverpool. There were no statistically significant 
differences in age, gender, duration of disease, BMI or BMD between the two 
study sites (data not shown). The median OPG-Ab titre was 3 (range 0, 30.8; 
interquartile range [IQR] 1.4, 4.3). OPG-Ab was positive in 16 patients 
(11.9%). Patient demographics and disease characteristics are shown in 
Table 5.1. The cohort was predominantly male (75%) with a mean age of 47 
years (SD±15) and medium disease duration of 6.5 years [IQR 1.9, 17.8]. 
Most patients reported a moderate to high disease activity as measured by 
BASDAI (median 5.4). Peripheral joint involvement was reported in 35% of 
patients and 11% had associated inflammatory bowel disease (IBD). A third 
of patients received TNFi at the time of recruitment.  
 
5.4.2 Association between OPG ab positivity and disease 
characteristics 
Differences in patient and disease characteristics between those positive and 
negative for OPG-Ab are shown in Table 5.1. There were non-significant 
trends for older age and longer disease duration in the OPG-Ab positive 
group. Measures of axSpA disease activity, spinal pain and functional 
impairment were similar in both groups. A greater proportion of patients 







Table 5.1 Patient and disease characteristics by OPG-Ab status. 






Demographics Age (years) 47.0 ± 15.0 53.1 ± 14.1 46.2 ± 14.9 0.086 
Males (%) 100 (75%) 11 (69%) 89 (75%) 0.551 
HLA-B27 
(n=58) 
42 (71%) 5 (63%) 37 (73%) 
0.678 






13.7 [1, 27.3] 5.6 [2, 17.5] 
0.194 







5.1 [2.8, 5.8] 5.4 [3.2, 7.7] 
0.390 
Median spVAS 5.5 [2.5, 8] 6 [2, 6] 5.3 [2.5, 8] 0.756  
Median BASFI 5.3 [3.4, 
7.4] 




8 [5, 19] 15 [5, 31] 8 [5, 17] 0.207 
Median CRP 
(md/L) 





46 (35%) 5 (31%) 41 (35%) 1.000 
Psoriasis 20 (15%) 3 (19%) 17 (15%) 0.709 
Uveitis 46 (35%) 5 (31%) 41 (35%) 1.000 
IBD 15 (11%) 1 (6%) 14 (12%) 0.694 
Medication TNFi 45 (34%) 8 (50%) 37 (31%) 0.138 
Synthetic 
DMARD 
15 (11%) 0 15 (13%) 0.132 
NSAIDs 83 (64%) 9 (56%) 74 (65%) 0.470 
Glucocorticoid 3 (2%) 1 (6%) 2 (2%) 0.319 
Bisphosphonat
es 
11 (8%) 4 (25%) 7 (6%) 0.027 
Calcium and 
vitamin D 
64 (48%) 9 (56%) 55 (47%) 0.469 
 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; spVAS, spinal 
pain visual analogue scale; BASFI, Bath AS Functional Index; ESR, 
erythrocyte sedimentation rate; CRP, C-reactive protein; IBD, inflammatory 









5.4.3 Difference in BMD between OPG ab status 
Differences in BMD between patients positive and negative for OPG-Ab are 
shown in Table 5.2. Both BMD g/cm2 (0.882 ± 0.137g/cm2 vs 1.004 ± 
0.173g/cm2, P=0.013) and T-scores (-1.26 ± 1.08 vs -0.33 ± 1.15, P=0.006) 
were significantly lower at the hip in the OPG-Ab positive patients. No 
significant differences in bone density were observed at the spine. Only four 
patients (3%) of the cohort were osteoporotic. However there was a higher 
prevalence of osteopenia in OPG-Ab positive patients (63% vs 22% in OPG-
Ab negative, P=0.002). OPG-Ab positive patients had a higher prevalence of 
history of fracture than OPG-Ab negative patients (50% vs 19%, P=0.007). 
There was trend toward shorter height in OPG-Ab positive patients (166 ± 







Table 5.2 Difference in bone mineral density (BMD) between OPG-Ab 
positive and negative patients. 





Height (cm) n=119 171 ± 9.8 166 ± 7.6 171 ± 10.0 0.064 
Weight (kg) n=122 81.8 ± 17.3 82.6 ± 15.2 81.7 ± 17.6 0.861 
BMI (kg/m2) n=119 28.0 ± 5.4 29.9 ± 5.4 27.7 ± 5.3 0.130 
Spine BMD (g/cm2) 
n=114 
1.161 ± 0.224 1.244 ± 
0.230 
1.149 ± 0.221 0.125 
Spine T-score n=113 0.027 ± 1.684 0.6 ± 1.650 -0.060 ± 1.681 0.158 
Spine Z-score n=70 0.333 ± 1.692 1.018 ± 
1.550 
0.205 ± 1.698 0.145 
Hip BMD (g/cm2) n=106 0.988 ± 0.173 0.890 ± 
0.144 
1.004 ± 0.173 0.018 
Hip T-score n=105 -0.449 ± 1.174 -1.167 ± 
1.095 
-0.329 ± 1.149 0.010 
Hip Z-score n=71 -0.132 ± 1.106 -0.909 ± 
0.903 
0.01 ± 1.087 0.010 
Hip osteopenia 36 (34%) 10 (67%) 26 (29%) 0.007 
Hip osteoporosis 4 (4%) 2 (13%) 2 (2%) 0.097 
History of previous 
fracture 
31 (23%) 8 (50%) 23 (19%) 0.007 
 




5.4.4 OPG ab positivity and clinical associations 
OPG-Ab positivity was shown to be associated with disease duration since 
diagnosis (OR 1.04; 95%CI 1.00, 1.07) and a trend was seen towards 
association with age (table 5.3). Markers of disease activity, spinal pain and 
functional impairment were not associated with OPG-Ab.  
 
Table 5.3 Univariate logistic regression for association with OPG-Ab 
positivity 
Table 3 Univariate logistic regression for association with OPG-Ab positivity. 




1.03 1.00, 1.07 0.090 
Gender 0.72 0.23, 2.24 0.566 
Duration (years) 1.04 1.00, 1.07 0.045 
HLA-B27 0.63 0.13, 2.99 0.562 
BMI (kg/m2) 1.08 0.98, 1.19 0.134 
BASDAI 0.92 0.74, 1.14 0.421 
spVAS 1.03 0.86, 1.24 0.726 
BASFI 1.06 0.84, 1.22 0.644 
Vit D (nmol/L) 1.00 0.98, 1.01 0.932 
ESR (mm/hr) 1.01 0.99, 1.04 0.329 
CRP (mg/L) 1.00 0.97, 1.03 0.823 
TNFi 2.19 0.76, 6.28 0.145 
BMI, body mass index; BASDAI, Bath Ankylosing Spondylitis Disease Activity 
Index; spVAS, spinal pain visual analogue scale; BASFI, Bath AS Functional 
Index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IBD, 




5.4.5 Correlation between OPG ab and bone mineral density 
An inverse correlation was observed between increasing OPG-Ab titre and 
hip T-score (Fig. 5.1A). Similar correlations were observed for hip BMD (rs = -
.20 p=0.042 and Z-score rs= -.26 p=0.026). No correlation was observed 
between OPG-Ab titre and  BMD spine (rs =.11 p=0.254), Spine BMD Z-score 





Figure 5.1 Scatterplot of OPG ab titres against 
(A) Hip BMD T-score and (B) Spine BMD T-
score. Black lines shows line of best fit. 
R2=0.10  p=0.004 




5.4.6 Association between OPG ab status and difference 
between spine and hip BMD 
In patients with longer disease duration (>6.5 years), 100% of OPG-Ab 
positive patients had higher spinal BMD compared with 65% of negative 
patients (p=0.026) (table 5.4). This was not significant in those with shorter 
disease duration. The difference between spinal and hip BMD increased with 
disease duration; and in those with longer than 6.5years’ duration, OPG-Ab 
positivity was associated with greater difference (table 5.5).  




OPG-Ab Bone mineral density g/cm2  P-value 
Spine ≤ hip Spine > hip 
Long duration 
n=68 
positive 0 11 (100%)  
0.026 
negative 20 (35%) 37 (65%) 
Short duration 
n=66 
positive 1 (20%) 4 (80%)  
0.645 
negative 23 (38%) 38 (62%) 
Long duration = disease duration >6.5 years, Short duration= disease 
duration >6.5 years 
 
Table 5.5 OPG ab status and BMD difference between spine and hip 
 OPG-Ab Mean (sd) P-value 
Long duration n=68 positive 0.424 (0.182)  
0.003 negative 0.227 (0.189) 
Short duration n=66 positive 0.158 (0.152)  
0.275 negative 0.091 (0.115) 
Long duration = disease duration >6.5 years, Short duration= disease 





5.4.7 Association between BMD and fractures and OPG ab 
status  
Multivariable logistic regression (adjusted for age, gender, duration since 
diagnosis, BMI, study site) demonstrated that OPG-Ab positivity was 
significantly and independently associated with lower BMD at the hip for T-
score, Z-score and density g/cm2 (table 4). Multivariate logistic regression 
revealed that OPG-Ab positivity was strongly associated with both hip 
osteopenia (OR 6.78; 95%CI 1.69, 27.2) and history of prior fracture (OR 
4.78; 95%CI 1.37, 16.7). No significant associations were observed with 
osteopenia at the spine. 
Table 5.6 Associations between BMD and fractures and OPG -Ab status 






Spine T-score 1.13 0.78, 1.65 0.519 
Spine Z-score 1.44 0.89, 2.34 0.142 
Spine BMD 
(g/cm2) 2.89 0.12, 69.8 0.513 
Hip T-score 0.43 0.22, 0.85 0.015 
Hip Z-score 0.35 0.14, 0.88 0.025 
Hip BMD (g/cm2) 0.00 0.00, 0.32 0.016 
Hip osteopenia 
(T-score <-1) 6.78 1.69, 27.2 0.007 
Hip osteoporosis 
(T-score ≤-2.5) 10.0 0.80, 125.5 0.074 
History of 
previous fracture 4.78 1.37, 16.7 0.014 









This cross-sectional study demonstrated the presence of anti-OPG 
antibodies (OPG-Ab) in 11.9% of patients with clinical diagnosis of axSpA, 
which is similar to previous prevalence rates reported in RA (9.3%) in 
Chapter 4 and Coeliac Disease (9.8%)(Real et al. 2015) but significantly 
higher than the prevalence rates we have reported previously in healthy 
control populations (1 -1.4%) in Chapter 4.4.2 and in a study looking into 
OPG ab prevalence in Coeliac Disease (Real et al. 2015). This is a 
somewhat unexpected finding as the pathophysiology of axSpA is usually not 
associated with the production of specific autoantibodies. 
Although previous studies have shown an association between OPG ab and 
increased bone resorption this is the first study to demonstrate OPG ab to be 
independently associated with reduced hip BMD and fractures. The lack of 
association with spinal BMD will likely reflect the difficulty in accurately 
assessing vertebral BMD using AP-DXA, where syndesmophytes lead to 
overestimation of BMD(Braun & Sieper 2007). 
Our results are compatible with previous molecular findings (Riches et al. 
2009) (Chapter 4.3.4) that showed that OPG ab interfere with the 
OPG/RANKL homeostasis by blocking  OPG which acts as decoy receptor to 
RANKL, an essential cytokine for osteoclast activation and proliferation. 
Therefore the development of OPG-Abs may contribute to systemic reduction 
in BMD observed in axSpA. 
Of interest is the finding that in patients with longer disease duration, those 
positive for OPG ab seemed to have higher spinal than hip BMD. This may 
be a result of increased loss of BMD at the hip with increasing disease 
duration. Another explanation could be that OPG Ab are associated with 
dysregulatjon of bone remodelling in axSpA given the BMD loss at hip and 
increase at spine, which might possibly be due to redistribution of bone from 




observations that systemic bone loss in axSpA is associated with increased 
syndesmophyte burden (Karberg et al. 2005;Klingberg et al. 2012).  
The study has also found that OPG ab positive patients are more commonly 
receiving Bisphosphonate treatment than patients without detectable OPG 
ab, which is in keeping with the finding of lower BMD in antibody positive 
patients. A trend towards lower height in OPG ab patients may also be 
attributable to loss of vertebral height due to fractures as noted previously 
(Vosse et al. 2006). 
We have also found an association between OPG ab positivity and longer 
disease duration, a phenomenon which was also seen in our previous 
studies examining OPG ab associations  in RA (Chapter 4.4.3) and a trend 
was noted in the Coeliac cohort (Real et al. 2015) . The reason for this 
association remains unexplained and I hypothesize that a perpetuate cycle of 
chronic inflammation, activation and proliferation of B and T-cells and 
chronically increased RANKL/OPG concentrations may increase the risk of 
breaking tolerance and promotes the production of autoantibodies. 
Interestingly there seems to be a different immunological  mechanism to 
other functional antibodies seen in rheumatic diseases such as anti-CCP 
antibodies,  which frequently precede the disease and symptom onset 
(Kleyer et al.2014;Real et al. 2015). Longitudinal studies are required to 
explore the timing or triggering factors of OPG ab development during the 
course of disease.  
Our data did not demonstrate any association between OPG-ab and disease 
activity or inflammatory markers which suggests that development of OPG ab 
may be an inflammation-independent mechanism for accelerated bone loss 
in ax-SpA. This links to the theory that bone formation in AS is at least partly 
independent of inflammation and thus less amenable to prevention using  
anti-TNF treatment (Schett et al. 2009).   
There are a few limitations in this study due to its observational character. 




bone loss (van der Weijden et al. 2011) and vertebral fractures (Vosse et al. 
2006;Vosse et al. 2009) but due to the small number of female patients we 
are unable to draw conclusions on the impact of gender on OPGab presence.  
There is also a time lag between patient recruitment and DXA scan however 
the usual small change (0.5 -1%) of BMD per year (Warming et al. 2002) 
should make this of minimal clinical relevance (Sambrook & Cooper 2006).  
Most patients had established disease which means that we can’t extrapolate 
our data to newly diagnosed younger patients which we know are at higher 
risk of osteoporotic fractures(van der Weijden et al. 2012). 
This small cross-sectional cohort had variable exposures to DMARDs, 
NSAIDs and biologic therapies and whilst no association between these drug 
exposures were observed, the study was not adequate to identify whether 
these therapies influenced the development of OPG-Abs. Lastly the 
independent association to history of fractures is an interesting finding but we 
are unable to specify fracture location as the study is underpowered and we 
don’t have systematic spine radiograph assessments for the identification of 
subclinical vertebral fractures.  
Previous studies have shown the efficacy of bisphosphonates in reducing 
accelerated bone resorption in AS (Cairns et al. 2004) and one study also 
showed a reduction of  disease activity and functional decline (Maksymowych 
et al. 2002).  Our data certainly reinforces that at least a subset of patients 
suffer of OP due to increased bone resorption and thus antiresoptive 
treatments are the right choice in treatment. The jury is out as to whether 
generalized suppression of osteoclasts with bisphosphonates or targeted 
suppression of RANKL induced Osteoclast activation with Denosumab 
(Lacey et al. 2012) is superior in treating OPG ab associated osteoporosis. 
Clearly further functional and longitudinal studies are needed to establish and 
quantify the impact of OPG ab in axSpA associated bone loss and to explore 





Chapter 6: Correlation of RANKL, OPG and 




RANKL and OPG play a key role in the pathogenesis of osteoporosis in 
rheumatic diseases. Our aim was to examine the relation between OPG ab 
concentration and RANKL and OPG levels and to investigate if OPG 
antibodies interfere with free RANKL ELISA which uses recombinant OPG as 
capture antigen. 
We measured circulating soluble RANKL, total soluble  RANKL and OPG in 
sera from patients with rheumatic diseases. In order to investigate the effect 
of OPG antibodies on free RANKL ELISA  purified IgG from 6 patients sera 
was added to different RANKL concentrations (200 and 800pg/ml) in order to 
be analysed by free RANKL ELISA. 
Free RANKL concentrations were measured in 55 patients and were 
undetectably low in 23 patients. Median OPG concentration in 44 patients 
was 4.66 pmol/l (2.26-11.81pmol/l) and there was no association to OPG ab 
found. However a significant correlation between free sRANKL and OPG Ab 
concentrations (r=0.273, p=0.001) was found. The addition of purified IgG 
reduced free RANKL detection through ELISA significantly (p<0.001) 
however there was no difference between IgG with high and low OPG ab 
levels . 
In conclusion there is no correlation between circulating OPG and OPG ab 
concentration. Purified Immunoglobulins but not OPG ab interfere with the 
measurement of free soluble RANKL. Surprisingly we found that high OPG 







The RANKL/RANK/OPG system is an essential factor in the regulation of 
bone resorption. As shown in chapter 1.6 chronic inflammation increases 
RANKL and OPG concentrations through activation of synovial cells, 
lymphocytes and osteoblasts. Various rheumatic diseases including 
Rheumatoid Arthritis(van Tuyl et al. 2010), Ankylosing Spondylitis(Crotti et al. 
2002), Psoriatic Arthritis (Chandran et al. 2010) and SLE (Carmona-
Fernandes et al. 2011) have been found  to have increased circulating 
RANKL or OPG concentrations or both. RANK is expressed on membranes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
of mesenchymal cells such as pre-osteoblasts and osteocytes as type II 
membrane protein. The membrane bound form can be cleaved by a TNF-α 
converting enzyme like protease to the extracellular soluble form of RANKL 
(sRANKL)(Hofbauer and Heufelder 2001;Nakashima et al. 2000). Total 
soluble RANKL consists  of free and OPG-bound soluble RANKL(described 
Chapter 2.1.3.2) . The ELISA measurement for this form is based on anti-
RANKL antibody as capture antigen. Free sRANKL is the unbound soluble 
form which can be measured using an ELISA with OPG as capture antigen 
(described Chapter 2.1.3.1) (Hofbauer et al. 2004).  
We hypothesized that circulating OPG ab might interfere with free sRANKL 
detection by competitive binding to OPG, expecting an inverse relationship 
between OPG ab and free sRANKL measurements. We further wanted to 










6.3.1 Study subjects 
Patient recruitment and ethical approval as per Chapter 4.3. We included 55 
patients with different rheumatic diseases including 27 RA, 8 PsA, 7 AS and 
14 SLE patient. Each patient donated a serum and plasma sample. 
 
6.3.2 Serum measurements 
Serum and plasma samples were stored frozen at -80oc until analysis. 
OPG ab serum concentrations were analyzed as described in Chapter 2.1.1. 
Free sRANKL, total sRANKL and OPG measurements using commercial 
available ELISA kits are described in Chapters 2.1.3.1, 2.1.3.2 and 2.1.3.3 
respectively.Immunoglobulins were purified from 6 patient’ samples as 
described in Chapter 2.2.1.   
 
6.3.3 Free RANKL ELISA with recombinant RANKL standard 
curve 
All reagents and samples were brought to room temperature before use. 
Recombinant RANKL (100ug/ml) was diluted with washbuffer (provided by 
Biomedica) to a concentration of 1000pg/ml. Further dilutions with washbuffer 
resulted in RANKL concentrations of 800pg/ml, 400pg/ml, 200pg/ml and 100 
pg/ml. 50μl of various RANKL concentrations were mixed with 50μl of 
samples or washbuffer in a 96 well plate beforehand. Samples, standards, 
controls and various RANKL concentrations were added to a 96 well plate. 






6.3.4 Statistical methods 
Analyses were performed using SPSS version 16.0 (SPSS, Chicago, IL, 
USA). Two tailed independent student t-test or one-way Anova testing was 
used for between-group comparisons of continuous data. For non parametric 
data the Mann Whitney U test was applied. The results are shown as the 
mean ± SD or median and interquartile range.  Correlations between OPG 
antibodies levels, serum free RANKL, total RANKL and OPG were performed 






6.4.1 Demographics and measurements of disease groups 
Basic demographic data, disease characteristics and free and total RANKL, 
OPG and OPG ab levels are shown in Table 6.1.  
 
Table 6.1 Demographic data and RANKL/OPG/OPG ab measurements of 
analysed samples  
 RA SpA (7 AS) SLE 
Number 27 15 14 
Age 64 ± 11 49 ±16 50 ±16 
Female 22 (82%) 7 (47%) 13 (93%) 
Disease Activity 5.8 ± 1.4     
(DAS 28) 
4.3  ± 1.3 
(BASDAI) 
 
ESR 28.4  ± 19.2 26.8  ± 25.6 18.5  ±9.9 
Total RANKL (pmol/L) 911  ± 1008 313  ± 99 446  ± 318 
free RANKL (pmol/L) 0.06  ±0.13 0.13  ± 0.15 0.08  ± 0.14 
OPG (pmol/L) 5.3  ± 1.7 5.3  ± 3.2 4.8  ± 1.2 







6.4.2 Osteoprotegerin concentration in Rheumatic Diseases 
Circulating OPG concentrations were measured in sera of 23 RA, 10 SLE 
and 11 patients with Spondyloarthropathy. Median OPG concentration in 44 
patients was 4.66 pmol/l (2.26-11.81pmol/l). There was no difference of 
mean OPG concentrations between the disease groups (p=0.819).There was 
a non significant trend of increased OPG concentration in older patients as 
shown in Figure 6.1. When split into groups mean OPG levels were 
significantly higher in patients above 67 years ( 6.31 ± 2.50 pmol/L) than in 












Figure 6.1 Correlation of circulating OPG level in serum of patients with 






6.4.3 Correlation between Osteoprotegerin and 
Osteoprotegerin autoantibody concentrations 
In order to investigate if high circulating OPG concentrations correlate to 
increased OPG ab concentrations, OPG concentration was measured in 44 
patients with known OPG ab concentrations. Median OPG concentration in 
44 patients was     4.66 pmol/l (2.26-11.81pmol/l). There was no correlation 
seen between circulating OPG concentrations and OPG ab concentrations 
(rs=-.18 p=0.235), as shown in Figure 6.2.  Mean OPG concentrations in 
patients with high OPG ab titre as defined in chapter 4.3.2 are not statistically 
different from mean OPG concentrations in patients with low OPG ab levels 

















Figure 6.2 Correlation between OPG antibody levels measured by 
ELISA with circulating OPG level in serum of patients with rheumatic 
diseases  
 
6.4.4 Correlation between OPG ab and free RANKL 
concentrations 
We further analyzed 55 patient’s sera with known OPG ab concentrations for 
the presence of free soluble RANKL. Amongst the patients were 26 patients 
with RA, 15 patients with Spondyloarthropathy and 14 patients with SLE. 
There was no difference of mean free sRANKL concentrations between 





sRANKL concentration was undetectable. The median free RANKL 
concentration was 0.022 pmol (0.00- 0.524 pmol/l). There was a significant 


















6.4.5 Total sRANKL concentrations  
Total mean sRANKL concentration (n=43) was 376.56 pmol/l (72.95pmol/l to 
3200 pmol/l) with significantly higher total sRANKL concentrations in patients 
with RA (910.79 ± 1007.27) than in patients with Spondyloarthropathies 
(313.01±98.58) (p=0.036), as shown in Figure 6.4. There was no significant 
correlation between total RANKL levels and OPG, OPG ab or free RANKL 
concentrations (Table 6.2). 
 
 
Figure 6.4 Total sRANKL concentrations in different rheumatic 
diseases, RA= Rheumatoid Arthritis, SpA= Spondyloarthropathy, 

































Table 6.2 Correlation between circulating OPG, total and free RANKL 
and OPG ab in rheumatic diseases 










Total RANKL  r 1 0.082 0.089 0.275 
(n=43) p-value  0.600 0.571 0.075 
OPG r 0.082 1 0.192 -0.183 
(n=44) p-value 0.600 . 0.217 0.235 
free RANKL r 0.089 0.192 1 0.430** 
(n=55) p-value 0.571 0.217 . 0.001 
OPG Ab r 0.275 -0.183 0.430** 1 
(n=55) p-value 0.075 0.235 0.001 . 
**Correlation is significant at the 0.01 level (2-tailed) 











6.4.6 Effect of OPG ab on free RANKL detection 
 
With the use of various concentrations of recombinant RANKL I have 
produced a RANKL standard curve on free RANKL ELISA, shown in Figure 
6.5. Purified IgG of 4 patients with high OPG ab titre and purified IgG of 2 
patients with low OPG ab levels were added to a simplified RANKL standard 
curve with three RANKL concentrations (0, 200 pg/ml and 800pg/ml) . Figure 
6.6.A shows the effect of added IgG purified from sera from AS patients with 
low OPG concentrations. The addition of IgG reduces RANKL detection by 
31% when 1:15 diluted IgG added and by 44% when undiluted IgG are 
added to a RANKL concentration of 800 pg/ml. A similar effect is seen with 
the addition of purified IgG from the index patient with high OPG ab titre 
(Riches et al. 2009), which reduces RANKL detection by 25%. Figure 6.6B 
shows the effect of added IgG with known low OPG ab titre.  
 
Figure 6.5 Indicative standard curve for free RANKL ELISA by addition 
of various recombinant RANKL concentrations  
 

































Figure 6.6 Effect on RANKL detection by addition of IgG 
Addition of IgG with high OPG ab concentrations result in a significant  
reduction to 75%(p=0.007) of RANKL detection when IgG added from pos 
Ctrl, 60% (p=0.005) with addition of 1:15 diluted IgG with high OPG ab and 
45%(p=0.017) with addition of undiluted IgG with high OPG ab 
concentrations. Addition of IgG with low OPG ab concentrations result in a 
reduction to 69% (p=0.064) reduction of RANKL detection when 1:15 diluted 
IgG added with low OPG ab and a significant reduction when to 56% 
(p=0.017) when undiluted IgG with low OPG ab levels added LO= IgG with 





As shown in Figure 6.7 the addition of purified IgG with high OPG ab titre 
showed a mean reduction to 58.8 ± 12.6% RANKL detection compared to the 
impact of IgG with low OPGab addition which reduces RANKL detection to 
61.4 ± 2.4%. The addition of purified IgG reduces free RANKL detection 
through ELISA significantly (p<0.001) but there is no significant difference 
between the addition of IgG with high or low OPG ab titre (p= 0.799).  
 
 
Figure 6.7 Mean reduction in RANKL detection by addition of purified 



































I have shown that circulating OPG levels are not associated with OPG ab 
concentrations. As reported previously (Szulc et al. 2001) our findings 
demonstrated that elevated OPG levels were more frequently found in the 
elderly (patients above 67 years of age) but levels were not associated with 
OPG ab concentration. We know that OPG levels are increased in individuals 
with  rheumatic diseases (Crotti et al. 2002) but we could not detect a 
difference in OPG concentrations between the disease groups possibly due 
to the small sample numbers in each group. Interestingly in previous studies 
looking into associations between OPG ab and disease characteristics in 
both RA (Chapter 4.4.3) and AS (Chapter 5.4.4),disease duration was found 
to be significantly associated with OPG ab concentrations. It would therefore 
be interesting to investigate, instead of single time point measurements of 
OPG, if serial measurements and the calculation of total OPG concentration 
over time is associated to OPG ab production.  
Unsurprisingly total circulating RANKL concentrations are found to be 
significantly higher in patients with RA than in patients with 
Spondyloarthropathy. As described in Chapter 1.6 high RANKL/OPG ratio in 
RA lead to increased osteoclast proliferation and activation and the 
development of erosive disease. However free RANKL concentrations did not 
differ in various disease groups and there was no association between total 
and free RANKL levels. This might be due to increased compensatory OPG 
production in RA which binds to free circulation RANKL as it was shown 
before (Hein et al. 2008).  
In order to investigate if OPG antibodies bind to recombinant OPG, which is 
used as capture antigen in free RANKL ELISA we initially compared OPG ab 
and free RANKL concentrations.  Surprisingly we have found a significant 
positive correlation between free RANKL and OPG Ab concentrations 




order to investigate this further we added purified Immunoglobulins with 
variable OPG antibody concentrations to a RANKL standard curve in the free 
RANKL ELISA. We found that the addition of immunoglobulin significantly 
decreases free RANKL detection but this effect was independent of OPG ab 
levels. These findings reject the hypothesis that OPG ab block binding of 
synthetic OPG to RANKL in the ELISA. However, OPG ab in serum may 
increase free circulating RANKL concentrations by stopping OPG binding it, 
hence the positive correlation between OPG ab and free RANKL 
concentrations.  
At this stage, we are unable to explain as to why purified Immunoglobulins 
interfere with free RANKL ELISA but this might be a reason for frequently 
undetectable free RANKL concentrations as seen in previous studies 
(Hofbauer et al.  2004). It is unlikely that OPG is the factor that decreases 
free RANKL detection as the sera underwent IgG purification. In view of the 
existence of OPG antibodies, which are antibodies against TNF receptor 
superfamily, we speculate that there might be other antibodies against TNF 
receptors, such as RANKL antibodies which might explain above findings.  
In conclusion OPG/RANK/RANKL system as crucial regulator of 
osteoclastogenesis in rheumatic diseases is complex and incompletely 
understood. Many factors such as circulating OPG, free RANKL, OPG 
antibodies and their relation to each other in rheumatic disease requires 











Chapter 7: Discussion and Conclusion 
 
Patients with rheumatic diseases are at increased risk of development of 
localized and systemic bone loss. Although chronic inflammation is thought to 
be the overarching key driver for accelerated bone loss in rheumatic 
diseases there are distinct differences in mechanism and mediators of 
systemic and localized bone loss in RA, seronegative Spondyloarthropathies, 
SLE and other rheumatic diseases as summarized in Chapter 1.6. Recent 
findings of autoimmune related bone pathophysiology highlight inflammation 
independent pathways, which may contribute to some extent to localized and 
systemic bone loss in autoimmune diseases. (Finzel et al. 2012;Harre et 
al.2012;Harre et al. 2015;Negishi-Koga et al. 2015;Riches et al. 2009).  
In order to investigate if prevalence and risk factors of osteoporosis in RA 
has changed since the introduction of a more aggressive treatment approach 
and biologic therapeutics, I have re-evaluated the frequency and predictors of 
osteoporosis in a contemporary Rheumatoid Arthritis cohort. In comparison 
to a gender and age matched control cohort bone mineral density was 
significantly lower in men and women with RA above the age of 45. I have 
found that about 30% of the RA cohort had Osteoporosis, which is in keeping 
with older reports which recorded a prevalence rate between 17% and 36%. 
Amongst the RA patients diagnosed with Osteoporosis there was a long 
delay between the diagnosis of Rheumatoid Arthritis and the referral for bone 
mineral density assessment which might represent lack of awareness of 
Osteoporosis risk in Rheumatoid Arthritis. In order to raise awareness and to 
better target DEXA screening of patients with RA I developed a osteoporosis 
prediction model for patients with RA which can be used in everyday clinical 
practice. However, the study was limited by its retrospective nature, 
incomplete data in particular that of disease activity and corticosteroid use 
and the inclusion of patients with long disease duration. The question, if a 




made a difference to osteoporosis and fracture prevalence, was not 
completely answered. A large prospective case control studies with 
systematic data collection and regular DEXA scanning would allow a better 
judgement if and how RA treatment alters BMD loss. 
Apart from understanding clinical risk factors for Osteoporosis one of the key 
question of this thesis was to explore the potential role of newly identified 
auto-antibodies against osteoprotegerin in the development of Osteoporosis 
in rheumatic diseases. Our research team in Edinburgh have previously 
described a young man who sustained multiple fractures and who was found 
to have severe osteoporosis due to autoantibodies, which have eliminated 
the bone protecting effect of osteoprotegerin (OPG). Our main question was 
if these antibodies do occur in patients with rheumatic diseases and if they 
are related to increased bone loss. We have found that antibodies against 
OPG can be detected in about 10% of patients with Rheumatoid Arthritis and 
Ankylosing Spondylitis. The detection of OPG ab in these rheumatic diseases 
is significantly higher than in control populations. We have also shown that 
there is a relation between high OPG antibody levels and bone resorption 
markers in RA and bone mineral density in AS. Additional functional studies 
have shown that OPG ab block OPG in a HEK-293 reporter assay. These 
findings are in keeping with our hypothesis that Osteoporosis may in some 
cases be caused by an immune ‘attack’. A summary of the proposed 
mechanism of OPG ab and their effect on osteoclastogenesis is shown in 
Figure 7.1. The fact that not all detectable OPG ab may be functional might 
be related to different epitope recognition as recently shown in the study by 
Real et al (2015). These findings may also help to explain why OPG ab are 
also detected in a small proportion (approx. 1%) of healthy controls with 
normal BMD ( T-score between -1 and 1 SD) as shown in Chapter 4.4.2. 
However in order to explore the question about antibody functionality further 
we would need to test detected OPG ab in further in-vitro or preferably in-vivo 





Figure 7.1 Schematic diagram of proposed mechanism of OPG antibodies on 
osteoclastogenesis  RANK (Receptor Activator of NfκB) is a receptor expressed on pre-
osteoclasts and osteoclasts. RANKL (RANK- Ligand) binds to RANK and promotes 
osteoclast differentiation and activation. OPG (Osteoprotegerin) acts as decoy receptor to 
RANKL. Osteoclastogenesis is largely regulated by RANKL/OPG ratio. OPG antibodies (ab) 
bind and neutralize OPG and allow RANKL induced increased osteoclastogenesis 
 
It is currently unknown if OPG ab play also a role in other rheumatic diseases 
such as Psoriatic Arthritis, SLE or Scleroderma. Our research group has 
identified increased prevalence of OPG ab in patients with coeliac disease 
and showed that OPG ab presence was independently associated with 
decreased hip bone mineral density Z-score.  
 It would be of interest to study OPG ab presence and role in Psoriatic 
Arthritis as in contrast to other rheumatic diseases systemic bone loss does 
not seem to be a cardinal problem, however localized bone loss in form of 
aggressive erosive disease and rapid osteolysis, can lead to a destructive, 




 Another disease of interest would be SLE where the pathophysiology is 
strongly linked to the formation and presence of auto-antibodies and where 
disease mechanism have been shown to involve functional antibodies.  
The results of chapter 6 have highlighted that the interplay between OPG, 
free and total RANKL and OPG antibodies are complex. It has also 
demonstrated that the measurement of one or more of these cytokines in 
clinical practice may at times not be reliable or useful and requires careful 
interpretation as suggested previously for OPG and RANKL measurements 
(Hofbauer et al 2001).  
In order to answer the question about clinical relevance of OPG ab further 
large scale and longitudinal studies are necessary. However if these studies 
confirm our findings that OPG ab do play a role in the development of 
osteoporosis in a subgroup of patients, the presence of OPG ab may guide 
future osteoporosis treatment. Clearly antiresoprtive treatment will be the 
preferred choice however the jury is out if RANKL blockade through 
administration of Denosumab or generalised Bisphosphonate induced 
osteoclast inhibition will be more effective in OPG ab associated 
osteoporosis.  
Additionally longitudinal studies may help to answer the question what drives 
OPG ab production, specially since longer disease duration was found to be 
associated to OPG ab presence in RA and AS. The positive correlation 
between disease activity and OPG ab in RA is thought to be more likely an 
epiphenomenon as CCP antibody and Rheumatoid Factor positivity are 
associated to more severe disease. We could not find an association 







Further areas of interest would be to investigate the role of OPG ab in the 
development of bone erosions in RA and PsA.  As shown in chapter 1.6 
Rheumatoid Arthritis is an autoimmune condition which is characterized by 
chronic inflammation and the development of articular and periarticular bone 
loss. Erosions can occur in the early stages of the disease and in some 
cases even precede disease onset. The development of erosions is in many 
ways similar to the pathogenesis of osteoporosis with the exception that the 
inflammatory pannus is in immediate vicinity to bone and cartilage. Erosions 
are the result of increased osteoclast activity and blunted bone formation. 
Therefore it would be of interest to investigate if OPG antibodies in early RA 
influence the development of bone erosions and if OPG ab levels are 
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A1 Materials and Reagents 
 
All materials and reagents are listed in the table below in an alphabetical 
order. 
Materials and reagents Supplier 
Α Minimum Essential Medium (α MEM) Sigma Aldrich, Dorset, UK 
alamarBlueTM reagent Invitrogen, Paisley, UK 
Bovine serum albumin (A7906) Sigma Aldrich, Dorset, UK 
Centrifuge tubes (15 and 50ml) Fisher Scientific, Leicestershire, UK 
Coating buffer (C3041) Sigma Aldrich, Dorset, Kent 
Costar ELISA plate (3369 EIA/RIA) Fisher Scientific, Leicestershire, UK 
D Minimum Essential Medium (dMEM) Sigma Aldrich, Dorset, UK 
DL-Dithiothreitol (DTT) Sigma Aldrich, Dorset, UK 
DMSO Sigma Aldrich, Dorset, UK 
EDTA Sigma Aldrich, Dorset, UK 
Ethanol absolute Fisher Scientific, Leicestershire, UK 
Fetal calf serum (FCS) Fisher Scientific, Leicestershire, UK 





Human recombinant RANKL Gift from Dr. Patrick Mollat (Proskelia 
SASU) 
IgG elution buffer (Cat 21004) Fisher Scientific, Leicestershire, UK 
Jackson ImmunoResearch Anti-rabbit 
secondary antibody 
Stratech Scientific Unit, Newmarket 
Suffolk, UK 
L-Glutamine Invitrogen, Paisley, UK 
LPS (IMG-2204) Imgenex,2B scientific, Oxford, UK 
Magic Marker Invitrogen, Paisley, UK 
Melon™ Gel IgG Spin Purification Kit 
Thermo Scientific 45206 
Fisher Scientific, Leicestershire, UK 
Methanol Fisher Scientific, Leicestershire, UK 
Micro titre plate (Sterilin, 611F96) Fisher Scientific, Leicestershire, UK 
Neubauer haemocytometer Hawksley, Lancing, UK 
Osteoprotegerin (Human recombinant Cat 
185-05) 
R&D Systems, Abingdon, UK 
Osteoprotegerin ELISA Biomedica, BI-
20403 
Oxford Biosystems, Oxford, UK 
PBS tablets Invitrogen, Paisley, UK 
Penicillin/Streptomycin Invitrogen, Paisley, UK 





Pierce SuperSignal® West Dura Extended 
Duration Substrate 
Fisher Scientific, Leicestershire, UK 
Pierce Protein G spin columns Fisher Scientific, Leicestershire, UK 
Primary mouse monoclonal antibody to 
OPG  
(Cat Ab1194 – clone number 98A1071) 
AbCam, Cambridge, UK 
Primary rabbit polyclonal antibody to OPG 
(Cat Ab 9986) 
AbCam, Cambridge, UK 
Primary rabbit polyclonal antibody to-
OPG biotin conjugated (Cat Ab18068) 
AbCam, Cambridge, UK 
Protein G IgG Binding Buffer (Cat 21019) Fisher Scientific, Leicestershire, UK 
RANKL ELISA Total (Biovendor 
RD193004200R) 
Oxford Biosystems, Oxford, UK 
RANKL ELISA Free (Biomedica BI-
20452) 
Oxford Biosystems, Oxford, UK 
Secondary anti-human peroxidase 
conjugated antibody (109-035-088) 
Stratech Scientific Unit, Newmarket 
Suffolk, UK 
Secondary anti- mouse secondary 
antibody 
(Cat 715-035-151) 
Stratech Scientific Unit, Newmarket 
Suffolk, UK 




Steady-Glo reagent Promega, Southampton, UK,  
Stripettes (5, 10, 25 and 50ml)  Sarstedt Ltd, Leicester, UK 
Syngene BIO imaging system Fisher Scientific, Leicestershire, UK 
Syringes (all sizes) Becton Dickinson, Berkshire, UK 
TBS 10x (T5912) Sigma Aldrich, Dorset, UK 
TBE buffer 10X Invitrogen, Paisley, UK 
2%TCH (serum replacement) MP-Biomedicals, Cambridge, UK 
Tissue culture 75cm2 flasks Fisher Scientific, Leicestershire, UK 
Tissue culture microplates (6– 96well 
plates) 
Fisher Scientific, Leicestershire, UK 
TMB Stop solution (50-85-06) KPL, Maryland, USA 
Tris Bio-Rad Laboratories, Hertfordshire, UK 
Tris-EDTA buffer Sigma Aldrich, Dorset, UK 
Trizol reagent Invitrogen, Paisley, UK 
Trizol® Reagent Invitrogen, Paisley, UK 
Trypsin/EDTA Sigma Aldrich, Dorset, UK 
Tween-20 (27,434-8) Sigma Aldrich, Dorset, UK 







All apparatus are listed in the table below in alphabetical order.  
 
Apparatus Supplier 
Balancer Fisherbrand Fisher Scientific, Leicestershire, UK 
Bench-top centrifuge SciQuip, Shropshire, UK 
Benchtop Eppendorf centrifuge Fisher Scientific, Leicestershire, UK 
Bio-Tek Synergy HT plate reader Fisher Scientific, Leicestershire, UK 
Envair Bio2 safety cabinets  H&V Commissioning Services Ltd., 
Ayrshire, UK 
Grant OLS 200 water bath Thistle Scientific, Glasgow, UK 
Nichiryo America Inc. Pipettes (2, 10, 100, 200 
and 1000μl) 
Thistle Scientific, Glasgow, UK 
NoAir Class II Biological safety cabinet TripleRed Ltd., Buckinghamshire, UK 
PowerPac basicTM Bio-Rad Laboratories, Hertfordshire, 
UK 
Syngene GeneGenius Gel Bio-Imaging system Fisher Scientific, Leicestershire, UK 
SynSyngene GeneGnome Bio-Imaging system for 
chemiluminescence 
Fisher Scientific, Leicestershire, UK 







All software are listed in the table below in alphabetical order. 
 
Software Supplier 
Bio-Tek Gen5TM plate reader software Fisher Scientific, Leicestershire, UK 
Minitab Release 16.2.4 Minitab Inc., Pennsylvania, US 
SPSS statistics 19 SPSS Inc 
Syngene GeneSnap software Fisher Scientific, Leicestershire, UK 









Appendix 3.3 Solution for ELISA  
 
TBST wash buffer 
0.05 % (v/v) Tween 20 in TBS (pH 7.4) made up in dH2O. 
 
Coating buffer 
Carbonate/bicarbonate buffer 0.2 M, pH 9.6, prepared commercially with deionised 
water from sigma and buffer capsules C3041-100cap. 
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